

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/162751 A1

(43) International Publication Date
31 October 2013 (31.10.2013)

WIPO | PCT

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 31/04* (2006.01)
A61K 38/17 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:
PCT/US2013/031927

(22) International Filing Date:
15 March 2013 (15.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/638,797 26 April 2012 (26.04.2012) US

(71) Applicant: UNIVERSITY OF CHICAGO [US/US];
5801 S. Ellis, Chicago, IL 60637 (US).

(72) Inventors: MCADOW, Molly; c/o University of Chicago, 5801 S. Ellis, Chicago, IL 60637 (US). EMOLO, Carla; c/o University of Chicago, 5801 S. Ellis, Chicago, IL 60637 (US). MISSIAKAS, Dominique, M.; c/o University of Chicago, 5801 S. Ellis, Chicago, IL 60637 (US). SCHNEEWIND, Olaf; c/o University of Chicago, 5801 S. Ellis, Chicago, IL 60637 (US).

(74) Agent: SHISHIMA, Gina, N.; Fulbright & Jaworski L.L.P., 98 San Jacinto Blvd., Suite 1100, Austin, TX 78701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2013/162751 A1

(54) Title: COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE

(57) Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a *Staphylococcus* bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria, in certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa).

DESCRIPTIONCOMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT
NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUSDISEASE

5 [0001] This invention was made with government support under AI092711 and AI052474 AI52767, awarded by the National Institutes of Health. HD009007 training grant to MM, D.M.M. and O.S. acknowledge membership within and support from the Region V “Great Lakes” Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (NIH Award 1-U54-AI-057153) from the National Institute of Allergy 10 and Infectious Diseases (NIAID) and 1-U54-AI-057153 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 61/638,797 filed on April 26, 2012, incorporated herein by reference in its entirety.

I. FIELD OF THE INVENTION

15 [0003] The present invention relates generally to the fields of immunology, microbiology, and pathology. More particularly, it concerns methods and compositions involving antibodies to bacterial proteins and bacterial peptides used to elicit such antibodies. The proteins include Coagulase (Coa).

II. BACKGROUND

20 [0004] North American hospitals are experiencing an epidemic of *Staphylococcus aureus*. This organism causes a wide range of diseases from minor skin infections to life-threatening sepsis, endocarditis, and pneumonia [2]. *S. aureus* is endowed with a wide range of virulence factors that enable its many disease manifestations. One of the defining characteristics of *S. aureus* that distinguishes it from less pathogenic species of staphylococci is its ability to clot 25 anticoagulated blood [48,75]. This characteristic is due to two proteins, coagulase (Coa) and von Willebrand factor binding protein (vWbp). Coa and vWbp bind to and induce a conformational change in host prothrombin, which mimics the transition from the zymogen to activated thrombin, enabling the complex to cleave fibrinogen to fibrin [66,67,71,72,133,146,188]. Fibrin forms the mesh network of a blood clot.

[0005] Coa and vWbp play an important role during the pathogenesis of *S. aureus* infection [212]. Infection with double mutants in *coa* and *vwb* results in delayed mortality in a murine sepsis model and nearly eliminates the ability of staphylococci to form abscesses (Cheng et al 2010). A humoral immune response against Coa and vWbp provides protection 5 against staphylococcal infection (Cheng et al 2010). Pharmacologic inhibition of the coagulases with direct thrombin inhibitors neutralizes the activity of Coa and vWbp and provides prophylactic protection against staphylococcal sepsis [20,177,213].

[0006] *S. aureus* can survive on dry surfaces, increasing the chance of transmission. Any 10 *S. aureus* infection can cause the staphylococcal scalded skin syndrome, a cutaneous reaction to exotoxin absorbed into the bloodstream. *S. aureus* can also cause a type of septicemia called pyaemia that can be life-threatening. Methicillin-resistant *Staphylococcus aureus* (MRSA) has become a major cause of hospital-acquired infections.

[0007] *S. aureus* infections are typically treated with antibiotics, with penicillin being the 15 drug of choice, but vancomycin being used for methicillin resistant isolates. The percentage of staphylococcal strains exhibiting wide-spectrum resistance to antibiotics has increased, posing a threat to effective antimicrobial therapy. In addition, the recent appearance of vancomycin-resistant *S. aureus* strain has aroused fear that MRSA strains for which no effective therapy is available are starting to emerge and spread.

[0008] An alternative approach to antibiotics in the treatment of staphylococcal infections 20 has been the use of antibodies against staphylococcal antigens in passive immunotherapy. Examples of this passive immunotherapy involves administration of polyclonal antisera (WO00/15238, WO00/12132) as well as treatment with monoclonal antibodies against lipoteichoic acid (WO98/57994).

[0009] The first generation of vaccines targeted against *S. aureus* or against the 25 exoproteins it produces have met with limited success (Lee, 1996) and there remains a need to develop additional therapeutic compositions for treatment of staphylococcus infections.

SUMMARY OF THE INVENTION

[0010] *Staphylococcus aureus* is the most frequent cause of bacteremia and hospital-acquired infection in the United States. An FDA approved vaccine that prevents 30 staphylococcal disease is currently unavailable.

[0011] In certain embodiments there are antibody compositions that inhibit, ameliorate, and/or prevent Staphylococcal infection.

[0012] Certain embodiments are directed to methods of inhibiting *Staphylococcus* infection in a patient determined to have or be at risk for *Staphylococcus* infection 5 comprising administering to the patient an effective amount of a Coa binding polypeptide that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide. In some embodiments, the method further comprises administering an effective amount of two or more Coa binding polypeptides. In some embodiments, the method further comprises administering an antibiotic or a Staphylococcal vaccine composition to the patient. In other 10 embodiments, there are methods for treating a patient with or determined to have a *Staphylococcus* infection. In further embodiments, there are methods for preventing a *Staphylococcus* infection.

[0013] In some aspects, the Coa binding polypeptide specifically binds to Domain 1 of a Staphylococcal Coa polypeptide. In other aspects, the Coa binding polypeptide specifically 15 binds to Domain 2 of a Staphylococcal Coa polypeptide. In further embodiments, the Coa binding polypeptide specifically binds to a region on both Domain 1 and Domain 2 of a Staphylococcal Coa polypeptide.

[0014] Certain embodiments are directed to a Coa binding polypeptide that specifically binds to an epitope in a polypeptide encoded by any of SEQ ID NOs: 1-8. In certain aspects, 20 the Coa binding polypeptide specifically binds to an epitope in amino acids 1-149, 150-282, or 1-282 of a polypeptide encoded by any of SEQ ID NOs: 1-8. In certain aspects the epitope comprises at least, or has at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 25 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more contiguous amino acids (or any range derivable therefrom) from any of the sequences provided herein or encoded by any of the sequences provided herein.

[0015] In particular embodiments, the Coa binding polypeptide competes for binding of Staphylococcal Coa polypeptide with the 5D5.4 or 7H4.25 monoclonal antibody. In further 30 embodiments, the monoclonal antibody is 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7. In some embodiments, the Coa binding

polypeptide has an association constant for the Staphylococcal Coa polypeptide of between about 0.5 and 20 nM⁻¹, 1.0 and 10 nM⁻¹, or 1.0 and 6.0 nM⁻¹ as measured by ELISA. In certain embodiments, the Coa binding polypeptide has an association constant for the Staphylococcal Coa Domain 1-2 of between about 0.5 and 20 nM⁻¹ or 1.0 and 10 nM⁻¹ as measured by ELISA.

[0016] The Coa binding polypeptide may be any polypeptide that specifically binds Coa proteins from staphylococcus bacteria. In certain embodiments, the Coa binding polypeptide is a purified monoclonal antibody or a purified polyclonal antibody. The polypeptide may be, for example, an antibody that is single domain, humanized, or chimeric. In some 10 embodiments, two or more Coa binding polypeptides (e.g., two or more purified monoclonal antibodies or purified polyclonal antibodies) may be administered to the patient. In certain aspects, the Coa binding polypeptide is recombinant. In other embodiments, there may be chemical modifications to the polypeptide, such as the addition of one or more chemical 15 modifications or moieties.

[0017] Embodiments are provided in which the Coa binding polypeptide comprises one or more CDR domains from an antibody that specifically binds to Domains 1-2 of a Staphylococcal Coa polypeptide. In particular embodiments, the Coa binding polypeptide comprises one, two, three, four, five, six, or more CDR domains from among the VH or VL domain of the 5D5.4 and 7H4.25 monoclonal antibodies. In certain aspects, the Coa binding 20 polypeptide comprises six CDR domains from among the VH or VL domains of the 5D5.4 and 7H4.25 monoclonal antibodies. In some embodiments, the Coa binding polypeptide comprises a sequence at least or at most 70%, 75%, 80%, 85%, 90%, 95%, or 99% (or any 25 range derivable therefrom) identical to the VH or VL domain of the 5D5.4 or 7H4.25 monoclonal antibodies. Embodiments are provided in which the Coa binding polypeptide comprises the VH domain from the 5D5.4 or 7H4.25 monoclonal antibody and/or the VL domain the 5D5.4 or 7H4.25 monoclonal antibody. In further embodiments, the monoclonal antibody is 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7.

[0018] In some embodiments the Coa binding polypeptide comprises one or more CDR 30 domains from a Coa binding polypeptide that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide and a scaffold from a polypeptide selected from the group consisting of an immunoglobulin, a fibronectin or a S. aureus protein Z.

[0019] The Coa binding polypeptide may be operatively coupled to a second Coa binding polypeptide. In some aspects, the first and second Coa binding peptides are operatively coupled recombinantly. In other aspects, the first and second Coa binding peptides are operatively coupled chemically.

5 [0020] Embodiments are provided in which the Coa binding polypeptide is administered at a dose of about, at least about, or at most about 0.1 mg/kg to 5 mg/kg, 1 mg/kg to 5 mg/kg, 0.1 mg/kg to 1 mg/kg, or 2 mg/kg to 5 mg/kg (or any range derivable therein).

10 [0021] Embodiments also provide a purified polypeptide comprising one or more Coa binding polypeptide CDR domains from an antibody that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide. In certain embodiments, the Coa binding polypeptide competes for binding of a Staphylococcal Coa polypeptide with the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 6C4.15, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 6C10.19, 5D5.4 or 7H4.25 monoclonal antibody. In certain aspects, the polypeptide has an association constant for a Staphylococcal Coa polypeptide of between about 0.1 and 20 nM⁻¹, 0.5 and 10 nM⁻¹, or 1.0 and 10 nM⁻¹ as measured by ELISA. The polypeptide may comprise, for example, a single domain antibody Coa binding polypeptide, a humanized antibody, or a chimeric antibody.

15 [0022] In certain embodiments, the polypeptide is recombinant. In certain aspects, the recombinant polypeptide comprises at least 90%, 95%, or 99% of one or more CDR domains from the VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 5D5.4 or 7H4.25 monoclonal antibodies. In some embodiments, the recombinant polypeptide comprises two, three, four, five, six, or more CDR domains from the VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 5D5.4 and/or 7H4.25 monoclonal antibodies.

20 [0023] In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 4H9.20; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 4H9.20. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 5D5.4; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 5D5.4. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 4B10.44; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of

4B10.44. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 3B3.14; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 3B3.14. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 7H4.25; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 7H4.25. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 2A3.1; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 2A3.1. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 2H10.12; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 2H10.12. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 6D1.22; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 6D1.22. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 6C4.15; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 6C4.15. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 6C10.19; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 6C10.19. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 8C2.9; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 8C2.9. In some embodiments, a recombinant polypeptide comprises i) CDR1, CDR2, and/or CDR3 from the variable light chain of 4F1.7; and/or ii) CDR1, CDR2, and/or CDR3 from the variable heavy chain of 4F1.7. The sequences for these CDRs can be found in Table 5.

[0024] In some embodiments, there is a purified polypeptide comprising one or more Coa binding polypeptide CDR domains from an antibody that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide. As indicated above, the polypeptide may comprise 1, 2, 3, 4, 5, or 6 CDRs from the light and/or heavy chain variable regions of a Coa antibody. Table 5 provides 12 different Coa antibodies and their CDR1, CDR2, and CDR3 sequences from both the light and heavy chain variable regions. In certain embodiments, a polypeptide contains CDR1, CDR2, and/or CDR3 from the light chain variable region of a particular antibody. It is contemplated that while in some embodiments a polypeptide has a CDR1, CDR2, and CDR3 from the variable region of a light chain and/or the variable region of a heavy chain that the CDR1, CDR2, and CDR3 need not be from the same antibody. While some polypeptides have CDR1, CDR2, and CDR3 from the same antibody or based on the same antibody, given

the overlap in amino acid sequences, a CDR1 from one antibody may be substituted with a CDR from or based on another antibody. For example, a polypeptide may comprise a CDR1 from or based on the light chain variable region of 4F1.7, a CDR2 from or based on the light chain variable region of 4F1., but have a CDR3 from or based on the variable light chain region of 6C4.15. It is generally contemplated, however, that when a single set of CDR1, CDR2, and CDR3 are employed together that they all be from a light chain variable region or from a heavy chain variable region, but not a mix from both.

[0025] Alternatively, the polypeptide may contain a CDR1 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:9, 15, 24, 33, 40, 44, 56, and 49, which are CDR1 sequences from the light chain variable region of a Coa antibody. Alternatively or additionally, the polypeptide may contain a CDR2 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:10, 16, 21, 25, and 34, which are CDR2 sequences from the light chain variable region of a Coa antibody. Alternatively or additionally, the polypeptide may contain a CDR3 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:11, 17, 22, 26, 30, 35, 36, 45, and 57, which are CDR3 sequences from the light chain variable region of a Coa antibody. Alternatively or additionally, the polypeptide may contain a CDR1 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:12, 18, 27, 37, 41, 46, 50, 53, and 58, which are CDR1 sequences from the heavy chain variable region of a Coa antibody. Alternatively or additionally, the polypeptide may contain a CDR2 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:13, 19, 28, 31, 38, 43, 47, 51, 54, and 59, which are CDR2 sequences from the heavy chain variable region of a Coa antibody. Alternatively or additionally, the polypeptide may contain a CDR3 sequence that is, is at most or is at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 100% identical (or any range derivable therein) to the entire sequence set forth in SEQ ID NOS:14, 20, 23, 29, 32, 39, 42, 48, 52, 55, and 60, which are CDR3 sequences from the heavy chain variable region of a Coa antibody. It is contemplated that in some embodiments, SEQ ID NO:61 is used in place of

any of SEQ ID NOS:10, 16, 21, 25, and 34. In some embodiments, a CDR2 has the sequence of SEQ ID NO:61.

[0026] Other embodiments provide a recombinant polypeptide that comprises one or more CDR domain from an antibody that specifically binds to Domains 1-2 of a

5 Staphylococcal Coa polypeptide and a scaffold from a polypeptide selected from the group consisting of an immunoglobulin, a fibronectin or a *S. aureus* protein Z. If it further contemplated that any polypeptide may be attached, fused or conjugated to an agent or substance, such a therapeutic moiety or a detectable moiety.

[0027] In certain aspects, the recombinant polypeptide is operatively coupled to a

10 recombinant polypeptide that specifically binds to a second Staphylococcal protein.

[0028] In other embodiments, the polypeptide is an antibody comprising (a) a heavy chain comprising said VH region, and a human hinge, CH1, CH2, and CH3 regions from an IgG1, IgG2, IgG3 or IgG4 subtype; and (b) a light chain comprising said VL region, and either a human kappa CL or human lambda CL.

15 [0029] Certain embodiments provide a purified monoclonal antibody that specifically binds to a Staphylococcal Coa polypeptide, wherein the purified monoclonal antibody is the 5A10, 8E2, 3A6, 7E2, 3F6, 1F10, 6D11, 3D11, 5A11, 1B10, 4C1, 2F2, 8D4, 7D11, 2C3, 4C5, 6B2, 4D5, 2B8, 1H7, 6C10.19 or 6C4.15 monoclonal antibody.

[0030] In some aspects, the purified polypeptide does not consist of the mouse

20 monoclonal antibody that is 4H9.20, 5D5.4, 4B10.44, 3B3.14, 7H4.25, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, and 4F1.7. In other embodiments the purified polypeptide is not an isolated mouse monoclonal antibody.

[0031] Other embodiments provide a pharmaceutical composition comprising one or more purified Coa binding polypeptide. In some embodiments, the pharmaceutical

25 composition provides a single unit dose of the purified polypeptide in a sealed container. The pharmaceutical composition may comprise at least a second anti-bacterial agent including, but not limited to, an antibiotic, a Staphylococcal vaccine composition or a polypeptide that specifically binds to a second Staphylococcal protein.

[0032] Certain embodiments, provide a polynucleotide comprising a nucleic acid sequence encoding a Coa binding polypeptide.

[0033] Other embodiments provide an expression vector comprising a nucleic acid sequence encoding a Coa binding polypeptide operably linked to an expression control sequence. Some embodiments provide a host cell comprising the expression vector.

[0034] Embodiments also provide a method manufacturing a Coa binding polypeptide comprising expressing a nucleic acid sequence encoding the polypeptide operably linked to an expression control sequence in a host cell.

[0035] Embodiments also provide for the use of Coa antibodies in methods and compositions for the treatment of bacterial and/or staphylococcal infection. In certain embodiments, compositions are used in the manufacture of medicaments for the therapeutic and/or prophylactic treatment of bacterial infections, particularly staphylococcus infections. Furthermore, in some embodiments there are methods and compositions that can be used to treat (e.g., limiting staphylococcal abscess formation and/or persistence in a subject) or prevent bacterial infection.

[0036] Certain aspects are directed to methods of reducing Staphylococcus infection or abscess formation comprising administering to a patient having or suspected of having a Staphylococcus infection an effective amount of one or more purified antibodies that specifically bind a Coa polypeptide. The antibody can be a purified polyclonal antibody, a purified monoclonal antibody, a recombinant polypeptide, or a fragment thereof. In certain aspects the antibody is humanized or human. In still further aspects the antibody is a recombinant antibody segment. In certain aspects a monoclonal antibody includes one or more of 5A10, 8E2, 3A6, 7E2, 3F6, 1F10, 6D11, 3D11, 5A11, 1B10, 4C1, 2F2, 8D4, 7D11, 2C3, 4C5, 6B2, 4D5, 2B8, 1H7, 6C10.19 or 6C4.15. An antibody can be administered at a dose of 0.1, 0.5, 1, 5, 10, 50, 100 mg or μ g/kg to 5, 10, 50, 100, 500 mg or μ g/kg, or any range derivable therefrom. The recombinant antibody segment can be operatively coupled to a second recombinant antibody segment. In certain aspects the second recombinant antibody segment binds a second Staphylococcal protein. The method can further comprise administering a second antibody that binds a second Staphylococcal protein. In certain aspects the method further comprises administering an antibiotic.

[0037] Embodiments are directed to monoclonal antibody polypeptides, polypeptides having one or more segments thereof, and polynucleotides encoding the same. In certain aspects a polypeptide can comprise all or part of the heavy chain variable region and/or the light chain variable region of Coa-specific antibodies. In a further aspect, a polypeptide can 5 comprise an amino acid sequence that corresponds to a first, second, and/or third complementary determining regions (CDRs) from the light variable chain and/or heavy variable chain of a Coa-specific antibody.

[0038] In still further aspects, embodiments provide a hybridoma cell line that produces a monoclonal antibody of the embodiments. In embodiments the hybridoma cell line is a line 10 that produces the 5A10, 8E2, 3A6, 7E2, 3F6, 1F10, 6D11, 3D11, 5A11, 1B10, 4C1, 2F2, 8D4, 7D11, 2C3, 4C5, 6B2, 4D5, 2B8, 1H7, 6C10.19 or 6C4.15 monoclonal antibody. In a further aspect, 1, 2, and/or 3 CDRs from the light and/or heavy chain variable region of a MAb can be comprised in a humanized antibody or variant thereof.

[0039] Certain aspects are directed to methods of treating a subject having or suspected 15 of having a *Staphylococcus* infection comprising administering to a patient having or suspected of having a *Staphylococcus* infection an effective amount of a purified antibody or polypeptide that specifically binds a Coa polypeptide.

[0040] In a further aspect methods are directed to treating a subject at risk of a *Staphylococcus* infection comprising administering to a patient at risk of a *Staphylococcus* 20 infection an effective amount of an antibody that binds a Coa polypeptide prior to infection with *Staphylococcus*.

[0041] Certain embodiments are directed to an antibody or binding polypeptide composition comprising an isolated and/or recombinant antibody or polypeptide that specifically binds a peptide segment as described above. In certain aspects the antibody or 25 polypeptide has a sequence that is, is at least, or is at most 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical (or any range derivable therein) to all or part of any monoclonal antibody provided herein.

[0042] In additional embodiments, there are pharmaceutical compositions comprising one or more polypeptides or antibodies or antibody fragments that are discussed herein. Such a 30 composition may or may not contain additional active ingredients.

[0043] In certain embodiments there is a pharmaceutical composition consisting essentially of a polypeptide comprising one or more antibodies or antibody fragments discussed herein. It is contemplated that the composition may contain non-active ingredients.

[0044] Other aspects are directed to pharmaceutical compositions comprising an effective 5 anti-bacterial amount of an antibody that specifically binds to a peptide described above and a pharmaceutically acceptable carrier.

[0045] The term “providing” is used according to its ordinary meaning to indicate “to supply or furnish for use.” In some embodiments, the protein is provided directly by administering a composition comprising antibodies or fragments thereof that are described 10 herein.

[0046] The subject typically will have (e.g., diagnosed with a persistent staphylococcal infection), will be suspected of having, or will be at risk of developing a staphylococcal infection. Compositions include Coa-binding polypeptides in amounts effective to achieve the intended purpose – treatment or protection of Staphylococcal infection. The term 15 “binding polypeptide” refers to a polypeptide that specifically binds to a target molecule, such as the binding of an antibody to an antigen. Binding polypeptides may but need not be derived from immunoglobulin genes or fragments of immunoglobulin genes. More specifically, an effective amount means an amount of active ingredients necessary to provide resistance to, amelioration of, or mitigation of infection. In more specific aspects, an 20 effective amount prevents, alleviates or ameliorates symptoms of disease or infection, or prolongs the survival of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any preparation used in the methods described herein, an effective amount or dose can be estimated initially from *in vitro*, cell culture, and/or animal 25 model assays. For example, a dose can be formulated in animal models to achieve a desired response. Such information can be used to more accurately determine useful doses in humans.

[0047] Compositions can comprise an antibody that binds Coa. An antibody can be an antibody fragment, a humanized antibody, a monoclonal antibody, a single chain antibody or 30 the like. In certain aspects, the Coa antibody is elicited by providing a Coa peptide or antigen or epitope that results in the production of an antibody that binds Coa in the subject. The Coa

antibody is typically formulated in a pharmaceutically acceptable composition. The Coa antibody composition can further comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 for more staphylococcal antigens or immunogenic fragments thereof. Staphylococcal antigens include, but are not limited to all or a segment of Eap, Ebh, Emp, 5 EsaB, EsaC, EsxA, EsxB, IsdA, IsdB, SdrC, SdrD, SdrE, ClfA, ClfB, Coa, Hla (e.g., H35 mutants), IsdC, SasF, vWa, SpA and variants thereof (See U.S. Provisional Application serial numbers 61/166,432, filed April 3, 2009; 61/170,779, filed April 20, 2009; and 61/103,196, filed October 6, 2009; each of which is incorporated herein by reference in their entirety), vWh, 52kDa vitronectin binding protein (WO 01/60852), Aaa (GenBank CAC80837), Aap 10 (GenBank accession AJ249487), Ant (GenBank accession NP_372518), autolysin glucosaminidase, autolysin amidase, Cna, collagen binding protein (US6288214), EFB (FIB), Elastin binding protein (EbpS), EPB, FbpA, fibrinogen binding protein (US6008341), Fibronectin binding protein (US5840846), FnbA, FnbB, GehD (US 2002/0169288), HarA, HBP, Immunodominant ABC transporter, IsaA/PisA, laminin receptor, Lipase GehD, MAP, 15 Mg²⁺ transporter, MHC II analogue (US5648240), MRPII, Npase, RNA III activating protein (RAP), SasA, SasB, SasC, SasD, SasK, SBI, SdrF(WO 00/12689), SdrG / Fig (WO 00/12689), SdrH (WO 00/12689), SEA exotoxins (WO 00/02523), SEB exotoxins (WO 00/02523), SitC and Ni ABC transporter, SitC/MntC/saliva binding protein (US5,801,234), SsaA, SSP-1, SSP-2, and/or Vitronectin binding protein (see PCT publications 20 WO2007/113222, WO2007/113223, WO2006/032472, WO2006/032475, WO2006/032500, each of which is incorporated herein by reference in their entirety). The staphylococcal antigen, or immunogenic fragment or segment can be administered concurrently with the Coa antibody. The staphylococcal antigen or immunogenic fragment and the Coa antibody can be administered in the same or different composition and at the same or different times. The 25 composition may comprises multiple (e.g., 2, 3, 4, or more) Coa antibodies that bind Coa polypeptides from multiple strains of *S. aureus*.

[0048] The Coa antibody composition can further comprise antibodies, antibody fragments or antibody subfragments to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 16, 17, 18, or 19 of more (or any range derivable therein) staphylococcal antigens or immunogenic fragments thereof. Staphylococcal antigens to which such antibodies, antibody fragments of antibody subfragments are directed include, but are not limited to all or a segment of Eap, Ebh, Emp, EsaB, EsaC, EsxA, EsxB, IsdA, IsdB, SdrC, SdrD, SdrE, ClfA, ClfB, Coa, Hla (e.g., H35 mutants), IsdC, SasF, vWa, SpA and variants thereof (See U.S.

Provisional Application serial numbers 61/166,432, filed April 3, 2009; 61/170,779, filed April 20, 2009; and 61/103,196, filed October 6, 2009; each of which is incorporated herein by reference in their entirety), vWh, 52kDa vitronectin binding protein (WO 01/60852), Aaa (GenBank CAC80837), Aap (GenBank accession AJ249487), Ant (GenBank accession 5 NP_372518), autolysin glucosaminidase, autolysin amidase, Cna, collagen binding protein (US6288214), EFB (FIB), Elastin binding protein (EbpS), EPB, FbpA, fibrinogen binding protein (US6008341), Fibronectin binding protein (US5840846), FnbA, FnbB, GehD (US 2002/0169288), HarA, HBP, Immunodominant ABC transporter, IsaA/PisA, laminin 10 receptor, Lipase GehD, MAP, Mg²⁺ transporter, MHC II analogue (US5648240), MRPII, 15 Npase, RNA III activating protein (RAP), SasA, SasB, SasC, SasD, SasK, SBI, SdrF(WO 00/12689), SdrG / Fig (WO 00/12689), SdrH (WO 00/12689), SEA exotoxins (WO 00/02523), SEB exotoxins (WO 00/02523), SitC and Ni ABC transporter, SitC/MntC/saliva 20 binding protein (US5,801,234), SsaA, SSP-1, SSP-2, and/or Vitronectin binding protein (see PCT publications WO2007/113222, WO2007/113223, WO2006/032472, WO2006/032475, WO2006/032500, each of which is incorporated herein by reference in their entirety). The 15 antibodies, antibody fragments or antibody subfragments to other staphylococcal antigens or immunogenic fragments thereof can be administered concurrently with the Coa antibody. The antibodies, antibody fragments or antibody subfragments to other staphylococcal antigens or immunogenic fragments thereof can be administered in the same or different 20 composition to the Coa antibody and at the same or different times.

[0049] Embodiments include compositions that contain or do not contain a bacterium. A composition may or may not include an attenuated or viable or intact staphylococcal bacterium. In certain aspects, the composition comprises a bacterium that is not a Staphylococci bacterium or does not contain Staphylococci bacteria. In certain embodiments 25 a bacterial composition comprises an isolated or recombinantly expressed Coa antibody or a nucleic acid encoding the same. In still further aspects, the Coa antibody is multimerized, e.g., a dimer, a trimer, a tetramer, etc.

[0050] In certain aspects, a peptide or an antigen or an epitope can be presented as multimers of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peptide segments or peptide mimetics.

30 [0051] The term “isolated” can refer to a nucleic acid or polypeptide that is substantially free of cellular material, bacterial material, viral material, or culture medium (when produced by recombinant DNA techniques) of their source of origin, or chemical precursors or other

chemicals (when chemically synthesized). Moreover, an isolated compound refers to one that can be administered to a subject as an isolated compound; in other words, the compound may not simply be considered “isolated” if it is adhered to a column or embedded in an agarose gel. Moreover, an “isolated nucleic acid fragment” or “isolated peptide” is a nucleic acid or 5 protein fragment that is not naturally occurring as a fragment and/or is not typically in the functional state.

[0052] Compositions such as antibodies, peptides, antigens, or immunogens may be conjugated or linked covalently or noncovalently to other moieties such as adjuvants, 10 proteins, peptides, supports, fluorescence moieties, or labels. The term “conjugate” or “immunoconjugate” is broadly used to define the operative association of one moiety with another agent and is not intended to refer solely to any type of operative association, and is particularly not limited to chemical “conjugation.” Recombinant fusion proteins are particularly contemplated.

[0053] The term “Coa antibody” refers to an antibody that specifically binds Coa proteins 15 from staphylococcus bacteria. In certain embodiments the antibody may bind a specific Coa protein from a particular staphylococcus bacteria strain.

[0054] In further aspects a composition may be administered more than one time to the subject, and may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more times (or any range derivable therein). The administration of the compositions include, but is not limited to 20 oral, parenteral, subcutaneous and intravenous administration, or various combinations thereof, including inhalation or aspiration.

[0055] Compositions are typically administered to human subjects, but administration to other animals that are capable of providing a therapeutic benefit against a staphylococcus bacterium are contemplated, particularly cattle, horses, goats, sheep, birds and other 25 domesticated animals. In further aspects the staphylococcus bacterium is a *Staphylococcus aureus*. In still further aspects, the methods and compositions may be used to prevent, ameliorate, reduce, or treat infection of tissues or glands. Other methods include, but are not limited to prophylactically reducing bacterial burden in a subject not exhibiting signs of 30 infection, particularly those subjects suspected of or at risk of being colonized by a target bacteria, e.g., patients that are or will be at risk or susceptible to infection during a hospital stay, treatment, and/or recovery.

[0056] Still further embodiments include methods for providing a subject a protective or therapeutic composition against a staphylococcus bacterium comprising administering to the subject an effective amount of a composition including (i) a Coa antibody; or, (ii) a nucleic acid molecule encoding the same, or (iii) administering an Coa antibody with any combination or permutation of bacterial proteins described herein.

5 [0057] The embodiments in the Example section are understood to be embodiments that are applicable to all aspects of the invention, including compositions and methods.

10 [0058] The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” It is also contemplated that anything listed using the term “or” may also be specifically excluded.

[0059] Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

15 [0060] Following long-standing patent law, the words “a” and “an,” when used in conjunction with the word “comprising” in the claims or specification, denotes one or more, unless specifically noted.

20 [0061] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

25 [0062] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

[0063] So that the matter in which the above-recited features, advantages and objects of the invention as well as others which will become clear are attained and can be understood in detail, more particular descriptions and certain embodiments of the invention briefly summarized above are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate certain embodiments of the invention and therefore are not to be considered limiting in their scope.

[0064] FIGs. 1A – 1B: Illustrations of the primary structure of coagulase from *S. aureus* Newman (Coa_{NM}) and the regions of coagulase targeted by certain Coa-specific monoclonal antibodies. FIG. 1A shows an illustration of the primary structure of coagulase from *S. aureus* Newman (Coa_{NM}), which was purified via an N-terminal His₆ tag from *E. coli*. Coa_{NM} encompasses the D1 and D2 domains involved in prothrombin binding, the linker (L) domain and the Repeat (R) domain, which is comprised of tandem repeats of a 27 residue peptide sequence that binds to fibrinogen. In addition to Coa_{NM}, the D1_{Coa}, D2_{Coa}, D12_{Coa}, L_{Coa}, and R_{Coa} domains as well as a construct of D1_{Coa} without amino acids 1-18, D1_{Δ1-18}, were purified with N-terminal His₆ tags. FIG. 1B shows an illustration of the regions of coagulase targeted by Coa-specific monoclonal antibodies 5D5, 8C2, 6C10, 3B3, 6C4, and 7H4.

[0065] FIGs. 2A – 2B: Mab 5D5.4 disrupts Coa-prothrombin activity. (A) Coa-prothrombin enzymatic activity was measured with chromogenic substrate S-2238. Following pre-incubation with Mab 5D5.4 or (ATCC Accession number ____) polyclonal purified α -Coa, activity was reduced. Statistical analysis was assessed using 1-way ANOVA followed by a post-hoc Dunnett's multiple comparison test. (B) The association of Coa_{NM} with human prothrombin was measured by ELISA and perturbed with increasing concentrations Mab 5D5.4 or control IgG1. Compared to isotype control, * P < 0.05, ** P < 0.01.

[0066] FIGs. 3A – 3B: Protective value of coagulation-neutralizing antibodies. Monoclonal antibodies 5D5.4, 7H4.25, (ATCC Accession number ____) or IgG1 isotype control (A) or 8C2.9 or IgG2a isotype control (B) were injected at a concentration of 5mg·kg⁻¹ body weight into the peritoneal cavity of naïve BALB/c mice. Passively immunized mice

were challenged by intravenous injection with *S. aureus* Newman isogenic mutant *vwb* (2×10^8 CFU) and survival of animals was monitored over 10 days.

[0067] **FIG. 4: Cross-protection of Mab 5D5.4 toward infection by clinical isolates of different Coa serotypes.** Monoclonal antibody 5D5.4 or IgG1 isotype control was 5 injected at a concentration of $5\text{mg}\cdot\text{kg}^{-1}$ body weight into the peritoneal cavity of naïve BALB/c mice. Passively immunized mice were challenged by intravenous injection with *S. aureus* strains (A) N315 (1×10^8 CFU) or (B) MW2 (2×10^8 CFU), and survival of animals was monitored over 10 days.

[0068] **FIGS. 5A-D:** Mice received intraperitoneal injections of 5D5.4 or an IgG1 10 isotype control, and were subsequently infected with a lethal dose of *S. aureus* strains Newman (Coa type III) (FIG. 5A), N315 (Coa type II) (FIG. 5B), CowanI (Coa type IV) (FIG. 5C), or MW2 (Coa type VII) (FIG. 5D), and were monitored over a ten-day 15 observation period to assess their protective role. 5D5.4 treatment resulted in a delay in time-to-death for animals challenged with strains Newman (IgG1 vs 5D5.4, $P < 0.01$), N315 (IgG1 vs. 5D5.4, $P < 0.05$), CowanI (IgG1 vs. 5D5.4, $P < 0.05$) or MW2 (IgG1 vs. 5D5.4, $P < 0.05$).

[0069] **FIGs. 6A – 6D: Monoclonal antibodies that recognize CT_{Coa}.** (A-B) The 20 association of CT_{Coa} with human fibrinogen was measured by ELISA and perturbed with increasing concentrations Mab 3B3.14 or control IgG1 (A) or Mab 6C4.15 or control IgG2b (B). Compared to isotype control, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. (C-D) Monoclonal antibody 3B3.14 or IgG1 control (C) or 6C4.15 or IgG2b (D) was injected at a concentration 25 of $5\text{mg}\cdot\text{kg}^{-1}$ body weight into the peritoneal cavity of naïve BALB/c mice. Passively immunized mice were challenged by intravenous injection with *S. aureus* strain *vwb* and survival of animals was monitored over 10 days.

[0070] **FIGS. 7A-D:** Mice received intraperitoneal injections of 3B3.14 or IgG1 isotype 25 control, and were subsequently infected with a lethal dose of *S. aureus* clinical isolate USA300 (Coa type III) (FIG. 7A), N315 (Coa type II) (FIG. 7B), CowanI (Coa type IV) (FIG. 7C), or MW2 (Coa type VII) (FIG. 7D), and were monitored over a ten-day observation period to assess their protective role. 3B3.14 did not protect mice against challenge with the wildtype Newman (IgG1 vs. 3B3.14 $p > 0.05$ FIG. 7A), N315 (IgG1 vs. 30 3B3.14 $p > 0.05$ FIG. 7B), or MW2 (IgG1 vs. 3B3.14 $p > 0.05$ FIG. 7D). 3B3.14 provided a

modest delay in time to death following challenge with strain CowanI (IgG1 vs. 3B3.14 p<0.001; FIG. 7C).

[0071] **FIG. 8:** Alignment of Coa sequences from USA300 (SEQ ID NO: 1), N315 (SEQ ID NO: 2), MRSA252 (SEQ ID NO: 4), MW2 (SEQ ID NO: 3), and WIS (SEQ ID NO: 5).

5

DETAILED DESCRIPTION OF THE INVENTION

[0072] *Staphylococcus aureus* is a commensal of the human skin and nares, and the leading cause of bloodstream, skin and soft tissue infections (Klevens *et al.*, 2007). Recent dramatic increases in the mortality of staphylococcal diseases are attributed to the spread of 10 methicillin-resistant *S. aureus* (MRSA) strains often not susceptible to antibiotics (Kennedy *et al.*, 2008). In a large retrospective study, the incidence of MRSA infections was 4.6% of all hospital admissions in the United States (Klevens *et al.*, 2007). The annual health care costs for 94,300 MRSA infected individuals in the United States exceed \$2.4 billion (Klevens *et al.*, 2007). The current MRSA epidemic has precipitated a public health crisis that needs to 15 be addressed by development of a preventive vaccine (Boucher and Corey, 2008). To date, an FDA licensed vaccine that prevents *S. aureus* diseases is not available.

Coagulase (Coa) is an important virulence factor in the pathogenesis of staphylococcal sepsis. The conversion of fibrinogen to fibrin by the Coa:prothrombin complex enables *Staphylococcus aureus* to evade immune defenses and disseminate throughout the body. 20 Humoral immunity toward Coa is protective in a murine sepsis model. Previous work demonstrated that there are protective epitopes in both the N- and C-terminus and that there is type-specific immunity, attributable to the genetic variation in the N-terminus of Coa among strains.

The inventors describe here staphylococcal coagulase-binding antibodies and the antigen 25 binding determinants thereof. In particular, a panel of monoclonal antibodies were generated against Coa and characterized based on their affinity for individual domains of the protein and their disturbance of clotting. Based on *in vitro* characteristics, several monoclonal antibodies were tested for protection in a murine sepsis model resulting in the identification 30 of a protective epitope in the conserved portion of the N-terminus. Importantly, antibodies targeting this epitope are able, when administered to animals, to reduce Staphylococcal sepsis following challenge with virulent *S. aureus*. Because these molecules are able to block the

prothrombin-activating effects of Coa, such antibodies may also enhance host immune response following staphylococcal infection. Thus, the Coa-binding molecules of the embodiments offer a new and effective avenue to treat or prevent staphylococcal disease.

I. COAGULASE POLYPEPTIDES

5 [0073] Certain aspects of the embodiments concern coagulase (Coa) polypeptides. An illustration of the primary structure of Coa from *S. Aureus* Newman (Coa_{NM}) is provided in FIG. 1A. Nucleic acid sequences for Coa from eight *S. aureus* strains are provided in SEQ ID NOS: 1-8 as follows: USA300 (SEQ ID NO: 1), N315 (SEQ ID NO: 2), MW2 (SEQ ID NO: 3), MRSA252 (SEQ ID NO: 4), WIS (SEQ ID NO: 5), MU50 (SEQ ID NO: 6), 85/2082 (SEQ ID NO: 7), and Newman (SEQ ID NO: 8). An alignment of Coa sequences from USA300 (SEQ ID NO: 1), N315 (SEQ ID NO: 2), MRSA252 (SEQ ID NO: 4), MW2 (SEQ ID NO: 3), and WIS (SEQ ID NO: 5) is provided in FIG. 6.

10 [0074] Coagulase interacts with host prothrombin through its N-terminal domains, D1 and D2. The three-helix bundles of D1 and D2 share structural similarity but are poorly 15 conserved at the sequence level [66]. The first 150 amino acids comprise the D1 domain [68]. The amino-terminal tetrapeptide of Coa inserts into the activation pocket of prothrombin and forms a salt bridge with prothrombin Asp194 [66]. The first of two high-affinity binding interactions between Coa and prothrombin occurs through a hydrophobic surface groove in 20 D1 with the 148 loop of prothrombin [66]. SC₁₅₀₋₂₈₂ comprises the D2 domain [68]. The second high-affinity binding interaction is between the side chain of Tyr76 of the prothrombin exosite I and D2 alpha helices [66]. Coa forms a dimer in solution, with each 25 monomer binding one molecule of prothrombin [66]. A complex formed by prothrombin and a recombinant construct of the D1D2 domain (SC₁₋₃₂₅) is able to bind fibrinogen through a distinct interaction from the substrate binding exosite on prothrombin [133].

25 [0075] Two other domains of Coa are less well understood. Following D2, there is a highly conserved Linker (L) region with unknown function [77]. Near the C-terminus is a region of tandem repeats of a 27 amino acid peptide, and the number of repeats varies among strains [77]. The repeat region is thought to be responsible for high affinity binding to fibrinogen [133,214].

30 [0076] The gene encoding Coa (*coa*) is found on all *S. aureus* chromosomes, yet it is one of the most variable proteins, with twelve known types (Watanabe et al 2005, Watanabe et al

2009). The majority of variability among Coa alleles resides in the D1 and D2 domains. The linker region is relatively conserved with 86.7% identity among serotypes (Watanabe et al 2005). Of note, the amino terminal end of mature Coa, i.e. the first seven residues following the signal peptidase cleavage site, activate prothrombin and these residues are conserved 5 among all strains analyzed [68]. The C-terminal tandem repeats of a 27 residue peptide vary in number from five to nine but have greater than 90% identity among serotypes (Watanabe et al 2005). Antibodies that recognize epitopes in SC₁₋₂₈₂ are necessary to block the enzymatic activities of the Coa-prothrombin complex [215]. *In vivo*, antibodies against the C-terminal repeats also confer protection [215], though the mechanism of protection is not yet 10 clear.

[0077] Coa polypeptides can be used as subunit vaccines and raise humoral immune responses and confer protective immunity against *S. aureus* challenge. In certain embodiments, polyvalent vaccines targeting Coa variation across multiple *S. aureus* strains are contemplated. This embodiment is discussed in a U.S. Provisional Patent Application 15 filed on April 26, 2012 entitled “STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF THEIR USE” in the names of Molly McAdow, Andrea DeDent, Alice Cheng, Carla Emolo, Dominique Missiakas, Olaf Schneewind, which is hereby incorporated by reference in its entirety.

II. PROTEINACEOUS COMPOSITIONS

20 [0078] Proteins may be recombinant, or synthesized *in vitro*. Alternatively, a non-recombinant or recombinant protein may be isolated from bacteria. It is also contemplated that a bacteria containing such a variant may be implemented in compositions and methods. Consequently, a protein need not be isolated.

25 [0079] The term “functionally equivalent codon” is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids (see Codon Table, below).

Codon Table

Amino Acids			Codons
Alanine	Ala	A	GCA GCC GCG GCU
Cysteine	Cys	C	UGC UGU
Aspartic acid	Asp	D	GAC GAU
Glutamic acid	Glu	E	GAA GAG
Phenylalanine	Phe	F	UUC UUU
Glycine	Gly	G	GGA GGC GGG GGU
Histidine	His	H	CAC CAU
Isoleucine	Ile	I	AUA AUC AUU
Lysine	Lys	K	AAA AAG
Leucine	Leu	L	UUA UUG CUA CUC CUG CUU
Methionine	Met	M	AUG
Asparagine	Asn	N	AAC AAU
Proline	Pro	P	CCA CCC CCG CCU
Glutamine	Gln	Q	CAA CAG
Arginine	Arg	R	AGA AGG CGA CGC CGG CGU
Serine	Ser	S	AGC AGU UCA UCC UCG UCU
Threonine	Thr	T	ACA ACC ACG ACU
Valine	Val	V	GUU GUC GUG GUU
Tryptophan	Trp	W	UGG
Tyrosine	Tyr	Y	UAC UAU

[0080] It also will be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids, or 5' or 3' sequences,

5 respectively, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region.

10 [0081] Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide, with or without the loss of other functions or properties. Substitutions may be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for 15 example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine;

tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Alternatively, substitutions may be non-conservative such that a function or activity of the polypeptide is affected. Non-conservative changes typically involve substituting a residue with one that is chemically dissimilar, such as a polar or charged amino acid for a nonpolar or uncharged amino acid, and vice versa.

[0082] The following is a discussion based upon changing of the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence, and in its underlying DNA coding sequence, and nevertheless produce a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the DNA sequences of genes without appreciable loss of their biological utility or activity.

[0083] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

[0084] It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.

[0085] As outlined above, amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity,

hydrophilicity, charge, size, and the like. Exemplary substitutions that take into consideration the various foregoing characteristics are well known and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

5 [0086] It is contemplated that in compositions there is between about 0.001 mg and about 10 mg of total polypeptide, peptide, and/or protein per ml. Thus, the concentration of protein in a composition can be about, at least about or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg/ml or more (or any range derivable therein). Of this, about, at least 10 about, or at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 15 97, 98, 99, 100% may be an antibody that binds Coa, and may be used in combination with other staphylococcal proteins or protein-binding antibodies described herein.

A. Polypeptides and Polypeptide Production

20 [0087] Embodiments involve polypeptides, peptides, and proteins and immunogenic fragments thereof for use in various aspects described herein. For example, specific antibodies are assayed for or used in neutralizing or inhibiting Staphylococcal infection. In specific embodiments, all or part of proteins described herein can also be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, (1984); Tam *et al.*, (1983); Merrifield, (1986); and Barany and Merrifield (1979), each incorporated herein by reference. Alternatively, 25 recombinant DNA technology may be employed wherein a nucleotide sequence that encodes a peptide or polypeptide is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression.

30 [0088] One embodiment includes the use of gene transfer to cells, including microorganisms, for the production and/or presentation of proteins. The gene for the protein of interest may be transferred into appropriate host cells followed by culture of cells under the appropriate conditions. A nucleic acid encoding virtually any polypeptide may be employed. The generation of recombinant expression vectors, and the elements included

therein, are discussed herein. Alternatively, the protein to be produced may be an endogenous protein normally synthesized by the cell used for protein production.

[0089] In a certain aspects an immunogenic Coa fragment comprises substantially all of the D1 and/or D2 domains of a Coa protein isolatable from *S. aureus*.

5 [0090] Also included in immunogenic compositions are fusion proteins composed of Staphylococcal proteins, or immunogenic fragments of staphylococcal proteins (e.g., Coa). Alternatively, embodiments also include individual fusion proteins of Staphylococcal proteins or immunogenic fragments thereof, as a fusion protein with heterologous sequences such as a provider of T-cell epitopes or purification tags, for example: β -galactosidase, 10 glutathione-S-transferase, green fluorescent proteins (GFP), epitope tags such as FLAG, myc tag, poly histidine, or viral surface proteins such as influenza virus haemagglutinin, or bacterial proteins such as tetanus toxoid, diphtheria toxoid, CRM197.

B. Antibodies and Antibody-Like Molecules

15 [0091] In certain aspects, one or more antibodies or antibody-like molecules (e.g., polypeptides comprsing antibody CDR domains) may be obtained or produced which have a specificity for an Coa. In particular embodiments, one or more antibodies or antibody-like molecules (e.g., polypeptides comprsing antibody CDR domains) may be obtained or produced which have a specificity for the D1 and/or D2 domain of Coa. These antibodies may be used in various diagnostic or therapeutic applications described herein.

20 [0092] As used herein, the term "antibody" is intended to refer broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD and IgE as well as polypeptides comprsing antibody CDR domains that retain antigen binding activity. Thus, the term "antibody" is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab', Fab, F(ab')₂, single domain antibodies (DABs), 25 Fv, scFv (single chain Fv), and polypeptides with antibody CDRs, scaffolding domains that display the CDRs (e.g., anticalins) or a nanobody. For example, the nanobody can be antigen-specific VHH (e.g., a recombinant VHH) from a camelid IgG2 or IgG3, or a CDR-displaying frame from such camelid Ig. The techniques for preparing and using various antibody-based constructs and fragments are well known in the art. Means for preparing and 30 characterizing antibodies are also well known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).

[0093] “Mini-antibodies” or “minibodies” are also contemplated for use with embodiments. Minibodies are sFv polypeptide chains which include oligomerization domains at their C-termini, separated from the sFv by a hinge region. Pack *et al.* (1992). The oligomerization domain comprises self-associating α -helices, *e.g.*, leucine zippers, that can

5 be further stabilized by additional disulfide bonds. The oligomerization domain is designed to be compatible with vectorial folding across a membrane, a process thought to facilitate *in vivo* folding of the polypeptide into a functional binding protein. Generally, minibodies are produced using recombinant methods well known in the art. See, *e.g.*, Pack *et al.* (1992); Cumber *et al.* (1992).

10 [0094] Antibody-like binding peptidomimetics are also contemplated in embodiments. Liu *et al.* (2003) describe “antibody like binding peptidomimetics” (ABiPs), which are peptides that act as pared-down antibodies and have certain advantages of longer serum half-life as well as less cumbersome synthesis methods.

15 [0095] Alternative scaffolds for antigen binding peptides, such as CDRs are also available and can be used to generate Coa-binding molecules in accordance with the embodiments. Generally, a person skilled in the art knows how to determine the type of protein scaffold on which to graft at least one of the CDRs arising from the original antibody. More particularly, it is known that to be selected such scaffolds must meet the greatest 20 number of criteria as follows (Skerra, 2000): good phylogenetic conservation; known three-dimensional structure (as, for example, by crystallography, NMR spectroscopy or any other technique known to a person skilled in the art); small size; few or no post-transcriptional modifications; and/or easy to produce, express and purify.

25 [0096] The origin of such protein scaffolds can be, but is not limited to, the structures selected among: fibronectin and preferentially fibronectin type III domain 10, lipocalin, anticalin (Skerra, 2001), protein Z arising from domain B of protein A of *Staphylococcus aureus*, thioredoxin A or proteins with a repeated motif such as the “ankyrin repeat” (Kohl *et al.*, 2003), the “armadillo repeat”, the “leucine-rich repeat” and the “tetratricopeptide repeat”. For example, anticalins or lipocalin derivatives are a type of binding proteins that have 30 affinities and specificities for various target molecules and can be used as SpA binding molecules. Such proteins are described in US Patent Publication Nos. 20100285564, 20060058510, 20060088908, 20050106660, and PCT Publication No. WO2006/056464, incorporated herein by reference.

[0097] Scaffolds derived from toxins such as, for example, toxins from scorpions, insects, plants, mollusks, etc., and the protein inhibitors of neuronal NO synthase (PIN) may also be used in certain aspects.

[0098] Monoclonal antibodies (MAbs) are recognized to have certain advantages, *e.g.*, 5 reproducibility and large-scale production. Embodiments include monoclonal antibodies of the human, murine, monkey, rat, hamster, rabbit and chicken origin.

[0099] “Humanized” antibodies are also contemplated, as are chimeric antibodies from mouse, rat, or other species, bearing human constant and/or variable region domains, bispecific antibodies, recombinant and engineered antibodies and fragments thereof. As used 10 herein, the term “humanized” immunoglobulin refers to an immunoglobulin comprising a human framework region and one or more CDR's from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR's is called the “donor” and the human immunoglobulin providing the framework is called the “acceptor”. A “humanized antibody” is an antibody comprising a humanized light chain and a humanized 15 heavy chain immunoglobulin.

1. Methods for Generating Antibodies

[00100] Methods for generating antibodies (*e.g.*, monoclonal antibodies and/or 20 monoclonal antibodies) are known in the art. Briefly, a polyclonal antibody is prepared by immunizing an animal with a Coa polypeptide or a portion thereof in accordance with embodiments and collecting antisera from that immunized animal.

[00101] A wide range of animal species can be used for the production of antisera. Typically the animal used for production of antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat. The choice of animal may be decided upon the ease of manipulation, costs or the desired amount of sera, as would be known to one of skill in the art. It will be 25 appreciated that antibodies can also be produced transgenically through the generation of a mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom. In connection with the transgenic production in mammals, antibodies can be produced in, and recovered from, the milk of goats, cows, or other mammals. See, *e.g.*, U.S. Pat. Nos. 5,827,690, 30 5,756,687, 5,750,172, and 5,741,957.

[00102] As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Suitable adjuvants include any acceptable immunostimulatory compound, such as cytokines, chemokines, cofactors, toxins, plasmodia, synthetic compositions or vectors encoding such adjuvants.

[00103] Adjuvants that may be used in accordance with embodiments include, but are not limited to, IL-1, IL-2, IL-4, IL-7, IL-12, -interferon, GM-CSF, BCG, aluminum hydroxide, MDP compounds, such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, and monophosphoryl lipid A (MPL). RIBI, which contains three components extracted from bacteria, MPL, trehalose dimycolate (TDM) and cell wall skeleton (CWS) in a 2% squalene/Tween 80 emulsion is also contemplated. MHC antigens may even be used. Exemplary adjuvants may include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and/or aluminum hydroxide adjuvant.

[00104] In addition to adjuvants, it may be desirable to coadminister biologic response modifiers (BRM), which have been shown to upregulate T cell immunity or downregulate suppressor cell activity. Such BRMs include, but are not limited to, Cimetidine (CIM; 1200 mg/d) (Smith/Kline, PA); low-dose Cyclophosphamide (CYP; 300 mg/m²) (Johnson/ Mead, NJ), cytokines such as -interferon, IL-2, or IL-12 or genes encoding proteins involved in immune helper functions, such as B-7.

[00105] The amount of immunogen composition used in the production of antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen including but not limited to subcutaneous, intramuscular, intradermal, intraepidermal, intravenous and intraperitoneal. The production of antibodies may be monitored by sampling blood of the immunized animal at various points following immunization.

[00106] A second, booster dose (e.g., provided in an injection), may also be given. The process of boosting and titrating is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate MAbs.

[00107] For production of rabbit polyclonal antibodies, the animal can be bled through an ear vein or alternatively by cardiac puncture. The removed blood is allowed to coagulate and then centrifuged to separate serum components from whole cells and blood clots. The serum may be used as is for various applications or else the desired antibody fraction may be 5 purified by well-known methods, such as affinity chromatography using another antibody, a peptide bound to a solid matrix, or by using, *e.g.*, protein A or protein G chromatography, among others.

[00108] MAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference. Typically, this 10 technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified protein, polypeptide, peptide or domain, be it a wild-type or mutant composition. The immunizing composition is administered in a manner effective to stimulate antibody producing cells.

[00109] The methods for generating monoclonal antibodies (MAbs) generally begin along 15 the same lines as those for preparing polyclonal antibodies. In some embodiments, Rodents such as mice and rats are used in generating monoclonal antibodies. In some embodiments, rabbit, sheep or frog cells are used in generating monoclonal antibodies. The use of rats is well known and may provide certain advantages (Goding, 1986, pp. 60-61). Mice (*e.g.*, BALB/c mice) are routinely used and generally give a high percentage of stable fusions.

[00110] The animals are injected with antigen, generally as described above. The antigen 20 may be mixed with adjuvant, such as Freund's complete or incomplete adjuvant. Booster administrations with the same antigen or DNA encoding the antigen may occur at approximately two-week intervals.

[00111] Following immunization, somatic cells with the potential for producing 25 antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Generally, spleen cells are a rich source of antibody-producing cells that are in the dividing plasmablast stage. Typically, peripheral blood cells may be readily obtained, as peripheral blood is easily accessible.

[00112] In some embodiments, a panel of animals will have been immunized and the 30 spleen of an animal with the highest antibody titer will be removed and the spleen

lymphocytes obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

[00113] The antibody producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma producing fusion procedures preferably are non antibody producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).

[00114] Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3 X63/Ag8, X63 Ag8.653, NS1/I.Ag 4.1, Sp210 Ag14, FO, NSO/U, MPC 11, MPC11 X45 GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3 Ag 1.2.3, IR983F and 4B210; and U 266, GM1500 GRG2, LICR LON HMy2 and UC729 6 are all useful in connection with human cell fusions. See Yoo *et al.* (2002), for a discussion of myeloma expression systems.

[00115] One murine myeloma cell is the NS-1 myeloma cell line (also termed P3-NS-1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8 azaguanine resistant mouse murine myeloma SP2/0 non producer cell line.

[00116] Methods for generating hybrids of antibody producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter *et al.*, (1977). The use of electrically induced fusion methods is also appropriate (Goding pp. 71-74, 1986).

[00117] Fusion procedures usually produce viable hybrids at low frequencies, about 1×10^{-6} to 1×10^{-8} . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that

would normally continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both 5 purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine.

[00118] The preferred selection medium is HAT. Only cells capable of operating 10 nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, *e.g.*, hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the 15 only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.

[00119] This culturing provides a population of hybridomas from which specific 20 hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.

[00120] The selected hybridomas would then be serially diluted and cloned into individual 25 antibody producing cell lines, which clones can then be propagated indefinitely to provide MAbs. The cell lines may be exploited for MAb production in two basic ways. First, a sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion (*e.g.*, a syngeneic mouse). Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. The injected animal develops tumors secreting the specific monoclonal antibody produced by the 30 fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide MAbs in high concentration. Second, the individual cell lines could be

cultured *in vitro*, where the MAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations.

[00121] Further, expression of antibodies (or other moieties therefrom) from production cell lines can be enhanced using a number of known techniques. For example, the glutamine synthetase and DHFR gene expression systems are common approaches for enhancing expression under certain conditions. High expressing cell clones can be identified using conventional techniques, such as limited dilution cloning and Microdrop technology. The GS system is discussed in whole or part in connection with European Patent Nos. 0 216 846, 0 256 055, and 0 323 997 and European Patent Application No. 89303964.4.

[00122] MAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography. Fragments of the monoclonal antibodies can be obtained from the monoclonal antibodies so produced by methods which include digestion with enzymes, such as pepsin or papain, and/or by cleavage of disulfide bonds by chemical reduction.

Alternatively, monoclonal antibody fragments can be synthesized using an automated peptide synthesizer.

[00123] It is also contemplated that a molecular cloning approach may be used to generate monoclonal antibodies. In one embodiment, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning using cells expressing the antigen and control cells. The advantages of this approach over conventional hybridoma techniques are that approximately 104 times as many antibodies can be produced and screened in a single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

[00124] Another embodiment concerns producing antibodies, for example, as is found in U.S. Patent No. 6,091,001, which describes methods to produce a cell expressing an antibody from a genomic sequence of the cell comprising a modified immunoglobulin locus using Cre-mediated site-specific recombination is disclosed. The method involves first transfecting an antibody-producing cell with a homology-targeting vector comprising a lox site and a targeting sequence homologous to a first DNA sequence adjacent to the region of the immunoglobulin loci of the genomic sequence which is to be converted to a modified region,

so the first lox site is inserted into the genomic sequence via site-specific homologous recombination. Then the cell is transfected with a lox-targeting vector comprising a second lox site suitable for Cre-mediated recombination with the integrated lox site and a modifying sequence to convert the region of the immunoglobulin loci to the modified region. This 5 conversion is performed by interacting the lox sites with Cre *in vivo*, so that the modifying sequence inserts into the genomic sequence via Cre-mediated site-specific recombination of the lox sites.

[00125] Alternatively, monoclonal antibody fragments can be synthesized using an automated peptide synthesizer, or by expression of full-length gene or of gene fragments in *E. 10 coli*.

C. Antibody and Polypeptide Conjugates

[00126] Embodiments provide antibodies and antibody-like molecules against Coa proteins, polypeptides and peptides that are linked to at least one agent to form an antibody conjugate or payload. In order to increase the efficacy of antibody molecules as diagnostic or 15 therapeutic agents, it is conventional to link or covalently bind or complex at least one desired molecule or moiety. Such a molecule or moiety may be, but is not limited to, at least one effector or reporter molecule. Effector molecules comprise molecules having a desired activity, *e.g.*, cytotoxic activity. Non-limiting examples of effector molecules which have been attached to antibodies include toxins, therapeutic enzymes, antibiotics, radio-labeled 20 nucleotides and the like. By contrast, a reporter molecule is defined as any moiety which may be detected using an assay. Non-limiting examples of reporter molecules which have been conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, luminescent molecules, photoaffinity molecules, colored particles or ligands, such as biotin.

25 [00127] Certain examples of antibody conjugates are those conjugates in which the antibody is linked to a detectable label. “Detectable labels” are compounds and/or elements that can be detected due to their specific functional properties, and/or chemical characteristics, the use of which allows the antibody to which they are attached to be detected, and/or further quantified if desired.

30 [00128] Antibody conjugates are generally preferred for use as diagnostic agents. Antibody diagnostics generally fall within two classes, those for use in *in vitro* diagnostics,

such as in a variety of immunoassays, and/or those for use *in vivo* diagnostic protocols, generally known as “antibody directed imaging”. Many appropriate imaging agents are known in the art, as are methods for their attachment to antibodies (see, for *e.g.*, U.S. Patent Nos. 5,021,236; 4,938,948; and 4,472,509, each incorporated herein by reference). The 5 imaging moieties used can be paramagnetic ions; radioactive isotopes; fluorochromes; NMR-detectable substances; X-ray imaging.

[00129] In the case of paramagnetic ions, one might mention by way of example ions such as chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium 10 (III), dysprosium (III), holmium (III) and/or erbium (III), with gadolinium being particularly preferred. Ions useful in other contexts, such as X-ray imaging, include but are not limited to lanthanum (III), gold (III), lead (II), and especially bismuth (III).

[00130] In the case of radioactive isotopes for therapeutic and/or diagnostic application, one might use astatine²¹¹, ¹⁴carbon, ⁵¹chromium, ³⁶chlorine, ⁵⁷cobalt, ⁵⁸cobalt, copper⁶⁷, ¹⁵²Eu, gallium⁶⁷, ³hydrogen, iodine¹²³, iodine¹²⁵, iodine¹³¹, indium¹¹¹, ⁵⁹iron, ³²phosphorus, rhenium¹⁸⁶, rhenium¹⁸⁸, ⁷⁵selenium, ³⁵sulphur, technetium^{99m} and/or yttrium⁹⁰. ¹²⁵I is often 15 used in certain embodiments, and technetium^{99m} and/or indium¹¹¹ are also often used due to their low energy and suitability for long range detection. Radioactively labeled monoclonal antibodies may be produced according to well-known methods in the art. For instance, 20 monoclonal antibodies can be iodinated by contact with sodium and/or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase. Monoclonal antibodies may be labeled with technetium99m by ligand exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this 25 column. Alternatively, direct labeling techniques may be used, *e.g.*, by incubating pertechnate, a reducing agent such as SnCl_2 , a buffer solution such as sodium-potassium phthalate solution, and the antibody. Intermediary functional groups which are often used to bind radioisotopes which exist as metallic ions to antibody are diethylenetriaminepentaacetic acid (DTPA) or ethylene diaminetetraacetic acid (EDTA).

30 [00131] Among the fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein

Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red, among others.

[00132] Antibody conjugates include those intended primarily for use *in vitro*, where the 5 antibody is linked to a secondary binding ligand and/or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include, but are not limited to, urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase. Preferred secondary binding ligands are biotin and/or avidin and streptavidin compounds. The use of such labels is well known to those of 10 skill in the art and are described, for example, in U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241; each incorporated herein by reference.

[00133] Yet another known method of site-specific attachment of molecules to antibodies 15 comprises the reaction of antibodies with hapten-based affinity labels. Essentially, hapten-based affinity labels react with amino acids in the antigen binding site, thereby destroying this site and blocking specific antigen reaction. However, this may not be advantageous since it results in loss of antigen binding by the antibody conjugate.

[00134] Molecules containing azido groups may also be used to form covalent bonds to 20 proteins through reactive nitrene intermediates that are generated by low intensity ultraviolet light (Potter & Haley, 1983). In particular, 2- and 8-azido analogues of purine nucleotides have been used as site-directed photoprobes to identify nucleotide binding proteins in crude cell extracts (Owens & Haley, 1987; Atherton *et al.*, 1985). The 2- and 8-azido nucleotides have also been used to map nucleotide binding domains of purified proteins (Khatoon *et al.*, 1989; King *et al.*, 1989; and Dholakia *et al.*, 1989) and may be used as antibody binding 25 agents.

[00135] Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Some attachment methods involve the use of a metal chelate complex employing, for example, an organic chelating agent such a 30 diethylenetriaminepentaacetic acid anhydride (DTPA); ethylenetriaminetetraacetic acid; N-chloro-p-toluenesulfonamide; and/or tetrachloro-3 -6 -diphenylglycouril-3 attached to the antibody (U.S. Patent Nos. 4,472,509 and 4,938,948, each incorporated herein by reference).

Monoclonal antibodies may also be reacted with an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate. In U.S. Patent No. 4,938,948, imaging of breast tumors is achieved using monoclonal antibodies and the 5 detectable imaging moieties are bound to the antibody using linkers such as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hydroxyphenyl)propionate.

[00136] In some embodiments, derivatization of immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of an immunoglobulin, using reaction conditions that do not alter the antibody combining site are contemplated. Antibody 10 conjugates produced according to this methodology are disclosed to exhibit improved longevity, specificity and sensitivity (U.S. Pat. No. 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region have also been disclosed in the literature (O'Shannessy *et al.*, 1987). This approach has been reported to 15 produce diagnostically and therapeutically promising antibodies which are currently in clinical evaluation.

[00137] In some embodiments, anti-Coa antibodies are linked to semiconductor nanocrystals such as those described in U.S. Pat. Nos. 6,048,616; 5,990,479; 5,690,807; 20 5,505,928; 5,262,357 (all of which are incorporated herein in their entireties); as well as PCT Publication No. 99/26299 (published May 27, 1999). In particular, exemplary materials for use as semiconductor nanocrystals in the biological and chemical assays include, but are not limited to, those described above, including group II-VI, III-V and group IV semiconductors such as ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, 25 SrSe, SrTe, BaS, BaSe, BaTe, GaN, GaP, GaAs, GaSb, InP, InAs, InSb, AlS, AlP, AlSb, PbS, PbSe, Ge and Si and ternary and quaternary mixtures thereof. Methods for linking semiconductor nanocrystals to antibodies are described in U.S. Patent Nos. 6,630,307 and 6,274,323.

III. NUCLEIC ACIDS

[00138] In certain embodiments, there are recombinant polynucleotides encoding the 30 proteins, polypeptides, or peptides described herein. Polynucleotide sequences contemplated include those encoding antibodies to Coa or Coa-binding portions thereof.

[00139] As used in this application, the term “polynucleotide” refers to a nucleic acid molecule that either is recombinant or has been isolated free of total genomic nucleic acid. Included within the term “polynucleotide” are oligonucleotides (nucleic acids 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, 5 viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein encoding sequences. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA or synthetic), analogs thereof, or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a 10 polynucleotide.

[00140] In this respect, the term “gene,” “polynucleotide,” or “nucleic acid” is used to refer to a nucleic acid that encodes a protein, polypeptide, or peptide (including any sequences required for proper transcription, post-translational modification, or localization). As will be understood by those in the art, this term encompasses genomic sequences, 15 expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins, and mutants. A nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide. It also is contemplated that a particular polypeptide may be encoded by nucleic acids containing 20 variations having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar protein (see above).

[00141] In particular embodiments, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode a polypeptide (e.g., an antibody or fragment thereof) that binds to Coa. The term “recombinant” may be used in 25 conjunction with a polypeptide or the name of a specific polypeptide, and this generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated *in vitro* or that is a replication product of such a molecule.

[00142] The nucleic acid segments, regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences, such as promoters, polyadenylation 30 signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length

preferably being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example to allow for purification of the polypeptide, transport, secretion, post-translational modification, or for therapeutic benefits such as targeting or efficacy. As discussed above, a tag or other heterologous polypeptide may be added to the modified polypeptide-encoding sequence, wherein “heterologous” refers to a polypeptide that is not the same as the modified polypeptide.

[00143] In certain embodiments, there are polynucleotide variants having substantial identity to the sequences disclosed herein; those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, including all values and ranges there between, compared to a polynucleotide sequence provided herein using the methods described herein (e.g., BLAST analysis using standard parameters). In certain aspects, the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 90%, preferably 95% and above, identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide.

A. Vectors

[00144] Polypeptides may be encoded by a nucleic acid molecule. The nucleic acid molecule can be in the form of a nucleic acid vector. The term “vector” is used to refer to a carrier nucleic acid molecule into which a heterologous nucleic acid sequence can be inserted for introduction into a cell where it can be replicated and expressed. A nucleic acid sequence can be “heterologous,” which means that it is in a context foreign to the cell in which the vector is being introduced or to the nucleic acid in which it is incorporated, which includes a sequence homologous to a sequence in the cell or nucleic acid but in a position within the host cell or nucleic acid where it is ordinarily not found. Vectors include DNAs, RNAs, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (for example Sambrook *et al.*, 2001; Ausubel *et al.*, 1996, both incorporated herein by reference). Vectors may be used in a host cell to produce an antibody that binds Coa.

[00145] The term “expression vector” refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described herein.

[00146] A “promoter” is a control sequence. The promoter is typically a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases “operatively positioned,” “operatively linked,” “under control,” and “under transcriptional control” mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and expression of that sequence. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a *cis*-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

[00147] The particular promoter that is employed to control the expression of a peptide or protein encoding polynucleotide is not believed to be critical, so long as it is capable of expressing the polynucleotide in a targeted cell, preferably a bacterial cell. Where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a bacterial, human or viral promoter.

[00148] A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals.

[00149] Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with

standard recombinant technology to digest the vector. (See Carbonelli *et al.*, 1999, Levenson *et al.*, 1998, and Cocea, 1997, incorporated herein by reference.)

[00150] Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. Vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression. (See Chandler *et al.*, 1997, incorporated herein by reference.)

[00151] The vectors or constructs will generally comprise at least one termination signal. A “termination signal” or “terminator” is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary *in vivo* to achieve desirable message levels. In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (polyA) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to be more stable and are translated more efficiently. Thus, in other embodiments involving eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message.

[00152] In expression, particularly eukaryotic expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript.

[00153] In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed “ori”), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast.

B. Host Cells

[00154] As used herein, the terms “cell,” “cell line,” and “cell culture” may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic acid

sequence, “host cell” refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors or viruses. A host cell may be “transfected” or “transformed,” which refers to a process by 5 which exogenous nucleic acid, such as a recombinant protein-encoding sequence, is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.

[00155] Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further 10 understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

15 C. Expression Systems

[00156] Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with an embodiment to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

20 [00157] The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patents 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™ BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH®.

25 [00158] In addition to the disclosed expression systems, other examples of expression systems include STRATAGENE®’s COMPLETE CONTROL™ Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an *E. coli* expression system. Another example of an inducible expression system is available from INVITROGEN®, which carries the T-REX™ 30 (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression

system called the *Pichia methanolica* Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast *Pichia methanolica*. One of skill in the art would know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

5 **D. Methods of Gene Transfer**

[00159] Suitable methods for nucleic acid delivery to effect expression of compositions are believed to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but 10 are not limited to, direct delivery of DNA such as by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation 15 (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; 20 U.S. Patents 5,610,042; 5,322,783, 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (Kaepller *et al.*, 1990; U.S. Patents 5,302,523 and 5,464,765, each incorporated herein by reference); by Agrobacterium mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG mediated transformation of protoplasts 25 (Omirulleh *et al.*, 1993; U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition mediated DNA uptake (Potrykus *et al.*, 1985). Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

IV. METHODS OF TREATMENT

30 [00160] As discussed above, the compositions and methods of using these compositions can treat a subject (e.g., limiting bacterial load or abscess formation or persistence) having, suspected of having, or at risk of developing an infection or related disease, particularly those

related to staphylococci. One use of the compositions is to prevent nosocomial infections by inoculating a subject prior to hospital treatment.

[00161] As used herein the phrase "immune response" or its equivalent "immunological response" refers to a humoral (antibody mediated), cellular (mediated by antigen-specific T

5 cells or their secretion products) or both humoral and cellular response directed against a protein, peptide, or polypeptide of the invention in a recipient patient. Treatment or therapy can be an active immune response induced by administration of immunogen or a passive therapy effected by administration of antibody, antibody containing material, or primed T-cells.

10 [00162] As used herein "passive immunity" refers to any immunity conferred upon a subject by administration of immune effectors including cellular mediators or protein mediators (e.g., an polypeptide that binds to Coa protein). An antibody composition may be used in passive immunization for the prevention or treatment of infection by organisms that carry the antigen recognized by the antibody. An antibody composition may include

15 antibodies or polypeptides comprsing antibody CDR domains that bind to a variety of antigens that may in turn be associated with various organisms. The antibody component can be a polyclonal antiserum. In certain aspects the antibody or antibodies are affinity purified from an animal or second subject that has been challenged with an antigen(s). Alternatively, an antibody mixture may be used, which is a mixture of monoclonal and/or polyclonal 20 antibodies to antigens present in the same, related, or different microbes or organisms, such as gram-positive bacteria, gram-negative bacteria, including but not limited to staphylococcus bacteria.

[00163] Passive immunity may be imparted to a patient or subject by administering to the patient immunoglobulins (Ig) or fragments thereof and/or other immune factors obtained

25 from a donor or other non-patient source having a known immunoreactivity. In other aspects, an antigenic composition can be administered to a subject who then acts as a source or donor for globulin, produced in response to challenge from the composition ("hyperimmune globulin"), that contains antibodies directed against Staphylococcus or other organism. A subject thus treated would donate plasma from which hyperimmune globulin would then be

30 obtained, *via* conventional plasma-fractionation methodology, and administered to another subject in order to impart resistance against or to treat staphylococcus infection. Hyperimmune globulins are particularly useful for immune-compromised individuals, for

individuals undergoing invasive procedures or where time does not permit the individual to produce their own antibodies in response to vaccination. See U.S. Patents 6,936,258, 6,770,278, 6,756,361, 5,548,066, 5,512,282, 4,338,298, and 4,748,018, each of which is incorporated herein by reference in its entirety, for exemplary methods and compositions related to passive immunity.

[00164] For purposes of this specification and the accompanying claims the terms “epitope” and “antigenic determinant” are used interchangeably to refer to a site on an antigen to which B and/or T cells respond or recognize. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include those methods described in Epitope Mapping Protocols (1996). T cells recognize continuous epitopes of about nine amino acids for CD8 cells or about 13-15 amino acids for CD4 cells. T cells that recognize the epitope can be identified by *in vitro* assays that measure antigen-dependent proliferation, as determined by ³H-thymidine incorporation by primed T cells in response to an epitope (Burke *et al.*, 1994), by antigen-dependent killing (cytotoxic T lymphocyte assay, Tigges *et al.*, 1996) or by cytokine secretion.

[00165] The presence of a cell-mediated immunological response can be determined by proliferation assays (CD4 (+) T cells) or CTL (cytotoxic T lymphocyte) assays. The relative contributions of humoral and cellular responses to the protective or therapeutic effect of an immunogen can be distinguished by separately isolating IgG and T-cells from an immunized syngeneic animal and measuring protective or therapeutic effect in a second subject. As used herein and in the claims, the terms “antibody” or “immunoglobulin” are used interchangeably.

[00166] Optionally, an antibody or preferably an immunological portion of an antibody, can be chemically conjugated to, or expressed as, a fusion protein with other proteins. For purposes of this specification and the accompanying claims, all such fused proteins are included in the definition of antibodies or an immunological portion of an antibody.

[00167] In one embodiment a method includes treatment for a disease or condition caused by a staphylococcus pathogen. In certain aspects embodiments include methods of treatment of staphylococcal infection, such as hospital acquired nosocomial infections. In some embodiments, the treatment is administered in the presence of staphylococcal antigens. 5 Furthermore, in some examples, treatment comprises administration of other agents commonly used against bacterial infection, such as one or more antibiotics.

[00168] The therapeutic compositions are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated. Precise amounts of active ingredient 10 required to be administered depend on the judgment of the practitioner. Suitable regimes for initial administration and boosters are also variable, but are typified by an initial administration followed by subsequent administrations.

[00169] The manner of application may be varied widely. Any of the conventional methods for administration of a polypeptide therapeutic are applicable. These are believed to 15 include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection and the like. The dosage of the composition will depend on the route of administration and will vary according to the size and health of the subject.

[00170] In certain instances, it will be desirable to have multiple administrations of the 20 composition, *e.g.*, 2, 3, 4, 5, 6 or more administrations. The administrations can be at 1, 2, 3, 4, 5, 6, 7, 8, to 5, 6, 7, 8, 9, 10, 11, 12 twelve week intervals, including all ranges there between.

A. Antibodies And Passive Immunization

[00171] Certain aspects are directed to methods of preparing an antibody for use in 25 prevention or treatment of staphylococcal infection comprising the steps of immunizing a recipient with a vaccine and isolating antibody from the recipient, or producing a recombinant antibody. An antibody prepared by these methods and used to treat or prevent a staphylococcal infection is a further aspect. A pharmaceutical composition comprising antibodies that specifically bind Coa and a pharmaceutically acceptable carrier is a further 30 aspect that could be used in the manufacture of a medicament for the treatment or prevention of staphylococcal disease. A method for treatment or prevention of staphylococcal infection

comprising a step of administering to a patient an effective amount of the pharmaceutical preparation is a further aspect.

[00172] Inocula for polyclonal antibody production are typically prepared by dispersing the antigenic composition (e.g., a peptide or antigen or epitope of Coa or a consensus thereof)

5 in a physiologically tolerable diluent such as saline or other adjuvants suitable for human use to form an aqueous composition. An immunostimulatory amount of inoculum is administered to a mammal and the inoculated mammal is then maintained for a time sufficient for the antigenic composition to induce protective antibodies. The antibodies can be isolated to the extent desired by well known techniques such as affinity chromatography

10 (Harlow and Lane, *Antibodies: A Laboratory Manual* 1988). Antibodies can include antiserum preparations from a variety of commonly used animals e.g., goats, primates, donkeys, swine, horses, guinea pigs, rats or man. The animals are bled and serum recovered.

[00173] An antibody can include whole antibodies, antibody fragments or subfragments.

Antibodies can be whole immunoglobulins of any class (e.g., IgG, IgM, IgA, IgD or IgE),

15 chimeric antibodies, human antibodies, humanized antibodies, or hybrid antibodies with dual specificity to two or more antigens. They may also be fragments (e.g., F(ab')2, Fab', Fab, Fv and the like including hybrid fragments). An antibody also includes natural, synthetic or genetically engineered proteins that act like an antibody by binding to specific antigens with a sufficient affinity.

20 [00174] A vaccine can be administered to a recipient who then acts as a source of antibodies, produced in response to challenge from the specific vaccine. A subject thus treated would donate plasma from which antibody would be obtained via conventional plasma fractionation methodology. The isolated antibody would be administered to the same or different subject in order to impart resistance against or treat staphylococcal infection.

25 Antibodies are particularly useful for treatment or prevention of staphylococcal disease in infants, immune compromised individuals or where treatment is required and there is no time for the individual to produce a response to vaccination.

[00175] An additional aspect is a pharmaceutical composition comprising two or more antibodies or monoclonal antibodies (or fragments thereof; preferably human or humanized)

30 reactive against at least two constituents of the immunogenic composition, which could be

used to treat or prevent infection by Gram positive bacteria, preferably staphylococci, more preferably *S. aureus* or *S. epidermidis*.

B. Combination Therapy

[00176] The compositions and related methods, particularly administration of an antibody that binds Coa or a peptide or consensus peptide thereof to a patient/subject, may also be used in combination with the administration of traditional therapies. These include, but are not limited to, the administration of antibiotics such as streptomycin, ciprofloxacin, doxycycline, gentamycin, chloramphenicol, trimethoprim, sulfamethoxazole, ampicillin, tetracycline or various combinations of antibiotics.

[00177] In one aspect, it is contemplated that a therapy is used in conjunction with antibacterial treatment. Alternatively, the therapy may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agents and/or a proteins or polynucleotides are administered separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the therapeutic composition would still be able to exert an advantageously combined effect on the subject. In such instances, it is contemplated that one may administer both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for administration significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

[00178] Various combinations of therapy may be employed, for example antibiotic therapy is "A" and an antibody therapy that comprises an antibody that binds Coa or a peptide or consensus peptide thereof is "B":

[00179] A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B

[00180] B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A

[00181] B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

[00182] Administration of the antibody compositions to a patient/subject will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the composition. It is expected that the treatment cycles would be repeated as

necessary. It is also contemplated that various standard therapies, such as hydration, may be applied in combination with the described therapy.

C. General Pharmaceutical Compositions

[00183] In some embodiments, pharmaceutical compositions are administered to a subject.

5 Different aspects may involve administering an effective amount of a composition to a subject. In some embodiments, an antibody that binds Coa or a peptide or consensus peptide thereof may be administered to the patient to protect against or treat infection by one or more bacteria from the *Staphylococcus* genus. Alternatively, an expression vector encoding one or more such antibodies or polypeptides or peptides may be given to a patient as a preventative 10 treatment. Additionally, such compositions can be administered in combination with an antibiotic. Such compositions will generally be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[00184] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic, or other 15 untoward reaction when administered to an animal or human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active 20 ingredients, its use in immunogenic and therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-infective agents and vaccines, can also be incorporated into the compositions.

[00185] The active compounds can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even 25 intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and, the preparations can also be emulsified.

[00186] The pharmaceutical forms suitable for injectable use include sterile aqueous 30 solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions

or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

5 [00187] The proteinaceous compositions may be formulated into a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic
10 bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

[00188] A pharmaceutical composition can include a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The
15 proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for
20 example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[00189] Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients
25 enumerated above, as required, followed by filtered sterilization or an equivalent procedure. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and
30 freeze-drying techniques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[00190] Administration of the compositions will typically be via any common route. This includes, but is not limited to oral, nasal, or buccal administration. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, or intravenous injection. In certain embodiments, a vaccine 5 composition may be inhaled (e.g., U.S. Patent 6,651,655, which is specifically incorporated by reference). Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

[00191] An effective amount of therapeutic or prophylactic composition is determined 10 based on the intended goal. The term “unit dose” or “dosage” refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the composition calculated to produce the desired responses discussed above in association with its administration, *i.e.*, the appropriate route and regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection desired.

[00192] Precise amounts of the composition also depend on the judgment of the 15 practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the subject, route of administration, intended goal of treatment (alleviation of symptoms versus cure), and potency, stability, and toxicity of the particular composition.

[00193] Upon formulation, solutions will be administered in a manner compatible with the 20 dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above.

V. EXAMPLES

[00194] The following examples are given for the purpose of illustrating various 25 embodiments and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as 30 limitations on the scope of the invention. Changes therein and other uses which are

encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

EXAMPLE 1

MONOCLONAL ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY 5 DURING STAPHYLOCOCCUS AUREUS DISEASE

[00195] **Coa Mab specificity and affinity.** Mabs were generated against Coa_{NM} and their affinity to Coa was measured (Table 1). The monoclonal antibodies were also tested for binding to an irrelevant protein (IsdA), and those that did not exhibit a specific interaction 10 were eliminated from further study. Because vWbp has some homology to Coa in its N-terminal D1 and D2 domains (Bjerketorp et al 2004, Watanabe et al 2005), binding of Coa monoclonals to vWbp was also tested. None of the Mabs displayed specific binding vWbp.

[00196] In order to determine the binding site of each Mab on Coa, subdomains representing D1 (D1_{Coa}), D2 (D2_{Coa}), the first 329 residues including the entire D1D2 domain 15 and part of the linker domain (D12_{Coa}), linker (L_{Coa}), repeat region (CT_{Coa}), and a truncated form of D1 missing the first 18 amino acids (D1_{Δ1-18}) were cloned and expressed in *E. coli* (FIG. 1). Eleven Mabs bound D12_{Coa}, all of which specifically recognized D1_{Coa} (Table 1). Two Mabs bound L_{Coa}, and none of the Mabs bound D2_{Coa}. Two Mabs bound CT_{Coa}.

Table 1. Biochemical attributes and biological values of Mabs raised against Coa

Mab	Isotype	Affinity ^a						
		Coa _{NM}	D12 _{Coa}	D1 _{Coa}	D1 _{Δ1-18}	D2 _{Coa}	L _{Coa}	CT _{Coa}
4H9.20	IgG1	0.04	0.01	0.01	<	<	<	<
5D5.4	IgG1	4.06	2.55	3.94	1.03	<	<	<
6C10.19	IgG1	3.82	4.39	0.01	<	<	6.58	<
4B10.44	IgG1	0.03	0.01	0.02	<	<	<	<
3B3.14	IgG1	3.2	<	<	<	<	<	5.25
7H4.25	IgG1	1.64	1.42	1.02	0.28	<	0.01	<
4F1.7	IgG1	0.68	0.05	1.01	0.1	<	<	<
8C2.9	IgG2a	3.4	3.2	0.78	0.57	<	<	<
2A3.1	IgG2a	0.17	0.24	0.12	0	<	<	<
5C3.2	IgG2b	0.4	0.3	0.35	0.02	<	<	<
2H10.12	IgG2b	2.39	2.87	2.13	0.03	<	<	<
6D1.22	IgG2b	2.79	3.28	2.13	0.03	<	<	<
6C4.15	IgG2b	5.97	<	<	<	<	<	6.70

^aDetermined by ELISA as the association constant (K_a) in $\times 10^{-9}$ M

[00197] **Inhibition of blood coagulation by monoclonal antibodies.** Coa-specific Mabs were screened for their ability to inhibit clotting of calcium-chelated mouse blood by *S. aureus* isogenic mutant *vwb*, which coagulates blood more slowly than wild-type (Cheng et al). Isolated *S. aureus* Newman *vwb* mutants (1×10^6 CFU) were mixed with Mabs (3 μ M) and

added to mouse blood. Samples were monitored at timed intervals for coagulation. Compared to blood incubated with isotype controls, several Mabs prolonged the coagulation time. Antibodies that generated the greatest delay in time to clotting were 5D5.4, 7H4.25, and 8C.9 (Table 2). All three of these antibodies recognize D1_{Coa} (Table 1), consistent with our previous observation that polyclonal rabbit serum that recognizes D12_{Coa}, but not those that recognize CT_{Coa}, delay clotting of whole mouse blood [215]. Antibodies that recognized CT_{Coa} (6C4.15, 3B3.14) and the antibody that recognized L_{Coa} (6C10.27) did not cause delays in staphylococcal coagulation (Table 2).

Table 2. Inhibition of clotting of whole blood by *S. aureus* mutant strain *vwb* in the presence of monoclonal antibodies generated against Coa

Isotype	Antibody	Fold delay in clotting time (SEM) ^a
IgG1	IgG1 control	1.0
	4H9.20	0.65 (0.18)
	5D5.4	2.07 (0.58)
	6C10.19	1.00 (0.14)
	4B10.44	1.19 (0.15)
	3B3.14	1.22 (0.18)
	7H4.25	1.63 (0.16)
	4F1.7	1.23 (0.14)
IgG2a	IgG2a control	1.0
	8C2.9	1.30 (0.15)
	2A3.11	0.83 (0.12)
IgG2b	IgG2b control	1.0
	5C3.2	1.12 (0.22)
	2H10.12	1.43 (0.18)
	6D1.22	1.08 (0.19)
	6C4.15	1.19 (0.15)

^aSEM, standard error of the mean as compared to isotype control

[00198] **Mab 5D5.4 prevents the formation of Coa-prothrombin complexes.** Mab 5D5.4, which caused the most pronounced delay in clotting of all Mabs tested, was examined for its ability to disrupt Coa-prothrombin activity. Mixture of recombinant Coa with 5D5.4 prior to the addition of purified human prothrombin and the S-2238 chromogenic substrate resulted in reduced enzymatic activity (IgG1 vs. 5D5.4, P < 0.05) (FIG. 2A). Interestingly, treatment with 7H4.25 and 8C2.9, which caused delays in the coagulation of whole blood, did not significantly reduce the enzymatic activity in this assay (IgG1 vs. 7H4.25, P > 0.05; IgG2a vs. 8C2.9, P > 0.05) (data not shown).

[00199] To test whether 5D5.4 prevents the association of Coa to prothrombin, Maxisorb ELISA plates (Nunc) were coated with recombinant Coa and incubated with antibodies prior

to incubation with human prothrombin. Prothrombin binding was detected by HRP-conjugated secondary antibody. 5D5.4 reduced the binding of prothrombin to Coa 3.3-fold at a concentration of 200 nM (IgG1 vs. 5D5.4, $P < 0.01$) (FIG. 2B). These results indicate that 5D5.4 prevents the formation of the Coa-prothrombin complex, resulting in reduced enzymatic activity.

[00200] Four amino acids at the N-terminal end of Coa activate prothrombin [66]. To investigate whether any of the monoclonal antibodies bind D1 in a manner dependent on the N-terminus, a recombinant construct consisting of the D1_{Coa} domain but lacking the first 18 amino acids (D1_{Δ1-18}) was expressed in *E. coli* and purified (FIG. 1). The association constant of each Mab that recognizes D1_{Coa} was measured for association with the truncated protein. All of the Mabs, with the exception of 8C2.9, had at least a one-log reduction in association constant for D1_{Δ1-18} (Table 1). Of note, 5D5.4 recognized D1_{Coa} with an affinity of 3.94 nM⁻¹ but interacted with D1_{Δ1-18} with an affinity of 1.03 nM⁻¹. This observation, combined with its direct inhibition on the enzymatic activity of Coa, supports the idea that 5D5.4 recognizes an epitope near the N-terminus that may be conserved among various Coa serotypes of different strains of *S. aureus*

[00201] **Reduction in Staphylococcal sepsis by Coa Mabs.** Previous results have suggested that type-specific immunity results from antibodies that recognize D12_{Coa} and neutralize Coa activity [215]. To test whether Coa Mabs that delay clotting *in vitro* confer protective immunity against *S. aureus* *in vivo*, mice received intraperitoneal injections of monoclonal antibodies or an isotype control preparation. Six hours later, mice were infected by retro-orbital injection with *S. aureus* strain *vwb* (2×10^8 CFU). Mice were monitored for survival over a ten-day observation period, and protection was assessed by the Log rank test (FIG. 3). Two antibodies, Mab 5D5.4 and 7H4.25 conferred significant delay in time to death compared to the IgG1 control (IgG1 vs. 5D5.4, $P < 0.05$; IgG1 vs. 7H4.25, $P < 0.001$) (FIG. 3A). Monoclonal antibody 8C2.9, which delayed clotting *in vitro*, did not protect mice against a lethal dose of *S. aureus* strain *vwb* (IgG2a vs. 8C2.9, $P = 0.06$) (FIG. 3B). These data are consistent with the hypothesis that protective immunity toward the D1 domain correlates with neutralization of coagulation activity. However, perturbation of *in vitro* coagulation is not sufficient to garner protective efficacy.

[00202] **Cross-reactivity by Coa Mabs.** Type-specific immunity toward Coa is derived from neutralizing antibodies that recognize D1_{Coa} [215]. However, the N-terminal seven

amino acids of Coa are conserved among Coa types [68]. To investigate whether the Mabs generated against recombinant Coa of strain Newman cross-react with Coa from other serotypes, Maxisorb ELISA plates (Nunc) were coated with Coa from epidemic strains USA300 (Coa type III), 85/2082 (Coa type IV), N315 (Coa type II), MRSA252 (Coa type IV), MW2 (Coa type VII), and WIS (Coa type VII). The association of Mabs to these alleles was measured (Table 3). The affinity of most antibodies to the other alleles of Coa is lower than the affinity to Coa_{NM}. 2H10.12, 5D5.4, 8C2.9, 4F1.7, and 7H4.25 recognize Coa_{USA300}, which is the same serotype as Coa_{NM}, albeit with lower affinity than Coa_{NM} (Table 3). Several antibodies also recognize the recombinant Coa of other *S. aureus* clinical isolates. 5D5.4 interacted with Coa_{N315}, Coa_{WIS} and Coa_{MW2} (Table 3), and 7H4.25 interacted with all serotypes of Coa albeit with low affinity (Table 3).

Table 3. Affinity of Mabs toward Coa of different strains

Mab ^a	Domain ^b	Affinity ^c						
		Coa _{NM}	Coa _{USA300}	Coa _{85/2082}	Coa _{N315}	Coa _{MRSA}	Coa _{MW2}	Coa _{WIS}
3B3.14	R	3.20	2.11	2.40	4.86	4.60	2.61	3.62
2H10.12	D1	2.39	3.20	<	<	<	<	<
5D5.4	D1	4.06	4.20	<	0.21	<	5.89	6.16
8C2.9	D1	3.4	0.7	<	0.05	0.04	<	<
4F1.7	D1	0.68	0.1	<	0	<	<	<
6C10.19	L	3.82	6.66	<	7.13	<	<	<
6C4.15	R	5.97	2.96	4.71	4.79	4.94	4.99	5.78
7H4.25	D1	1.64	0.35	0.20	0.11	0.13	0.06	0.10

^aMouse monoclonal antibodies were purified from isolated hybridoma clones

^bCoa domain recognized by each Mab (Table 1)

^cAffinity was determined by ELISA as the association constant (K_a) in 10⁹ M⁻¹ for each protein.

[00203] To investigate whether mAb 5D5.4 has cross-protective effect in delaying the coagulation by strains of other coagulase serotypes, preparations of *S. aureus* strains Newman, N315, MW2, CowanI, and WIS (1×10⁶ CFU) were mixed with mAbs (3μM final) and added to citrate-treated rabbit plasma. Plasma was incubated at 37°C and monitored over time. mAb 5D5.4 failed to delay clotting by strains of any other coagulase serotype (FIG. 4).

[00204] The possibility that candidate Mabs may recognize an epitope conserved by all Coa serotypes was investigated. For example, 5D5.4 provided broad protection in animals but not in the clotting assay. Indeed, mice received intraperitoneal injections of 5D5.4 or an IgG1 isotype control, and were subsequently infected with a lethal dose of *S. aureus* strains

Newman (Coa type III), N315 (Coa type II), CowanI (Coa type IV), or MW2 (Coa type VII), and were monitored over a ten-day observation period to assess their protective role (FIG. 5). 5D5.4 treatment resulted in a delay in time-to-death for animals challenged with strains Newman (IgG1 vs 5D5.4, P <0.01), N315 (IgG1 vs. 5D5.4, P < 0.05), CowanI (IgG1 vs. 5D5.4, P<0.05) or MW2 (IgG1 vs. 5D5.4, P <0.05). Together, these data suggest that by recognizing a conserved epitope within the Coa D1 domain, 5D5.4 provides protection against lethal disease by strains with the three most common Coa serotypes in North America [144].

[00205] **Role of Coa_{CT} monoclonal antibodies in immunity.** The C-terminal domains of Coa display less sequence variation among staphylococcal isolates [68]. We isolated two monoclonal antibodies that recognize CT_{Coa}, 3B3.14 and 6C4.15 (Table 1). ELISA was used to investigate whether the Mabs generated against CT_{Coa} of strain Newman cross-react with Coa from other strains (Table 3). Consistent with our expectations, 3B3.14 and 6C4.15 recognize Coa_{USA300}, Coa_{85/2082}, Coa_{N315}, Coa_{MW2}, and Coa_{WIS}.

[00206] Polyclonal antisera that recognize CT_{Coa} (α CT_{Coa}) block the interaction between CT_{Coa} and fibrinogen and confer protection against lethal staphylococcal disease [68,215]. Therefore, it is of interest whether any of the Mabs possess these activities. To test whether 3B3.14 and 6C4.15 inhibit the association of CT_{Coa} with fibrinogen, Maxisorb ELISA plates (Nunc) were coated with CT_{Coa} and incubated with Mabs or isotype controls prior to incubation with human fibrinogen. Fibrinogen binding was detected by HRP-conjugated secondary antibody. 3B3.14 reduced the binding of fibrinogen to CT_{Coa} by 54% at a concentration of 1 μ M (IgG1 vs. 3B3.14, P < 0.001) (FIG. 6A). 6C4.15 did not disrupt the association of CT_{Coa} to fibrinogen in this assay (FIG. 6B).

[00207] To investigate the effect of Mabs that recognize Coa_{CT} on survival during staphylococcal disease, mice received intraperitoneal injections of 3B3.14, 6C4.15, or their isotype controls, and were challenged with 2×10^8 CFU of the *S. aureus* Newman variant with a deletion of *vwb* (FIG. 6C-6D). Animals were monitored over a ten-day observation period to assess the contribution of antibody treatment on survival. Treatment with 3B3.14 or 6C4.15 did not result in a significant delay in time to death (P > 0.05) (FIG. 6C-6D). Thus, neither of the Mabs generated here retain the protective value of the polyclonal α CT_{Coa} antibodies that had been raised in rabbits.

CT_{Coa} is relatively conserved among strains of *S. aureus*, to investigate whether an antibody that neutralizes this portion of Coa would provide protection against staphylococcal infection by several *S. aureus* types, mice received intraperitoneal injections of 3B3.14 or IgG1 isotype control, and were subsequently infected with a lethal dose of *S. aureus* clinical isolate USA300 (Coa type III), N315 (Coa type II), CowanI (Coa type IV), or MW2 (Coa type VII), and were monitored over a ten-day observation period to assess their protective role (FIG. 7). 3B3.14 did not protect mice against challenge with the wildtype Newman (IgG1 vs. 3B3.14 p>0.05 FIG. 7A), N315 (IgG1 vs. 3B3.14 p>0.05 FIG. 7B), or MW2 (IgG1 vs. 3B3.14 p>0.05 FIG. 7D). 3B3.14 provided a modest delay in time to death following challenge with strain CowanI (IgG1 vs. 3B3.14 p<0.001FIG. 7C)

[00208] **Discussion.** Coagulase expression has been correlated with the virulence of *S. aureus* for nearly a century [212]. Recently, it was demonstrated that a humoral immune response generated against Coa and vWbp provides protection against challenge with *S. aureus* (Cheng et al 2010, McAdow et al 2011, [215]). Neutralization of Coa activity results in type-specific immune responses, while immune responses to CT_{Coa} also confer protection, presumably by removal of the antigen from circulation [215]. Here, we identify monoclonal antibodies that neutralize Coa activity and exhibit some cross-protection toward coagulases of other serotypes. In this study, we generated monoclonal antibodies against Coa from strain Newman and mapped their binding to specific domains of the polypeptide.

[00209] Three Mabs (5D5.4, 8C2.9, and 7H4.25) bind D1_{Coa} and delay blood coagulation by strain Newman. Mab 5D5.4, which results in the greatest delay in coagulation, also disrupts the formation of the Coa prothrombin complex, thereby diminishing assembly of the enzyme that converts fibrinogen to fibrin. Mabs 5D5.4 and 7H4.25 provide protection against lethal disease by *S. aureus* strain vwb.

[00210] Because the N-terminal amino acids of Coa are required for activation of prothrombin, we wondered whether any of the monoclonal antibodies recognize this domain. To address this question, we asked whether the first 18 amino acids of D1_{Coa} were required for Mabs to bind. 5D5.4 had greater than 1-log reduction in affinity to D1_{Δ1-18}, and 7H4.25 failed to bind this construct. This finding supports the hypothesis that these two monoclonal antibodies disrupt coagulation by specifically interfering with the ability of the Coa N-terminus to insert into the prothrombin activation pocket.

[00211] If this hypothesis were true, Mabs 5D5.4 and 7H4.25 should recognize and neutralize recombinant Coa cloned from other strains of *S. aureus*. These antibodies do recognize recombinant Coa cloned from *S. aureus* strains that represent other common serotypes in the current epidemic, but they fail to delay clotting by strains of other Coa

5 serotypes in our experiments. It therefore seems unlikely that these Mabs recognize specifically the amino terminus. Nevertheless, 5D5.4 provides protection against at least two other strains of *S. aureus*. This indicates that while the antibody does not specifically recognize the most conserved portion of Coa, its interaction with Coa does require the conserved residues.

10 [00212] Previously, we demonstrated that antibodies to the D1D2 domains of Coa generate type-specific immunity. The identification of a Mab that protects animals against several staphylococcal strains of distinct Coa serotypes provides evidence that it may be possible to generate protective immunity that neutralizes the Coa activity by an array of staphylococcal isolates.

15 [00213] Two monoclonal antibodies recognize CT_{Coa}. Neither has an effect on blood coagulation, consistent with previous observations [215]. One of these, 3B3.14 disrupted binding of fibrinogen to the C-terminal repeat region. A more refined mapping of the epitope recognized by Mab 3B3.14 could reveal how the Coa C-terminus binds fibrinogen, which has not been studied to date. Passive transfer of these Mabs did not protect mice against lethal 20 challenge with staphylococci.

[00214] The monoclonal antibodies described here provide pharmacologic tools for the prevention of staphylococcal disease. They also can serve as tools for understanding the mechanisms of Coa during staphylococcal pathogenesis and immunity.

EXAMPLE 2

25 MATERIALS AND METHODS

[00215] **Bacterial strains and growth of cultures.** *S. aureus* strains were cultured on tryptic soy agar or broth at 37°C. Generation of strain *vwb* was described previously (Cheng 30 et al 2010). *Escherichia coli* strains DH5 α and BL21 (DE3) were cultured on Luria Bertani agar or broth at 37°C. Ampicillin (100 μ g/ml) was used for pET15b and pGEX6P-1 selection.

[00216] **Protein purification.** *E. coli* BL21(DE3) harboring expression vectors containing *coa* and its subdomains from *S. aureus* strain Newman were grown at 37°C and induced with 100 mM IPTG overnight at room temperature. Because of degradation during the purification of Coa, pGEX6P-1 expression vectors in *E. coli* DH5 α were used to express *coa* from USA300, N315, MW2, MRSA252, 85/2082, and WIS as GST-tagged constructs. Three hours following induction, cells were centrifuged at 7,000 \times g, suspended in 1 \times column buffer (0.1 M Tris-HCl, pH 7.5, 0.5 M NaCl) and lysed in a French pressure cell at 14,000 lb/in². Lysates were subjected to ultracentrifugation at 40,000 \times g for 30 min. The supernatant of pET15b constructs was subjected to Ni-NTA chromatography, washed with column buffer containing 10 mM imidazole, and eluted with 500 mM imidazole. For GST-tagged proteins, culture supernatants were subjected to glutathione sepharose chromatography. To remove the GST tag, after washing with column buffer, PreScission protease cleavage buffer containing 1mM DTT was flowed over the column, and the column was incubated with PreScission protease (GE Healthcare) overnight at the unit definition provided by the manufacturer. Liberated protein lacking the GST tag was then eluted with additional protease cleavage buffer. Eluates were desalted against phosphate buffered saline (PBS). For vaccine preparations, endotoxin was removed by the addition of 1:100 Triton-X114 was added and the solution was chilled for 10 min, incubated at 37°C for 10 min, and centrifuged at 13,000 \times g. This was repeated twice. Supernatant was loaded onto a HiTrap desalting column to remove remnants of Triton-X114.

[00217] **Production of monoclonal antibodies against Coagulase.** Three eight-week-old BALB/c female mice (Jackson Laboratory, Bar Harbor, ME) were immunized intraperitoneally with 100 μ g purified Coa, which was cloned from *S. aureus* strain Newman, in PBS emulsified 1:1 in Complete Freund's Adjuvant (DIFCO). On days 21 and 42, mice were boosted by intraperitoneal injection with 100 μ g purified Coa emulsified 1:1 in Incomplete Freund's Adjuvant (DIFCO). On days 31 and 52, mice were bled and screened by ELISA on Nunc MaxiSorp 96-well flat bottom plates coated with Coa. Seventy-nine days after the initial immunization, mice that showed strong immunoreactivity to antigen were boosted with 25 μ g Coa in PBS. Three days later splenocytes were harvested and fused, according to standard methods, with the mouse myeloma cell line SP2/mIL-6, an interleukin 6 secreting derivative of SP2/0 myeloma cell line. Hybridomas were screened by ELISA and antigen-specific clones were subcloned, by limiting dilution, to produce monoclonal

antibody-secreting hybridomas arising from single cells. Antibodies were purified from the culture supernatant of cell lines and stored at a concentration of 1 mg ml⁻¹ in PBS.

[00218] **Coa affinity mapping.** For the determination of binding affinity of Coa specific Mabs, Nunc MaxiSorp 96-well plates were coated with the Coa variants at a concentration of 20 nM in 0.1M sodium bicarbonate. Plates were blocked with 3% BSA in PBS, followed by incubation with variable concentrations of Mabs in PBS-Tween. The affinity of Mabs to bind each Coa variant was measured as the ratio of the concentration of bound to free antibody using secondary antibody-HRP conjugates and chemiluminescence detection. Using this data, the association constant of antibody for antigen was calculated (Table 1). Moreover, in order to test the specificity of Mabs raised against Coa, ELISA plates (NUNC Maxisorp) were coated with affinity purified vWbp and IsdA

[00219] **Blocking protein interactions by ELISA.** MaxSorb 96-well ELISA plates were coated with recombinant Coa variants (20 nM in 1X coating buffer) overnight. After blocking, wells were then incubated with Mabs ranging in concentration from 20 nM to 1 μ M. Wells were subsequently incubated with either 100 nM human fibrinogen or 20 nM human prothrombin. Sheep anti-human antibodies against the respective proteins were added at 1:1000 dilution followed by HRP-conjugated goat-anti-sheep antibody at 1:10,000. The wells were developed using OpEIA Kit (BD Lifesciences) and the absorbance at 450 nm was measured. Statistical analyses were performed using a two-tailed Student's t-test with GraphPad Prism.

[00220] **Coagulation assay.** Overnight cultures of staphylococcal strains were diluted 1:100 into fresh TSB and grown at 37°C until they reached an OD₆₀₀ 0.4. One mL of culture was centrifuged, and staphylococci were washed and suspended in 1 mL of sterile PBS to generate a suspension of 1 \times 10⁸ CFU/mL. Whole blood from naïve BALB/c mice was collected and sodium citrate was added to a final concentration 1% (w/v). To assess bacterial blood coagulating activity in the presence of antibodies, 10 μ L of the stock bacterial culture was mixed with 10 μ L of PBS containing 30 μ M of antibodies in a sterile plastic test tube (BD Falcon) and incubated for fifteen minutes. To each tube, 80 μ L of anti-coagulated mouse blood in a sterile plastic test tube (BD falcon). Test tubes were incubated at 37°C and blood coagulation was verified by tipping the tubes to 45° angles at timed intervals. All experiments were repeated in at least two independent experiments.

[00221] **Measurement of coagulase activity.** 5×10^{-8} M prothrombin (Innovative Research) was pre-incubated for 10 min with an equimolar amount of functional Coa at room temperature, followed by addition of S-2238 (a chromogenic substrate) to a final concentration of 1 mM in a total reaction buffer of 100 μ l PBS. The change in absorbance was measured at 450 nm for 10 minutes in a spectrophotometer, plotted as a function of time, and fit to a linear curve. The slope of the curve (dA/dt) was interpreted to be the rate of S-2238 hydrolysis, and thus reflective of enzymatic function. The assay was repeated in presence of monoclonal antibodies added at 5×10^{-9} M and data were normalized to the average activity without inhibition. All experiments were performed in triplicate.

[00222] **Murine sepsis with passive immunization.** Affinity purified antibodies in PBS were injected at a concentration $5 \text{ mg} \cdot \text{kg}^{-1}$ of experimental animal weight into the peritoneal cavity of BALB/c mice (6 week old, female, Charles River Laboratories) 6 hours prior to challenge with *S. aureus*. An overnight culture of *S. aureus* strain *vwb* was diluted 1:100 into fresh TSB and grown for 2 hours at 37°C. Staphylococci were sedimented, washed and suspended in PBS to the desired concentration. The following inocula were used: *vwb*, 2×10^8 CFU; N315, 1×10^8 CFU; MW2, 2×10^8 CFU. Inocula were confirmed by spreading sample aliquots on TSA and enumerating colonies formed on agar plates. Mice were anesthetized via intraperitoneal injection with 100 mg mL^{-1} ketamine and 20 mg mL^{-1} xylazine per kilogram of body weight. Mice were infected by retro-orbital injection with 100 μL of a staphylococcal suspension (*vide supra*). Mice were monitored for survival. Statistical analysis was performed using two-tailed Log Rank test using GraphPad Prism. All mouse experiments were performed in accordance with the institutional guidelines following experimental protocol review and approval by the Institutional Biosafety Committee (IBC) and the Institutional Animal Care and Use Committee (IACUC) at the University of Chicago.

25

EXAMPLE 3

COA MAB HEAVY AND LIGHT CHAIN AMINO ACID SEQUENCES

ALIGNMENT AND ANALYSIS

[00223] The light and heavy chain variable regions of the different monoclonal antibodies were sequenced. The CDRs of these regions in the antibodies is provided in Table 5 below. Following alignment of mAb sequences via IMGT vquest, CDRs were identified and amino acid sequences of heavy and light CDRs 1,2, and 3 were aligned using Clustal Omega. Following sequence alignment and analysis, a handful of informative themes were present.

Based on the full sequences (both heavy and light chains) available, no mAbs appeared to be identical in sequence, though families of mAbs with similar sequences did emerge. One of these included 4F1.7,2A3.1, 2H10.12, with the main sequence differences present in CDR3 of both heavy and light chain.7H4.25, 4H9.20, 4B10.44 shared exact CDR sequence matches within the light chain, while their light chains were different. An interesting group to emerge based on sequence similarity was 3B3.14 and 6C4.15 which bind the C terminal region of the protein, shared the same CRD1 in the light chain, but the heavy chain are different. Instead 5D5.4 which bind the D1 domain, inhibit the binding of coa to prothrombin and is protective in “ in vivo experiment” I very different in both light and heavy chain from all the others.

TABLE 5

Amino acid sequences of CDR regions of variable light chain of monoclonal antibodies							
*Antibody	Variable chain	Amino acid sequencing data of coagulase specific monoclonal antibodies					
		CDR1	SEQ ID NO.	CDR2	SEQ ID NO.	CDR3	SEQ ID NO.
4H9.20	Light	QSVDYNGISY	9	AAS	10	QQSIEDPRT	11
5D5.4	Light	SSVSSSY	15	STS	16	QQYHRSPPPT	17
4B10.44	Light	QSVDYNGISY	9	AAS	21	HQSIEDPRT	22
3B3.14	Light	QSIVHSNGNTY	24	KVS	25	FQGSHVPLT	26
7H4.25	Light	QSVDYNGISY	9	AAS	21	HQSIEDPRT	30
2A3.1	Light	QSLLNSRARKNY	33	WAS	34	KQSYNLWT	35
2H10.12	Light	QSLLNSRARKNY	40	WAS	34	KQSYYLWT	36
6D1.22	Light	QSLLNSRARKNY	40	WAS	34	KQSYNLWT	35
6C4.15	Light	QSLLNSRTRKIY	44	WAS	34	KQSYYLYT	45
6C10.19	Light	QNIVHSNGNTY	56	KVS	25	LQGSNCSNH	57
8C2.9	Light	QSLLNSRARKNY	40	WAS	34	KQSYNLWT	35
4F1.7	Light	QSLEFNSRARKNY	49	WAS	34	KQSYNLWT	35

^aAmplified PCR products from cDNA which was synthesized from total RNA extracted from hybridoma cells were sequenced and analyzed using IMGT Vquest.

TABLE 5 Continued

Amino acid sequences of CDR regions of variable heavy chain of monoclonal antibodies							
^a Ab	Amino acid sequencing data of coagulase specific monoclonal antibodies						
	Variable chain	CDR1	SEQ ID NO.	CDR2	SEQ ID NO.	CDR3	SEQ ID NO.
4H9.20	Heavy	GFNKDIY	12	IDPANGNT	13	SRSGAY	14
			18	ISYSGNT	19	AATYYDFNYD	20
5D5.4	Heavy	GASITTSY				GYLDV	
4B10.44	Heavy	GFNKDIY	12	IDPANGNT	13	SRSGAF	23
			27	IFPGDGSS	28	VKNHGGWSFD	29
3B3.14	Heavy	GYTFTSFD				V	
7H4.25	Heavy	GFNKDIY	12	IDPADGHS	31	SRSGAI	32
			37	INTETGEP	38		
2A3.1	Heavy	YTLTDYS				ARTARDY	39
2H10.12	Heavy	GYTLTDYS	41	INTETGEP	38	GRTARADY	42
6D1.22	Heavy	GYTLTDYS	41	INTETGDP	43	ARTARADY	38
			46	IRLKSDNY	47		
6C4.15	Heavy	GFSFSNYW		GT		SAYGDYEY	48
			50		51	SRFHYYGRTA	52
6C10.19	Heavy	GYEFTDFE		FDPETGRS		Y	
8C2.9	Heavy	GFTFSNYY	53	IKSNGVST	54	VRHDGYYFAY	55
4F1.7	Heavy	GFSIKDTT	58	IDPTDGHN	59	KQSYNLWT	60

^aAmplified PCR products from cDNA which was synthesized from total RNA extracted from hybridoma cells were sequenced and analyzed using IMGT Vquest.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- 5 1. Ryan KJ, Ray CG, Sherris JC, editors (2004) Sherris medical microbiology : an introduction to infectious diseases. 4th ed. New York: McGraw-Hill. xiii, 979 p. p.
2. Lowy FD (1998) *Staphylococcus aureus* infections. *The New England journal of medicine* 339: 520-532.
3. Boucher HW, Corey GR (2008) Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 46 Suppl 5: S344-349.
- 10 10. Boucher HW, Corey GR (2008) Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 46 Suppl 5: S344-349.
4. Chu VH, Crosslin DR, Friedman JY, Reed SD, Cabell CH, et al. (2005) *Staphylococcus aureus* bacteremia in patients with prosthetic devices: costs and outcomes. *The American journal of medicine* 118: 1416.
- 15 5. Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, et al. (2009) *Staphylococcus aureus* community-acquired pneumonia during the 2006 to 2007 influenza season. *Annals of emergency medicine* 53: 358-365.
6. Kang J, Sickbert-Bennett EE, Brown VM, Weber DJ, Rutala WA (2011) Relative frequency of health care-associated pathogens by infection site at a university hospital from 20 1980 to 2008. *American journal of infection control*.
7. Gravenkemper CF, Brodie JL, Kirby WM (1965) Resistance of Coagulase-Positive *Staphylococci* to Methicillin and Oxacillin. *Journal of bacteriology* 89: 1005-1010.
8. Saravolatz LD, Pohlod DJ, Arking LM (1982) Community-acquired methicillin-resistant *Staphylococcus aureus* infections: a new source for nosocomial outbreaks. *Annals of internal medicine* 97: 325-329.
- 25 9. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, et al. (1998) Community-acquired methicillin-resistant *Staphylococcus aureus* in children with no identified predisposing risk. *JAMA : the journal of the American Medical Association* 279: 593-598.
- 30 10. Noble WC, Virani Z, Cree RG (1992) Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS microbiology letters* 72: 195-198.

11. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, et al. (2003) Genetic analysis of a high-level vancomycin-resistant isolate of *Staphylococcus aureus*. *Science* 302: 1569-1571.

12. McAleese FM, Foster TJ (2003) Analysis of mutations in the *Staphylococcus aureus* *clfB* promoter leading to increased expression. *Microbiology* 149: 99-109.

5 13. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, et al. (2008) Vancomycin-resistant *Staphylococcus aureus* in the United States, 2002-2006. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 46: 668-674.

10 14. Ferry T, Perpoint T, Vandenesch F, Etienne J (2005) Virulence determinants in *Staphylococcus aureus* and their involvement in clinical syndromes. *Current infectious disease reports* 7: 420-428.

15 15. Hartleib J, Kohler N, Dickinson RB, Chhatwal GS, Sixma JJ, et al. (2000) Protein A is the von Willebrand factor binding protein on *Staphylococcus aureus*. *Blood* 96: 2149-2156.

16. Clarke SR, Foster SJ (2006) Surface adhesins of *Staphylococcus aureus*. *Advances in microbial physiology* 51: 187-224.

15 17. Schneewind O, Fowler A, Faull KF (1995) Structure of the cell wall anchor of surface proteins in *Staphylococcus aureus*. *Science* 268: 103-106.

18. Mazmanian SK, Liu G, Ton-That H, Schneewind O (1999) *Staphylococcus aureus* sortase, an enzyme that anchors surface proteins to the cell wall. *Science* 285: 760-763.

20 19. Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O (2000) *Staphylococcus aureus* sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. *Proceedings of the National Academy of Sciences of the United States of America* 97: 5510-5515.

25 20. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, et al. (2011) Preventing *Staphylococcus aureus* sepsis through the inhibition of its agglutination in blood. *PLoS pathogens* 7: e1002307.

21. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, et al. (2009) Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 23: 3393-3404.

30 22. Mazmanian SK, Skaar EP, Gaspar AH, Humayun M, Gornicki P, et al. (2003) Passage of heme-iron across the envelope of *Staphylococcus aureus*. *Science* 299: 906-909.

23. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, et al. (2004) Role of teichoic acids in *Staphylococcus aureus* nasal colonization, a major risk factor in nosocomial infections. *Nature medicine* 10: 243-245.

24. Lee JC, Betley MJ, Hopkins CA, Perez NE, Pier GB (1987) Virulence studies, in mice, of transposon-induced mutants of *Staphylococcus aureus* differing in capsule size. *The Journal of infectious diseases* 156: 741-750.

5 25. Lin WS, Cunneen T, Lee CY (1994) Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in *Staphylococcus aureus*. *Journal of bacteriology* 176: 7005-7016.

10 26. Baddour LM, Lowrance C, Albus A, Lowrance JH, Anderson SK, et al. (1992) *Staphylococcus aureus* microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. *The Journal of infectious diseases* 165: 749-753.

15 27. Tuchscherer LP, Buzzola FR, Alvarez LP, Caccuri RL, Lee JC, et al. (2005) Capsule-negative *Staphylococcus aureus* induces chronic experimental mastitis in mice. *Infection and immunity* 73: 7932-7937.

28. Na'was T, Hawwari A, Hendrix E, Hebden J, Edelman R, et al. (1998) Phenotypic and genotypic characterization of nosocomial *Staphylococcus aureus* isolates from trauma patients. *Journal of clinical microbiology* 36: 414-420.

20 29. Paul-Satyaseela M, van Belkum A, Shivannavar CT, Gaddad SM (2004) Carriage of capsulated strains of *Staphylococcus aureus*: a population-based study performed in Gulbarga, South India. *Epidemiology and infection* 132: 831-838.

30. Melles DC, Taylor KL, Fattom AI, van Belkum A (2008) Serotyping of Dutch *Staphylococcus aureus* strains from carriage and infection. *FEMS immunology and medical microbiology* 52: 287-292.

25 31. Lattar SM, Tuchscherer LP, Caccuri RL, Centron D, Becker K, et al. (2009) Capsule expression and genotypic differences among *Staphylococcus aureus* isolates from patients with chronic or acute osteomyelitis. *Infection and immunity* 77: 1968-1975.

32. Sutter DE, Summers AM, Keys CE, Taylor KL, Frasch CE, et al. (2011) Capsular serotype of *Staphylococcus aureus* in the era of community-acquired MRSA. *FEMS immunology and medical microbiology* 63: 16-24.

30 33. Gonzalez MR, Bischofberger M, Pernot L, van der Goot FG, Freche B (2008) Bacterial pore-forming toxins: the (w)hole story? *Cellular and molecular life sciences : CMLS* 65: 493-507.

34. Wilke GA, Bubeck Wardenburg J (2010) Role of a disintegrin and metalloprotease 10 in *Staphylococcus aureus* alpha-hemolysin-mediated cellular injury. *Proceedings of the National Academy of Sciences of the United States of America* 107: 13473-13478.

35. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, et al. (2011) A 5 *Staphylococcus aureus* pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. *Nature medicine*.

36. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J (2012) ADAM10 Mediates Vascular Injury Induced by *Staphylococcus aureus* alpha-Hemolysin. *The Journal of infectious diseases*.

10 37. Kanyka T, Shaw LN, Potempa J (2011) Papain-like proteases of *Staphylococcus aureus*. *Advances in experimental medicine and biology* 712: 1-14.

38. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, et al. (2004) Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial antiinflammatory agent. *The Journal of experimental medicine* 199: 687-695.

15 39. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, et al. (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. *Nature immunology* 6: 920-927.

40. Thammavongsa V, Kern JW, Missiakas DM, Schneewind O (2009) *Staphylococcus aureus* synthesizes adenosine to escape host immune responses. *The Journal of experimental 20 medicine* 206: 2417-2427.

41. Palmqvist N, Patti JM, Tarkowski A, Josefsson E (2004) Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. *Microbes and infection / Institut Pasteur* 6: 188-195.

42. Peterson PK, Verhoef J, Sabath LD, Quie PG (1977) Effect of protein A on 25 staphylococcal opsonization. *Infection and immunity* 15: 760-764.

43. Goodyear CS, Silverman GJ (2004) Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America* 101: 11392-11397.

44. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O (2010) Nontoxicogenic 30 protein A vaccine for methicillin-resistant *Staphylococcus aureus* infections in mice. *The Journal of experimental medicine* 207: 1863-1870.

45. Wang Z, Wilhelmsson C, Hyrsil P, Loof TG, Dobes P, et al. (2010) Pathogen entrapment by transglutaminase--a conserved early innate immune mechanism. *PLoS pathogens* 6: e1000763.

46. Loof TG, Morgelin M, Johansson L, Oehmcke S, Olin AI, et al. (2011) Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. *Blood*.

47. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB (2007) Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. *PLoS one* 2: e623.

5 48. Loeb L (1903) The Influence of certain Bacteria on the Coagulation of the Blood. *The Journal of medical research* 10: 407-419.

49. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, et al. (2010) Contribution of coagulases towards *Staphylococcus aureus* disease and protective immunity. *PLoS pathogens* 6.

10 50. Adams RL, Bird RJ (2009) Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants. *Nephrology* 14: 462-470.

51. Gailani D, Renne T (2007) Intrinsic pathway of coagulation and arterial thrombosis. *Arteriosclerosis, thrombosis, and vascular biology* 27: 2507-2513.

15 52. Procyk R, Blomback B (1990) Disulfide bond reduction in fibrinogen: calcium protection and effect on clotability. *Biochemistry* 29: 1501-1507.

53. Kollman JM, Pandi L, Sawaya MR, Riley M, Doolittle RF (2009) Crystal structure of human fibrinogen. *Biochemistry* 48: 3877-3886.

20 54. Blomback B, Hessel B, Hogg D, Therkildsen L (1978) A two-step fibrinogen--fibrin transition in blood coagulation. *Nature* 275: 501-505.

55. Yang Z, Mochalkin I, Doolittle RF (2000) A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. *Proceedings of the National Academy of Sciences of the United States of America* 97: 14156-14161.

25 56. Lorand L (2000) Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies. *Arteriosclerosis, thrombosis, and vascular biology* 20: 2-9.

57. Delvaeye M, Conway EM (2009) Coagulation and innate immune responses: can we view them separately? *Blood* 114: 2367-2374.

30 58. Walker JB, Nesheim ME (1999) The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. *The Journal of biological chemistry* 274: 5201-5212.

59. Rijken DC, Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. *Journal of thrombosis and haemostasis : JTH* 7: 4-13.

60. Lord ST (2011) Molecular mechanisms affecting fibrin structure and stability. *Arteriosclerosis, thrombosis, and vascular biology* 31: 494-499.

61. Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, et al. (2011) Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation 5 through direct interaction with fibrin. *Blood*.

62. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, et al. (2000) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. *Blood* 96: 988-995.

63. Andersen MD, Kjalke M, Bang S, Lautrup-Larsen I, Becker P, et al. (2009) Coagulation 10 factor XIII variants with altered thrombin activation rates. *Biological chemistry* 390: 1279-1283.

64. Wolberg AS (2010) Plasma and cellular contributions to fibrin network formation, structure and stability. *Haemophilia : the official journal of the World Federation of Hemophilia* 16 Suppl 3: 7-12.

65. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA (2010) Polyphosphate 15 modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. *Blood* 115: 3980-3988.

66. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, et al. (2003) Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. 20 *Nature* 425: 535-539.

67. Kroh HK, Panizzi P, Bock PE (2009) Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. *Proceedings of the National Academy of Sciences of the United States of America* 106: 7786-7791.

68. Watanabe S, Ito T, Takeuchi F, Endo M, Okuno E, et al. (2005) Structural comparison of 25 ten serotypes of staphylocoagulases in *Staphylococcus aureus*. *Journal of bacteriology* 187: 3698-3707.

69. Kawabata S, Morita T, Iwanaga S, Igarashi H (1985) Staphylocoagulase-binding region in human prothrombin. *Journal of biochemistry* 97: 325-331.

70. Cheung AI, Projan SJ, Edelstein RE, Fischetti VA (1995) Cloning, expression, and 30 nucleotide sequence of a *Staphylococcus aureus* gene (fbpA) encoding a fibrinogen-binding protein. *Infection and immunity* 63: 1914-1920.

71. Phonimdaeng P, O'Reilly M, O'Toole PW, Foster TJ (1988) Molecular cloning and expression of the coagulase gene of *Staphylococcus aureus* 8325-4. *Journal of general microbiology* 134: 75-83.

72. Bjerketorp J, Jacobsson K, Frykberg L (2004) The von Willebrand factor-binding protein (vWbp) of *Staphylococcus aureus* is a coagulase. *FEMS microbiology letters* 234: 309-314.

73. Bjerketorp J, Nilsson M, Ljungh A, Flock JI, Jacobsson K, et al. (2002) A novel von Willebrand factor binding protein expressed by *Staphylococcus aureus*. *Microbiology* 148: 2037-2044.

5 74. Chapman GH, Berens C, Peters A, Curcio L (1934) Coagulase and Hemolysin Tests as Measures of the Pathogenicity of Staphylococci. *Journal of bacteriology* 28: 343-363.

75. Spink WW, Vivino JJ (1942) The Coagulase Test for Staphylococci and Its Correlation with the Resistance of the Organisms to the Bactericidal Action of Human Blood. *The 10 Journal of clinical investigation* 21: 353-356.

76. Ekstedt RD, Yotis WW (1960) Studies on staphylococci. II. Effect of coagulase on the virulence of coagulase negative strains. *Journal of bacteriology* 80: 496-500.

77. Phonimdaeng P, O'Reilly M, Nowlan P, Bramley AJ, Foster TJ (1990) The coagulase of *Staphylococcus aureus* 8325-4. Sequence analysis and virulence of site-specific coagulase-15 deficient mutants. *Molecular microbiology* 4: 393-404.

78. Baddour LM, Tayidi MM, Walker E, McDevitt D, Foster TJ (1994) Virulence of coagulase-deficient mutants of *Staphylococcus aureus* in experimental endocarditis. *Journal of medical microbiology* 41: 259-263.

79. Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, et al. (1995) Role of 20 *Staphylococcus aureus* coagulase and clumping factor in pathogenesis of experimental endocarditis. *Infection and immunity* 63: 4738-4743.

80. Stutzmann Meier P, Entenza JM, Vaudaux P, Francioli P, Glauser MP, et al. (2001) Study of *Staphylococcus aureus* pathogenic genes by transfer and expression in the less virulent organism *Streptococcus gordonii*. *Infection and immunity* 69: 657-664.

25 81. Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, et al. (1997) Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of *Staphylococcus aureus* enmeshed in agar beads. *Infection and immunity* 65: 466-471.

82. Haraldsson I, Jonsson P (1984) Histopathology and pathogenesis of mouse mastitis 30 induced with *Staphylococcus aureus* mutants. *Journal of comparative pathology* 94: 183-196.

83. Jonsson P, Lindberg M, Haraldsson I, Wadstrom T (1985) Virulence of *Staphylococcus aureus* in a mouse mastitis model: studies of alpha hemolysin, coagulase, and protein A as possible virulence determinants with protoplast fusion and gene cloning. *Infection and immunity* 49: 765-769.

84. Seki K, Ogasawara M, Sakurada J, Murai M, Masuda S (1989) Altered virulence of a pleiotropic *Staphylococcus aureus* mutant with a low producibility of coagulase and other factors in mice. *Microbiology and immunology* 33: 981-990.

85. Johnstone JM, Smith DD (1956) Coagulase activity in vivo. *Nature* 178: 982-983.

5 86. Lam GT, Sweeney FJ, Jr., Witmer CM, Wise RI (1963) Abscess-Forming Factor(S) Produced by *Staphylococcus Aureus*. I. Collodion Bag Implantation Technique. *Journal of bacteriology* 86: 611-615.

87. Lam GT, Sweeney FJ, Jr., Witmer CM, Wise RI (1963) Abscess-Forming Factor(S) Produced by *Staphylococcus Aureus*. II. Abscess Formation and Immunity by a

10 10. *Staphylococcus and Its Mutants*. *Journal of bacteriology* 86: 87-91.

88. Cawdery M, Foster WD, Hawgood BC, Taylor C (1969) The role of coagulase in the defence of *Staphylococcus aureus* against phagocytosis. *British journal of experimental pathology* 50: 408-412.

89. Kapral FA (1966) Clumping of *Staphylococcus aureus* in the peritoneal cavity of mice.

15 15. *Journal of bacteriology* 92: 1188-1195.

90. Yeaman MR, Norman DC, Bayer AS (1992) Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy* 36: 1665-1670.

91. Fitzgerald JR, Foster TJ, Cox D (2006) The interaction of bacterial pathogens with

20 20. platelets. *Nature reviews Microbiology* 4: 445-457.

92. Ni Eidhin D, Perkins S, Francois P, Vaudaux P, Hook M, et al. (1998) Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of *Staphylococcus aureus*. *Molecular microbiology* 30: 245-257.

93. O'Brien L, Kerrigan SW, Kaw G, Hogan M, Penades J, et al. (2002) Multiple mechanisms

25 25. for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Molecular microbiology* 44: 1033-1044.

94. Niemann S, Spehr N, Van Aken H, Morgenstern E, Peters G, et al. (2004) Soluble fibrin is the main mediator of *Staphylococcus aureus* adhesion to platelets. *Circulation* 110: 193-

30 30. 200.

95. Much H (1908) Über eine Vorstufe des Fibrinfermentes in Kulturen von *Staphylokokkus aureus*. *Biochem Z* 14: 143-155.

96. Birch-Hirschfeld L (1934) Über die Agglutination von *Staphylokokken* durch Bestandteile des Säugetierblutplasmas. *Klinische Wochenschrift* 13: 331.

97. Cadness-Graves B, WR, Harper C.J., Miles A.A. (1943) Slide test for coagulase- positive staphylococci. *Lancet* 2: 736-738.

98. Berger F (1943) Clumping of pathogenic staphylococci in plasma. *Journal of Pathology and Bacteriology* 55.

5 99. Duthie ES (1954) Evidence for two forms of staphylococcal coagulase. *Journal of general microbiology* 10: 427-436.

100. McDevitt D, Francois P, Vaudaux P, Foster TJ (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Molecular microbiology* 11: 237-248.

10 101. Que YA, Haefliger JA, Francioli P, Moreillon P (2000) Expression of *Staphylococcus aureus* clumping factor A in *Lactococcus lactis* subsp. *cremoris* using a new shuttle vector. *Infection and immunity* 68: 3516-3522.

102. Umeda A, Ikebuchi T, Amako K (1980) Localization of bacteriophage receptor, clumping factor, and protein A on the cell surface of *Staphylococcus aureus*. *Journal of bacteriology* 141: 838-844.

15 103. Jensen K (2007) A normally occurring *Staphylococcus* antibody in human serum. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica* 115: 533-539; discussion 540-531.

104. Deisenhofer J, Jones TA, Huber R, Sjodahl J, Sjoquist J (1978) Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from *Staphylococcus aureus*. *Hoppe-Seyler's Zeitschrift fur physiologische Chemie* 359: 975-985.

20 105. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, et al. (2000) Crystal structure of a *Staphylococcus aureus* protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. *Proceedings of the National Academy of Sciences of the United States of America* 97: 5399-5404.

25 106. O'Seaghda M, van Schooten CJ, Kerrigan SW, Emsley J, Silverman GJ, et al. (2006) *Staphylococcus aureus* protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. *The FEBS journal* 273: 4831-4841.

30 107. Projan SJ, Nesin M, Dunman PM (2006) Staphylococcal vaccines and immunotherapy: to dream the impossible dream? *Current opinion in pharmacology* 6: 473-479.

108. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, et al. (2002) Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. *The New England journal of medicine* 346: 491-496.

109. Fattom A, Fuller S, Propst M, Winston S, Muenz L, et al. (2004) Safety and immunogenicity of a booster dose of *Staphylococcus aureus* types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. *Vaccine* 23: 656-663.

110. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, et al. (2006) A novel *Staphylococcus aureus* vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine *S. aureus* sepsis model. *Infection and immunity* 74: 2215-2223.

111. Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, et al. (2010) Safety and immunogenicity of a novel *Staphylococcus aureus* vaccine: results from the first study of the vaccine dose range in humans. *Clinical and vaccine immunology : CVI* 17: 1868-1874.

112. Kernodle DS (2011) Expectations regarding vaccines and immune therapies directed against *Staphylococcus aureus* alpha-hemolysin. *The Journal of infectious diseases* 203: 1692-1693; author reply 1693-1694.

113. DeDent A, Kim HK, Missiakas D, Schneewind O (2012) Exploring *Staphylococcus aureus* pathways to disease for vaccine development. *Seminars in immunopathology* 34: 317-333.

114. Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, et al. (1998) Autoinducer of virulence as a target for vaccine and therapy against *Staphylococcus aureus*. *Science* 280: 438-440.

115. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, et al. (2008) Vaccination with clumping factor A and fibronectin binding protein A to prevent *Staphylococcus aureus* infection of an aortic patch in mice. *The Journal of infectious diseases* 198: 571-575.

116. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against *Staphylococcus aureus* pneumonia. *The Journal of experimental medicine* 205: 287-294.

117. Gong R, Hu C, Xu H, Guo A, Chen H, et al. (2010) Evaluation of clumping factor A binding region A in a subunit vaccine against *Staphylococcus aureus*-induced mastitis in mice. *Clinical and vaccine immunology : CVI* 17: 1746-1752.

118. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T (2001) Protection against experimental *Staphylococcus aureus* arthritis by vaccination with clumping factor A, a novel virulence determinant. *The Journal of infectious diseases* 184: 1572-1580.

119. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, et al. (2010) IsdA and IsdB antibodies protect mice against *Staphylococcus aureus* abscess formation and lethal challenge. *Vaccine* 28: 6382-6392.

120. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A (1998) Vaccination with a recombinant fragment of collagen adhesin provides protection against *Staphylococcus aureus*-mediated septic death. *The Journal of clinical investigation* 101: 2640-2649.

5 121. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, et al. (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. *The Journal of infectious diseases* 202: 1050-1058.

10 122. Stranger-Jones YK, Bae T, Schneewind O (2006) Vaccine assembly from surface proteins of *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences of the United States of America* 103: 16942-16947.

123. Kim HK, Kim HY, Schneewind O, Missiakas D (2011) Identifying protective antigens of *Staphylococcus aureus*, a pathogen that suppresses host immune responses. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 25: 3605-3612.

15 124. Watanabe S, Ito T, Sasaki T, Li S, Uchiyama I, et al. (2009) Genetic diversity of staphylocoagulase genes (coa): insight into the evolution of variable chromosomal virulence factors in *Staphylococcus aureus*. *PLoS one* 4: e5714.

20 125. McCarthy AJ, Lindsay JA (2010) Genetic variation in *Staphylococcus aureus* surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. *BMC microbiology* 10: 173.

126. Klevens RM, Edwards JR, Gaynes RP, System NNIS (2008) The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States.

25 127. Rogers DE, Melly MA (1965) Speculations on the immunology of staphylococcal infections. *Annals of the New York Academy of Sciences* 128: 274-284.

128. Goodyear CS, Silverman GJ (2003) Death by a B cell superantigen: In vivo VH-targeted apoptotic suprACLonal B cell deletion by a Staphylococcal Toxin. *The Journal of experimental medicine* 197: 1125-1139.

30 129. Field HI, Smith, H.W. (1945) Coagulase test for staphylococci. *J Comp Pathol* 55: 63.

130. Smith W, Hale JH, Smith MM (1947) The role of coagulase in staphylococcal infections. *British journal of experimental pathology* 28: 57-67.

131. Kinoshita M, Kobayashi N, Nagashima S, Ishino M, Otokozawa S, et al. (2008) Diversity of staphylocoagulase and identification of novel variants of staphylocoagulase gene in *Staphylococcus aureus*. *Microbiology and immunology* 52: 334-348.

5 132. Duthie ES, Lorenz LL (1952) Staphylococcal coagulase: mode of action and antigenicity. *J Gen Microbiol* 6: 95-107.

133. Panizzi P, Friedrich R, Fuentes-Prior P, Richter K, Bock PE, et al. (2006) Fibrinogen substrate recognition by staphylocoagulase.(pro)thrombin complexes. *The Journal of biological chemistry* 281: 1179-1187.

10 134. Tager M, Drummond MC (1965) Staphylocoagulase. *Annals of the New York Academy of Sciences* 128: 92-111.

135. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K (2007) Genome sequence of *Staphylococcus aureus* strain Newman and comparative analysis of staphylococcal genomes. *J Bacteriol* 190: 300-310.

15 136. Albus A, Arbeit RD, Lee JC (1991) Virulence of *Staphylococcus aureus* mutants altered in type 5 capsule production. *Infection and immunity* 59: 1008-1014.

137. Rothfork JM, Dessus-Babus S, Van Wamel WJ, Cheung AL, Gresham HD (2003) Fibrinogen depletion attenuates *Staphylococcus aureus* infection by preventing density-dependent virulence gene up-regulation. *Journal of immunology* 171: 5389-5395.

20 138. Silberman S, Bernik MB, Potter EV, Kwaan HC (1973) Effects of Ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity. *British journal of haematology* 24: 101-113.

139. Bae T, Schneewind O (2006) Allelic replacement in *Staphylococcus aureus* with inducible counter-selection. *Plasmid* 55: 58-63.

25 140. Schneewind O, Mihaylova-Petkov D, Model P (1993) Cell wall sorting signals in surface proteins of gram-positive bacteria. *The EMBO journal* 12: 4803-4811.

141. Schneewind O, Model P, Fischetti VA (1992) Sorting of protein A to the staphylococcal cell wall. *Cell* 70: 267-281.

30 142. Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, et al. (1986) Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, *Hirudo medicinalis*. *Proceedings of the National Academy of Sciences of the United States of America* 83: 1084-1088.

143. Markwardt F (1955) Untersuchungen über Hirudin: naturwiss. F.

144. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA : the journal of the American Medical Association* 298: 1763-1771.

145. DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, et al. (2006) Immunogenicity and protective immunity against bubonic and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. *Infect Immun* 74: 4910-4914.

146. Panizzi P, Friedrich R, Fuentes-Prior P, Kroh HK, Briggs J, et al. (2006) Novel fluorescent prothrombin analogs as probes of staphylocoagulase-prothrombin interactions.

10 The Journal of biological chemistry 281: 1169-1178.

147. Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L, et al. (2008) Epidemic community-associated methicillin-resistant *Staphylococcus aureus*: recent clonal expansion and diversification. *Proceedings of the National Academy of Sciences of the United States of America* 105: 1327-1332.

15 148. Mainiero M, Goerke C, Geiger T, Gonser C, Herbert S, et al. (2010) Differential target gene activation by the *Staphylococcus aureus* two-component system saeRS. *Journal of bacteriology* 192: 613-623.

149. Geoghegan JA, Ganesh VK, Smeds E, Liang X, Hook M, et al. (2010) Molecular characterization of the interaction of staphylococcal microbial surface components recognizing adhesive matrix molecules (MSCRAMM) ClfA and Fbl with fibrinogen. *The Journal of biological chemistry* 285: 6208-6216.

20 150. Josefsson E, Higgins J, Foster TJ, Tarkowski A (2008) Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for *Staphylococcus aureus* virulence. *PloS one* 3: e2206.

25 151. Palma M, Wade D, Flock M, Flock JI (1998) Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from *Staphylococcus aureus* and fibrinogen. *The Journal of biological chemistry* 273: 13177-13181.

152. Heilmann C, Herrmann M, Kehrel BE, Peters G (2002) Platelet-binding domains in 2 fibrinogen-binding proteins of *Staphylococcus aureus* identified by phage display. *The Journal of infectious diseases* 186: 32-39.

30 153. Hussain M, Becker K, von Eiff C, Schrenzel J, Peters G, et al. (2001) Identification and characterization of a novel 38.5-kilodalton cell surface protein of *Staphylococcus aureus* with extended-spectrum binding activity for extracellular matrix and plasma proteins. *Journal of bacteriology* 183: 6778-6786.

154. Streitfeld MM, Sallman B, Shoelson SM (1959) Staphylocoagulase inhibition by pooled human gamma-globulin. *Nature* 184(Suppl 21): 1665-1666.

155. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW (1990) Use of T7 RNA polymerase to direct expression of cloned genes. *Methods in enzymology* 185: 60-89.

5 156. Chambers HF, Deleo FR (2009) Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature reviews Microbiology* 7: 629-641.

157. Fowler VG, Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, et al. (2005) *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA : the journal of the American Medical Association* 293: 3012-3021.

10 158. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF (2010) Community-associated meticillin-resistant *Staphylococcus aureus*. *Lancet* 375: 1557-1568.

159. Foster TJ (2005) Immune evasion by staphylococci. *Nature reviews Microbiology* 3: 948-958.

160. Walsh EJ, Mijajlovic H, Gorkun OV, Foster TJ (2008) Identification of the 15 *Staphylococcus aureus* MSCRAMM clumping factor B (ClfB) binding site in the alphaC-domain of human fibrinogen. *Microbiology* 154: 550-558.

161. Cheng AG, DeDent AC, Schneewind O, Missiakas D (2011) A play in four acts: *Staphylococcus aureus* abscess formation. *Trends in microbiology* 19: 225-232.

20 162. Doolittle RF (2003) Structural basis of the fibrinogen-fibrin transformation: contributions from X-ray crystallography. *Blood reviews* 17: 33-41.

163. Kolle W, Otto, R. (1902) Die Differenzierung der Staphylokokken mittelst der Agglutination. *Z Hygiene* 41.

164. Hawiger J, Timmons S, Strong DD, Cottrell BA, Riley M, et al. (1982) Identification of 25 a region of human fibrinogen interacting with staphylococcal clumping factor. *Biochemistry* 21: 1407-1413.

165. McDevitt D, Francois P, Vaudaux P, Foster TJ (1995) Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of *Staphylococcus aureus*. *Molecular microbiology* 16: 895-907.

166. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, et al. (1997) 30 Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. *European journal of biochemistry / FEBS* 247: 416-424.

167. Strong DD, Laudano AP, Hawiger J, Doolittle RF (1982) Isolation, characterization, and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle. *Biochemistry* 21: 1414-1420.

168. Ganesh VK, Rivera JJ, Smeds E, Ko YP, Bowden MG, et al. (2008) A structural model of the *Staphylococcus aureus* ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. *PLoS pathogens* 4: e1000226.

169. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, et al. (2010) Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of *Staphylococcus aureus* and decreases complement-mediated phagocytosis. *Infection and immunity* 78: 1717-1727.

5 170. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syrbeys PJ, et al. (2003) Characterization of a protective monoclonal antibody recognizing *Staphylococcus aureus* MSCRAMM protein clumping factor A. *Infection and immunity* 71: 6864-6870.

10 171. Weems JJ, Jr., Steinberg JP, Filler S, Baddley JW, Corey GR, et al. (2006) Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of *Staphylococcus aureus* bacteremia. *Antimicrobial agents and chemotherapy* 50: 2751-2755.

15 172. Bae T, Banger AK, Wallace A, Glass EM, Aslund F, et al. (2004) *Staphylococcus aureus* virulence genes identified by bursa aurealis mutagenesis and nematode killing. *Proceedings of the National Academy of Sciences of the United States of America* 101: 12312-12317.

20 173. Kaida S, Miyata T, Yoshizawa Y, Kawabata S, Morita T, et al. (1987) Nucleotide sequence of the staphylocoagulase gene: its unique COOH-terminal 8 tandem repeats. *Journal of biochemistry* 102: 1177-1186.

174. Palma M, Nozohoor S, Schennings T, Heimdal A, Flock JI (1996) Lack of the extracellular 19-kilodalton fibrinogen-binding protein from *Staphylococcus aureus* decreases virulence in experimental wound infection. *Infection and immunity* 64: 5284-5289.

25 175. Hawiger J, Hammond DK, Timmons S (1975) Human fibrinogen possesses binding site for staphylococci on Aalpha and Bbeta polypeptide chains. *Nature* 258: 643-645.

176. Hijikata-Okunomiya A, Kataoka N (2003) Argatroban inhibits staphylothrombin. *Journal of thrombosis and haemostasis : JTH* 1: 2060-2061.

30 177. Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P (2010) Dabigatran inhibits *Staphylococcus aureus* coagulase activity. *Journal of clinical microbiology* 48: 4248-4250.

178. Hauel NH, Nar H, Priecke H, Ries U, Stassen JM, et al. (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. *Journal of medicinal chemistry* 45: 1757-1766.

179. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359: 1819-1827.

180. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, et al. (2001) Whole genome sequencing of meticillin-resistant *Staphylococcus aureus*. Lancet 357: 1225-1240.

5 181. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52: 285-292.

10 182. Walsh CT (1993) Vancomycin resistance: decoding the molecular logic. Science 261: 308-309.

183. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, et al. (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. The New England journal of medicine 355: 653-665.

15 184. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, et al. (2006) Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant *Staphylococcus aureus*. Lancet 367: 731-739.

185. Donahue JP, Patel H, Anderson WF, Hawiger J (1994) Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen gamma chain obtained by carrier protein-driven crystallization. Proceedings of the National Academy of Sciences of the United States of America 91: 12178-12182.

20 186. Ware S, Donahue JP, Hawiger J, Anderson WF (1999) Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein science : a publication of the Protein Society 8: 2663-2671.

187. DeDent A, Bae T, Missiakas DM, Schneewind O (2008) Signal peptides direct surface proteins to two distinct envelope locations of *Staphylococcus aureus*. The EMBO journal 27: 2656-2668.

25 188. Panizzi P, Friedrich R, Fuentes-Prior P, Bode W, Bock PE (2004) The staphylocoagulase family of zymogen activator and adhesion proteins. Cellular and molecular life sciences : CMLS 61: 2793-2798.

189. Hale JH, Smith W (1945) The influence of coagulase on the phagocytosis of staphylococci. Br J Exp Pathol 26: 209-216.

30 190. Smith DD, Johnstone JM (1956) Coagulase activity *in vivo*. Nature 178: 982-983.

191. Kanemitsu K, Yamamoto H, Takemura, Kaku M, Shimada J (2001) Relatedness between the coagulase gene 3'-end region and coagulase serotypes among *Staphylococcus aureus* strains. *Microbiol Immunol* 45: 23-27.

192. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence 5 typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* 38: 1008-1015.

193. Panizzi P, Nahrendorf M, Figueiredo JL, Panizzi J, Marinelli B, et al. (2011) In vivo detection of *Staphylococcus aureus* endocarditis by targeting pathogen-specific prothrombin activation. *Nat Med* 17: 1142-1146.

194. Patel G, Jenkins SG, Mediavilla JR, Kreiswirth BN, Radbill B, et al. (2011) Clinical and 10 Molecular Epidemiology of Methicillin-Resistant *Staphylococcus aureus* among Patients in an Ambulatory Hemodialysis Center. *Infection control and hospital epidemiology* : the official journal of the Society of Hospital Epidemiologists of America 32: 881-888.

195. Tager M, Hales HB (1948) Properties of coagulase-reacting factor, and relation to blood 15 clotting components. *Journal of immunology* 60: 1-9.

196. Lominski I, Roberts GB (1946) A substance in human serum inhibiting staphylocoagulase. *The Journal of pathology and bacteriology* 58: 187-199.

197. Lominski I (1949) Susceptibility and resistance to staphylococcal infection. *Journal of general microbiology* 3: ix.

198. Lominski I, Smith DD, Scott AC, Arbuthnott JP, Gray S, et al. (1962) Immunisation 20 against experimental staphylococcal infection with coagulase-rich preparations. *Lancet* 1: 1315-1318.

199. Boake WC (1956) Antistaphylocoagulase in experimental staphylococcal infections. *Journal of immunology* 76: 89-96.

200. Rammelkamp CH, Hezebicks MM, Dingle JH (1950) Specific Coagulases of 25 *Staphylococcus Aureus*. *The Journal of experimental medicine* 91: 295-307.

201. Duthie ES (1952) Variation in the antigenic composition of staphylococcal coagulase. *Journal of general microbiology* 7: 320-326.

202. Harrison KJ (1964) The Protection of Rabbits against Infection with Staphylococci by 30 Immunisation with Staphylocoagulase Toxin or Toxoid. *The Journal of pathology and bacteriology* 87: 145-150.

203. Rammelkamp Jr CH, Lebovitz JJ (1956) Immunity, epidemiology and antimicrobial resistance. The role of coagulase in staphylococcal infections. *Ann NY Acad Sci* 65: 144-151.

204. Harrison KJ (1963) Clinical trial of coagulase and alpha-hemolysin toxoids in chronic furunculosis. *Br Med J* 2: 149-152.

205. Koreen L, Ramaswamy SV, Graviss EA, Naidich S, Musser JM, et al. (2004) *spa* typing method for discriminating among *Staphylococcus aureus* isolates: implications for use of a single marker to detect genetic micro- and macrovariation. *J Clin Microbiol* 42: 792-799.

5 206. Lancefield RC (1928) The antigenic complex of *Streptococcus hemolyticus*. I. Demonstration of a type-specific substance in extracts of *Streptococcus hemolyticus*. *J Exp Med* 47: 91-103.

10 207. Lancefield R (1962) Current knowledge of type-specific M antigens of group A streptococci. *J Immunol* 89: 307-313.

208. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, et al. (2005) Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. *Proc Natl Acad Sci USA* 102: 15641-15646.

15 209. Nuccitelli A, Cozzi R, Goutlay LJ, Donnarumma D, Necchi F, et al. (2011) A structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B *Streptococcus* infections. *Proc Natl Acad Sci USA* 108: 10278-10283.

210. Schneewind O, Missiakas D (2011) Structural vaccinology to thwart antigenic variation in microbial pathogens. *Proc Natl Acad Sci USA* 108: 10029-10030.

211. Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Mediavilla JR, et al. (2012) 20 Characterization of nasal and blood culture isolates of methicillin-resistant *Staphylococcus aureus* from patients in the United States. *Antimicrob Agents Chemother* 56: 1324-1330.

212. McAdow M, Missiakas DM, Schneewind O (2012) *Staphylococcus aureus* Secretes Coagulase and von Willebrand Factor Binding Protein to Modify the Coagulation Cascade and Establish Host Infections. *Journal of innate immunity* 4: 141-148.

25 213. Vanassche T, Verhaegen J, Peetermans WE, J VANR, Cheng A, et al. (2011) Inhibition of staphylothrombin by dabigatran reduces *Staphylococcus aureus* virulence. *Journal of thrombosis and haemostasis* : JTH 9: 2436-2446.

214. Palma M, Shannon O, Quezada HC, Berg A, Flock JI (2001) Extracellular fibrinogen-binding protein, Efb, from *Staphylococcus aureus* blocks platelet aggregation due to its 30 binding to the alpha-chain. *The Journal of biological chemistry* 276: 31691-31697.

215. McAdow MD, A.C.; Emolo, C.; Cheng, A.G.; Kreiswirth, B.; Missiakas, D.M.; Schneewind, O. (2012) Coagulases as determinants of protective immune responses against *Staphylococcus aureus*. In preparation.

216. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, et al. (2006) Prevalence of *Staphylococcus aureus* nasal colonization in the United States, 2001-2002. *The Journal of infectious diseases* 193: 172-179.

217. Kluytmans J, van Belkum A, Verbrugh H (1997) Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clinical microbiology reviews* 10: 505-520.

5 218. Camargo IL, Gilmore MS (2008) *Staphylococcus aureus*--probing for host weakness? *Journal of bacteriology* 190: 2253-2256.

219. Plotkin SA, Orenstein WA, editors (2004) *Vaccines*. 4th ed. Philadelphia, Pa.: Saunders.

10 10 xxi, 1662 p. p.

220. Levine MM, editor (2010) *New generation vaccines*. 4th ed. New York: Informa Healthcare USA. xxvii, 1011 p. p.

221. Zajdel M, Wagrzynowicz Z, Jeljaszewicz J (1975) Action of staphylothrombin on bovine fibrinogen. *Thrombosis research* 6: 501-510.

15 222. Soulier JP, Prou-Wartelle O (1967) Study of thrombin-coagulase. *Thrombosis et diathesis haemorrhagica* 17: 321-334.

223. Kawabata S, Morita T, Iwanaga S, Igarashi H (1985) Difference in enzymatic properties between alpha-thrombin-staphylocoagulase complex and free alpha-thrombin. *Journal of biochemistry* 97: 1073-1078.

20 224. Kawabata S, Morita T, Iwanaga S, Igarashi H (1985) Enzymatic properties of staphylothrombin, an active molecular complex formed between staphylocoagulase and human prothrombin. *Journal of biochemistry* 98: 1603-1614.

225. Hendrix H, Lindhout T, Mertens K, Engels W, Hemker HC (1983) Activation of human prothrombin by stoichiometric levels of staphylocoagulase. *The Journal of biological chemistry* 258: 3637-3644.

25 226. Kopec M, Wegrzynowicz Z, Budzynski AZ, Jeljaszewicz J, Latallo ZS, et al. (1967) Formation and properties of fibrin clots resulting from staphylocoagulase (SC) action. *Thrombosis et diathesis haemorrhagica* 18: 475-486.

227. Crawley JT, Zanardelli S, Chion CK, Lane DA (2007) The central role of thrombin in hemostasis. *Journal of thrombosis and haemostasis : JTH* 5 Suppl 1: 95-101.

30 228. Vanassche T, Kauskot A, Verhaegen J, Peetermans WE, van Ryn J, et al. (2012) Fibrin formation by staphylothrombin facilitates *Staphylococcus aureus* -induced platelet aggregation. *Thrombosis and haemostasis* 107.

229. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, et al. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. *Nature medicine* 12: 682-687.

230. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, et al. (2002) A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. *The EMBO journal* 21: 6660-6672.

5 231. Lack CH (1948) Staphylokinase; an activator of plasma protease. *Nature* 161: 559.

232. Sakharov DV, Lijnen HR, Rijken DC (1996) Interactions between staphylokinase, 10 plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. *The Journal of biological chemistry* 271: 27912-27918.

15 233. Kwiecinski J, Josefsson E, Mitchell J, Higgins J, Magnusson M, et al. (2010) Activation of plasminogen by staphylokinase reduces the severity of *Staphylococcus aureus* systemic infection. *The Journal of infectious diseases* 202: 1041-1049.

234. Karesh A (2009) Pediatric Focused Safety Review: Argatroban. Pediatric Advisory Committee Meeting.

235. Walsh S (2010) FDA approves Pradaxa to prevent stroke in people with atrial fibrillation.

20 236. Rammelkamp CH (1948) Serologic Test for Staphylococcal Infections. *American Journal of Medicine* 4: 782-782.

237. Etz H, Minh DB, Henics T, Dryla A, Winkler B, et al. (2002) Identification of in vivo expressed vaccine candidate antigens from *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences of the United States of America* 99: 6573-6578.

25

U.S. Patent 3,817,837

U.S. Patent 3,850,752

U.S. Patent 3,939,350

U.S. Patent 3,996,345

30 U.S. Patent 4,196,265

U.S. Patent 4,275,149

U.S. Patent 4,277,437

U.S. Patent 4,338,298

U.S. Patent 4,366,241

- U.S. Patent 4,472,509
- U.S. Patent 4,472,509
- U.S. Patent 4,554,101
- U.S. Patent 4,684,611
- 5 U.S. Patent 4,748,018
- U.S. Patent 4,879,236
- U.S. Patent 4,938,948
- U.S. Patent 4,938,948
- U.S. Patent 4,952,500
- 10 U.S. Patent 5,021,236
- U.S. Patent 5,196,066
- U.S. Patent 5,262,357
- U.S. Patent 5,302,523
- U.S. Patent 5,310,687
- 15 U.S. Patent 5,322,783
- U.S. Patent 5,384,253
- U.S. Patent 5,464,765
- U.S. Patent 5,505,928
- U.S. Patent 5,512,282
- 20 U.S. Patent 5,538,877
- U.S. Patent 5,538,880
- U.S. Patent 5,548,066
- U.S. Patent 5,550,318
- U.S. Patent 5,563,055
- 25 U.S. Patent 5,580,859
- U.S. Patent 5,589,466
- U.S. Patent 5,591,616
- U.S. Patent 5,610,042
- U.S. Patent 5,648,240
- 30 U.S. Patent 5,656,610
- U.S. Patent 5,690,807
- U.S. Patent 5,702,932
- U.S. Patent 5,736,524
- U.S. Patent 5,741,957

- U.S. Patent 5,750,172
- U.S. Patent 5,756,687
- U.S. Patent 5,780,448
- U.S. Patent 5,789,215
- 5 U.S. Patent 5,801,234
- U.S. Patent 5,827,690
- U.S. Patent 5,840,846
- U.S. Patent 5,871,986
- U.S. Patent 5,945,100
- 10 U.S. Patent 5,981,274
- U.S. Patent 5,990,479
- U.S. Patent 5,994,624
- U.S. Patent 6,008,341
- U.S. Patent 6,048,616
- 15 U.S. Patent 6,091,001
- U.S. Patent 6,274,323
- U.S. Patent 6,288,214
- U.S. Patent 6,630,307
- U.S. Patent 6,651,655
- 20 U.S. Patent 6,756,361
- U.S. Patent 6,770,278
- U.S. Patent 6,793,923
- U.S. Patent 6,936,258
- U.S. Patent Serial 61/103,196
- 25 U.S. Patent Serial 61/166,432
- U.S. Patent Serial 61/170,779
- U.S. Patent Publn. 2002/0169288
- U.S. Patent Publn. 20050106660
- U.S. Patent Publn. 20060058510
- 30 U.S. Patent Publn. 20060088908
- U.S. Patent Publn. 20100285564

Atherton *et al.*, *Biol. of Reproduction*, 32:155-171, 1985.

Atkins *et al.*, *Mol. Immunol.*, 45:1600-1611, 2008.

Ausubel *et al.*, In: *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc, New York, 1996.

Baba *et al.*, *J. Bacteriol.*, 190:300-310, 2007.

Baba *et al.*, *Lancet*, 359:1819-1827, 2002.

5 Barany and Merrifield, In: *The Peptides*, Gross and Meienhofer (Eds.), Academic Press, NY, 1-284, 1979.

Boucher and Corey, *Clin. Infect. Dis.*, 46(5):S344-349, 2008.

Burke *et al.*, *J. Inf. Dis.*, 170:1110-1119, 1994.

Burman *et al.*, *J. Biol. Chem.*, 283:17579-17593, 2008.

10 Campbell, In: *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology*, Burden and Von Knippenberg (Eds.), Elseview, Amsterdam, 13:71-74/75-83, 1984.

Carbonelli *et al.*, *FEMS Microbiol. Lett.*, 177(1):75-82, 1999.

Cary *et al.*, *Mol. Immunol.*, 36:769-776, 1999.

15 Chandler *et al.*, *Proc. Natl. Acad. Sci. USA*, 94(8):3596-601, 1997.

Chen and Okayama, *Mol. Cell Biol.*, 7(8):2745-2752, 1987.

Cheng *et al.*, *FASEB J.*, 23:3393-3404, 2009.

Cocea, *Biotechniques*, 23(5):814-816, 1997.

Cumber *et al.*, *J. Immunology*, 149B:120-126, 1992.

20 de Bono *et al.*, *J. Mol. Biol.*, 342(1):131-143, 2004.

DeDent *et al.*, *Semin. Immunopathol.*, 34:317-333, 2012.

Dholakia *et al.*, *J. Biol. Chem.*, 264, 20638-20642, 1989.

Emori and Gaynes, *Clin. Microbiol. Rev.*, 6:428-442, 1993.

Epitope Mapping Protocols In: *Methods in Molecular Biology*, Vol. 66, Morris (Ed.), 1996,

25 European Patent 0 216 846

European Patent 0 256 055

European Patent 0 323 997

European Patent Appln. 89303964.4

Fechheimer, *et al.*, *Proc Natl. Acad. Sci. USA*, 84:8463-8467, 1987.

30 Fischetti, *Clin. Microbiol. Rev.*, 2:285-314, 1989.

Fraley *et al.*, *Proc. Natl. Acad. Sci. USA*, 76:3348-3352, 1979.

Gefter *et al.*, *Somatic Cell Genet.*, 3:231-236, 1977.

Goding, In: *Monoclonal Antibodies: Principles and Practice*, 2d ed., Academic Press, Orlando, Fl, pp 60-61, 71-74, 1986.

Goding, In: *Monoclonal Antibodies: Principles and Practice*, 2d ed., Academic Press, Orlando, FL, pp 65, 66, 1986.

Goodyear and Silverman, *J. Exp. Med.*, 197:1125-1139, 2003.

Gopal, *Mol. Cell Biol.*, 5:1188-1190, 1985.

5 Graham and Van Der Eb, *Virology*, 52:456-467, 1973.

Harland and Weintraub, *J. Cell Biol.*, 101(3):1094-1099, 1985.

Harlow *et al.*, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., Chapter 8, 1988.

Haupt *et al.*, *PLoS Pathog.*, 4:e1000250, 2008.

10 Hollingshead *et al.*, *Infect. Immun.*, 55:3237-3239, 1987.

Jones and Fischetti, *J. Exp. Med.*, 167:1114-1123, 1988.

Jones *et al.*, *J. Exp. Med.*, 164:1226-1238, 1986.

Kaeppler *et al.*, *Plant Cell Rep.*, 8:415-418, 1990.

Kaneda *et al.*, *Science*, 243:375-378, 1989.

15 Kato *et al.*, *J. Biol. Chem.*, 266:3361-3364, 1991.

Kennedy *et al.*, *Proc. Natl. Acad. Sci., USA*, 105(4):1327-1332, 2008.

Khatoon *et al.*, *Ann. of Neurology*, 26, 210-219, 1989.

Kim *et al.*, *FASEB J.*, 25:3605-3612, 2011.

Kim *et al.*, *J. Exp. Med.*, 207:1863-1870, 2010a.

20 Kim *et al.*, *Vaccine*, 28:6382-6392, 2010b.

King *et al.*, *J. Biol. Chem.*, 269, 10210-10218, 1989.

Klevens *et al.*, *JAMA*, 298:1763-1771, 2007.

Kohl *et al.*, *Proc. Natl. Acad. Sci., USA*, 100(4):1700-1705, 2003.

Kohler and Milstein, *Eur. J. Immunol.*, 6:511-519, 1976.

25 Kohler and Milstein, *Nature*, 256:495-497, 1975.

Kyte and Doolittle, *J. Mol. Biol.*, 157(1):105-132, 1982.

Lancefield, *J. Exp. Med.*, 47:91-103, 1928.

Lancefield, *J. Immunol.*, 89:307-313, 1962.

Lee, *Trends Microbiol.*, 4(4):162-166, 1996.

30 Levenson *et al.*, *Hum. Gene Ther.*, 9(8):1233-1236, 1998.

Liu *et al.*, *Cell Mol. Biol.*, 49(2):209-216, 2003.

McCarthy and Lindsay, *BMC Microbiology*, 10:173, 2010.

Merrifield, *Science*, 232(4748):341-347, 1986.

Nicolau and Sene, *Biochim. Biophys. Acta*, 721:185-190, 1982.

Nicolau *et al.*, *Methods Enzymol.*, 149:157-176, 1987.

Nimmerjahn and Ravetch, *Nat. Rev. Immunol.*, 8(1):34-47, 2008.

Omirulleh *et al.*, *Plant Mol. Biol.*, 21(3):415-28, 1993.

O'Shannessy *et al.*, *J. Immun. Meth.*, 99, 153-161, 1987.

5 Owens and Haley, *J. Biol. Chem.*, 259:14843-14848, 1987.

Pack *et al.*, *Biochem.*, 31:1579-1584, 1992.

PCT Appln. PCT/US11/42845

PCT Appln. WO 00/02523

PCT Appln. WO 00/12132

10 PCT Appln. WO 00/12689

PCT Appln. WO 00/15238

PCT Appln. WO 01/60852

PCT Appln. WO 2006/032472

PCT Appln. WO 2006/032475

15 PCT Appln. WO 2006/032500

PCT Appln. WO 2007/113222

PCT Appln. WO 2007/113223

PCT Appln. WO 2011/005341

PCT Appln. WO 94/09699

20 PCT Appln. WO 95/06128

PCT Appln. WO 98/57994

PCT Publn. WO 2006/056464

PCT Publn. WO 99/26299

Phillips *et al.*, *Proc. Natl. Acad. Sci., USA*, 78:4689-4693, 1981.

25 Potrykus *et al.*, *Mol. Gen. Genet.*, 199(2):169-177, 1985.

Potter and Haley, *Methods Enzymol.*, 91:613-633, 1983.

Rippe, *et al.*, *Mol. Cell Biol.*, 10:689-695, 1990.

Robbins *et al.*, *Adv. Exp. Med. Biol.*, 397:169-182, 1996.

Sambrook *et al.*, In: *Molecular cloning*, Cold Spring Harbor Laboratory Press, Cold Spring

30 Harbor, NY, 2001.

Scott *et al.*, *J. Exp. Med.*, 164:1641-1651, 1986.

Silverman and Goodyear, *Nat. Rev. Immunol.*, 6:465-475, 2006.

Skerra, *J. Biotechnol.*, 74(4):257-75, 2001.

Skerra, *J. Mol. Recogn.*, 13:167-187, 2000.

Smith *et al.*, *Mol. Microbiol.*, 83:789-804, 2012.

Stewart and Young, In: *Solid Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co., 1984.

Stranger-Jones *et al.*, *Proc. Natl. Acad. Sci., USA*, 103:16942-16947, 2006.

Tam *et al.*, *J. Am. Chem. Soc.*, 105:6442, 1983.

5 Tigges *et al.*, *J. Immunol.*, 156(10):3901-3910, 1996.

Ton-That *et al.*, *Proc. Natl. Acad. Sci., USA*, 96:12424-12429, 1999.

Wong *et al.*, *Gene*, 10:87-94, 1980.

Yoo *et al.*, *J. Immunol. Methods*, 261(1-2):1-20, 2002.

Zhang *et al.*, *Microbiology*, 144:985-991, 1998.

10 Zhang *et al.*, *Microbiology*, 145:177-183, 1999.

CLAIMS

1. A method of inhibiting *Staphylococcus* infection in a patient determined to have or be at risk for *Staphylococcus* infection comprising administering to the patient an effective amount of a composition comprising a Coa binding polypeptide that specifically binds to Domain 1-2 of a *Staphylococcal* Coa polypeptide.
2. The method of claim 1, wherein the Coa binding polypeptide specifically binds to Domain 1 of a *Staphylococcal* Coa polypeptide.
3. The method of claim 3, wherein the Coa binding polypeptide competes for binding of *Staphylococcal* Coa polypeptide with the 5D5.4 or 7H4.25 monoclonal antibody.
4. The method of any of claims 1 to 3, wherein the Coa binding polypeptide has an association constant for the *Staphylococcal* Coa polypeptide of between about 0.5 and 20 nM⁻¹, 1.0 and 10 nM⁻¹, or 1.0 and 6.0 nM⁻¹ as measured by ELISA.
5. The method of any of claims 1 to 4, wherein the Coa binding polypeptide has an association constant for the *Staphylococcal* Coa Domain 1-2 of between about 0.5 and 20 nM⁻¹ or 1.0 and 10 nM⁻¹ as measured by ELISA.
6. The method of any of claims 1 to 5, wherein the purified Coa binding polypeptide comprises a monoclonal antibody.
7. The method of claim 6, further comprising administering an effective amount of two or more purified monoclonal antibodies.
8. The method of any of claims 1 to 7, wherein the Coa binding polypeptide is recombinant.
9. The method of any of claims 1 to 8, wherein the recombinant Coa binding polypeptide is a single domain antibody.
10. The method of any of claims 1 to 9, wherein the Coa binding polypeptide is a humanized or chimeric antibody.

11. The method of any of claims 1 to 10, wherein the Coa binding polypeptide comprises one or more CDR domains from an antibody that specifically binds to Domains 1-2 of a Staphylococcal Coa polypeptide.
12. The method of claim 11, wherein the Coa binding polypeptide comprises one or more CDR domains from among the VH or VL domain of the 5D5.4, 7H4.25, 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7 monoclonal antibodies.
13. The method of claim 12, wherein the Coa binding polypeptide comprises two or more CDR domains from among the VH or VL domain of the 5D5.4, 7H4.25, 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7 monoclonal antibodies.
14. The method of claim 13, wherein the Coa binding polypeptide comprises three, four, five or six CDR domains from among the VH or VL domain of the 5D5.4, 7H4.25, 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7 monoclonal antibodies.
15. The method of any of claims 1 to 11, wherein the Coa binding polypeptide comprises a sequence at least 70% identical to the VH or VL domain of the 5D5.4 or 7H4.25 monoclonal antibodies.
16. The method of any of claim 1 to 15, wherein the Coa binding polypeptide comprises all six CDR domains from among the VH or VL domains of the 5D5.4, 7H4.25, 4H9.20, 4B10.44, 3B3.14, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, or 4F1.7 monoclonal antibodies.
17. The method of any of claims 1 to 16, wherein the Coa binding polypeptide comprises the VH domain from the 5D5.4 or 7H4.25 monoclonal antibody.
18. The method of any of claims 1 to 17, wherein the Coa binding polypeptide comprises the VL domain from the 5D5.4 or 7H4.25 monoclonal antibody.
19. The method of any of claims 1 to 18, wherein the Coa binding polypeptide comprises one or more CDR domains from a Coa binding polypeptide that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide and a scaffold from a polypeptide selected from the group consisting of an immunoglobulin, a fibronectin or a *S. aureus* protein Z.

20. The method of any of claims 1 to 19, wherein the Coa binding polypeptide is operatively coupled to a second recombinant Coa binding polypeptide.

21. The method of claim 20, wherein the second recombinant Coa binding polypeptide binds a second Staphylococcal protein.

22. The method of any of claims 1 to 21, further comprising administering a second Coa binding polypeptide that binds a second Staphylococcal protein.

23. The method of any of claims 1 to 22, further comprising administering an antibiotic or a Staphylococcal vaccine composition.

24. The method of any of claims 1 to 23, wherein the Coa binding polypeptide is administered at a dose of about 0.1 mg/kg to 5 mg/kg.

25. A purified polypeptide comprising one or more Coa binding polypeptide CDR domains from an antibody that specifically binds to Domain 1-2 of a Staphylococcal Coa polypeptide.

26. The purified polypeptide of claim 25, comprising a CDR1, CDR2, and CDR3 that is at least 80% identical to each of CDR1, CDR2, CDR3, respectively, from the variable region of a light or heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

27. The purified polypeptide of claim 25 or 26, wherein the CDR1, CDR2, and CDR3 are 85% identical to each of CDR1, CDR2, CDR3, respectively, from the variable region of a light or heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

28. The purified polypeptide of any of claims 25 to 27, wherein the CDR1, CDR2, and CDR3 are 90% identical to each of CDR1, CDR2, CDR3, respectively, from the variable region of a light or heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

29. The purified polypeptide of any of claims 25 to 28, wherein the CDR1, CDR2, and CDR3 are 95% identical to each of CDR1, CDR2, CDR3, respectively, from the variable region of a light or heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

30. The purified polypeptide of any of claims 25 to 29, wherein the CDR1, CDR2, and CDR3 are 100% identical to each of CDR1, CDR2, CDR3, respectively, from the variable region of a light or heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

31. The purified polypeptide of any of claims 26 to 30, wherein CDR1, CDR2, and CDR3 are at least 80% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody.

32. The purified polypeptide of any of claims 26 to 31, wherein CDR1, CDR2, and CDR3 are at least 85% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody.

33. The purified polypeptide of any of claims 26 to 32, wherein CDR1, CDR2, and CDR3 are at least 90% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody.

34. The purified polypeptide of any of claims 26 to 33, wherein CDR1, CDR2, and CDR3 are at least 95% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody.

35. The purified polypeptide of any of claims 26 to 34, wherein CDR1, CDR2, and CDR3 are 100% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody.

36. The purified polypeptide of any of claims 31 to 35, wherein CDR1 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:49, or SEQ ID NO:56.

37. The purified polypeptide of any of claims 31 to 36, wherein CDR2 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, or SEQ ID NO:61 (X₁X₂S, where X₁ is A, S, K, or W and X₂ is A, T, or V).

38. The purified polypeptide of any of claims 31 to 37, wherein CDR3 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID

NO:11, SEQ ID NO:17, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:45, or SEQ ID NO:57.

39. The purified polypeptide of any of claims 26 to 30, wherein CDR1, CDR2, and CDR3 are at least 80% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

40. The purified polypeptide of any of claims 26 to 30 or 39, wherein CDR1, CDR2, and CDR3 are at least 85% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

41. The purified polypeptide of any of claims 26 to 30 or 39 to 40, wherein CDR1, CDR2, and CDR3 are at least 90% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

42. The purified polypeptide of any of claims 26 to 30 or 39 to 41, wherein CDR1, CDR2, and CDR3 are at least 95% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

43. The purified polypeptide of any of claims 26 to 30 or 39 to 42, wherein CDR1, CDR2, and CDR3 are 100% identical to each of CDR1, CDR2, and CDR3, respectively, from the variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody.

44. The purified polypeptide of any of claims 26 to 30 or 39 to 43, wherein CDR1 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:49, or SEQ ID NO:56.

45. The purified polypeptide of any of claims 26 to 30 or 39 to 44, wherein CDR2 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:38, SEQ ID NO:37, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:54, or SEQ ID NO:59.

46. The purified polypeptide of any of claims 26 to 30 or 39 to 45, wherein CDR3 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:14, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:55, or SEQ ID NO:60.

47. The purified polypeptide of any of claims 26 to 44, comprising a CDR1, CDR2, and CDR3 from each of a variable light chain and a variable heavy chain of a Domain 1-2 Staphylococcal Coa antibody, wherein the CDR1, CDR2, and CDR3 from the variable light chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable light chain and the CDR1, CDR2, and CDR3 from the variable heavy chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable heavy chain.

48. The purified polypeptide of any of claims 26 to 47, comprising a CDR1, CDR2, and CDR3 from each of a variable light chain and a variable heavy chain of a Domain 1-2 Staphylococcal Coa antibody, wherein the CDR1, CDR2, and CDR3 from the variable light chain is least 85% identical to CDR1, CDR2, and CDR3, respectively, from a variable light chain and the CDR1, CDR2, and CDR3 from the variable heavy chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable heavy chain.

49. The purified polypeptide of any of claims 26 to 48, comprising a CDR1, CDR2, and CDR3 from each of a variable light chain and a variable heavy chain of a Domain 1-2 Staphylococcal Coa antibody, wherein the CDR1, CDR2, and CDR3 from the variable light chain is least 90% identical to CDR1, CDR2, and CDR3, respectively, from a variable light chain and the CDR1, CDR2, and CDR3 from the variable heavy chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable heavy chain.

50. The purified polypeptide of any of claims 26 to 49, comprising a CDR1, CDR2, and CDR3 from each of a variable light chain and a variable heavy chain of a Domain 1-2 Staphylococcal Coa antibody, wherein the CDR1, CDR2, and CDR3 from the variable light chain is least 95% identical to CDR1, CDR2, and CDR3, respectively, from a variable light chain and the CDR1, CDR2, and CDR3 from the variable heavy chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable heavy chain.

51. The purified polypeptide of any of claims 26 to 49, comprising a CDR1, CDR2, and CDR3 from each of a variable light chain and a variable heavy chain of a Domain 1-2 Staphylococcal Coa antibody, wherein the CDR1, CDR2, and CDR3 from the variable light chain is least 100% identical to CDR1, CDR2, and CDR3, respectively, from a variable light chain and the CDR1, CDR2, and CDR3 from the variable heavy chain is least 80% identical to CDR1, CDR2, and CDR3, respectively, from a variable heavy chain.

52. The purified polypeptide of any of claims 47 to 51, wherein

- a) CDR1 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:49, or SEQ ID NO:56;
- b) CDR2 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, or SEQ ID NO:61;
- c) CDR3 from a variable region of a light chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:45, or SEQ ID NO:57;
- d) CDR1 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:49, or SEQ ID NO:56;
- e) CDR2 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:38, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:54, or SEQ ID NO:59; and
- f) CDR3 from a variable region of a heavy chain of a Domain 1-2 Staphylococcal Coa antibody comprises SEQ ID NO:14, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:39, SEQ ID NO:42,

SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:55, or SEQ ID NO:60.

53. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, respectively.

54. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively.

55. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:9, SEQ ID NO:21, and SEQ ID NO:22, respectively.

56. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively.

57. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:9, SEQ ID NO:21, and SEQ ID NO:22, respectively.

58. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35, respectively.

59. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:36, respectively.

60. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:35, respectively.

61. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:44, SEQ ID NO:34, and SEQ ID NO:45, respectively.

62. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:56, SEQ ID NO:25, and SEQ ID NO:57, respectively.

63. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:35, respectively.

64. The purified polypeptide of any of claims 25 to 52, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:49, SEQ ID NO:34, and SEQ ID NO:35, respectively.

65. The purified polypeptide of any of claims 25 to 53, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively.

66. The purified polypeptide of any of claims 25 to 52 or 54, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively.

67. The purified polypeptide of any of claims 25 to 52 or 55, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:23, respectively.

68. The purified polypeptide of any of claims 25 to 52 or 56, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively.

69. The purified polypeptide of any of claims 25 to 52 or 57, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:31, and SEQ ID NO:32, respectively.

70. The purified polypeptide of any of claims 25 to 52 or 58, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively.

71. The purified polypeptide of any of claims 25 to 52 or 59, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:41, SEQ ID NO:38, and SEQ ID NO:42, respectively.

72. The purified polypeptide of any of claims 25 to 52 or 60, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:38, respectively.

73. The purified polypeptide of any of claims 25 to 52 or 61, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48, respectively.

74. The purified polypeptide of any of claims 25 to 52 or 101, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:50, SEQ ID NO:51, and SEQ ID NO:52, respectively.

75. The purified polypeptide of any of claims 25 to 52 or 102, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55, respectively.

76. The purified polypeptide of any of claims 25 to 52 or 103, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60, respectively.

77. The purified polypeptide of claim 53, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively.

78. The purified polypeptide of claim 54, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively.

79. The purified polypeptide of claim 55, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:23, respectively.

80. The purified polypeptide of claim 56, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively.

81. The purified polypeptide of claim 57, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:12, SEQ ID NO:31, and SEQ ID NO:32, respectively.

82. The purified polypeptide of claim 58, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively.

83. The purified polypeptide of claim 59, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:41, SEQ ID NO:38, and SEQ ID NO:42, respectively.

84. The purified polypeptide of claim 60, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:38, respectively.

85. The purified polypeptide of claim 61, wherein the polypeptide comprises a CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48, respectively.

86. The purified polypeptide of claim 101, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:50, SEQ ID NO:51, and SEQ ID NO:52, respectively.

87. The purified polypeptide of claim 102, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55, respectively.

88. The purified polypeptide of claim 103, wherein the polypeptide further comprises a second CDR1, CDR2, and CDR3 that are at least 80% identical in sequence to SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60, respectively.

89. The purified polypeptide of claim 65, wherein the polypeptide comprises the sequences of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11 from the light chain variable region of 4H9.20 and SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14 from the heavy chain variable region of 4H9.20.

90. The purified polypeptide of claim 66, wherein the polypeptide comprises the sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17 from the light chain variable region of 5D5.4 and SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20 from the heavy chain variable region of 5D5.4.

91. The purified polypeptide of claim 67, wherein the polypeptide comprises the sequences of SEQ ID NO:9, SEQ ID NO:21, and SEQ ID NO:22 from the light chain variable region of 4B10.44 and SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:23 from the heavy chain variable region of 4B10.44.

92. The purified polypeptide of claim 68, wherein the polypeptide comprises the sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 from the light chain variable region of 3B3.14 and SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29 from the heavy chain variable region of 3B3.14.

93. The purified polypeptide of claim 69, wherein the polypeptide comprises the sequences of SEQ ID NO:9, SEQ ID NO:21, and SEQ ID NO:30 from the light chain variable region of 7H4.25 and SEQ ID NO:12, SEQ ID NO:31, and SEQ ID NO:32 from the heavy chain variable region of 7H4.25.

94. The purified polypeptide of claim 70, wherein the polypeptide comprises the sequences of SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35 from the light chain variable region of 2A3.1 and SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39 from the heavy chain variable region of 2A3.1.

95. The purified polypeptide of claim 71, wherein the polypeptide comprises the sequences of SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:36 from the light chain

variable region of 2H10.12 and SEQ ID NO:41, SEQ ID NO:38, and SEQ ID NO:42 from the heavy chain variable region of 2H10.12.

96. The purified polypeptide of claim 72, wherein the polypeptide comprises the sequences of SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:35 from the light chain variable region of 6D1.22 and SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:38 from the heavy chain variable region of 6D1.22.

97. The purified polypeptide of claim 73, wherein the polypeptide comprises the sequences of SEQ ID NO:44, SEQ ID NO:34, and SEQ ID NO:45 from the light chain variable region of 6C4.15 and SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48 from the heavy chain variable region of 6C4.15.

98. The purified polypeptide of claim 74, wherein the polypeptide comprises the sequences of SEQ ID NO:56, SEQ ID NO:25, and SEQ ID NO:57 from the light chain variable region of 6C10.19 and SEQ ID NO:50, SEQ ID NO:51, and SEQ ID NO:52 from the heavy chain variable region of 6C10.19.

99. The purified polypeptide of claim 75, wherein the polypeptide comprises the sequences of SEQ ID NO:40, SEQ ID NO:34, and SEQ ID NO:35 from the light chain variable region of 8C2.9 and SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55 from the heavy chain variable region of 8C2.9.

100. The purified polypeptide of claim 76, wherein the polypeptide comprises the sequences of SEQ ID NO:49, SEQ ID NO:34, and SEQ ID NO:35 from the light chain variable region of 4F1.7 and SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60 from the heavy chain variable region of 4F1.7.

101. The purified polypeptide of any of claims 25 to 61, wherein the polypeptide does not consist of the mouse monoclonal antibody that is 4H9.20, 5D5.4, 4B10.44, 3B3.14, 7H4.25, 2A3.1, 2H10.12, 6D1.22, 6C4.15, 6C10.19, 8C2.9, and 4F1.7.

102. The purified polypeptide of any of claims 25 to 101, wherein the polypeptide is not an isolated mouse monoclonal antibody.

103. The purified polypeptide of any of claims 25 to 102, wherein the polypeptide is humanized or chimeric.

104. The polypeptide of claim 25, wherein the Coa binding polypeptide competes for binding of a Staphylococcal Coa polypeptide with the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibody.

105. The polypeptide of claim 25, wherein the polypeptide has an association constant for a Staphylococcal Coa polypeptide of between about 0.1 and 20 nM⁻¹, 0.5 and 10 nM⁻¹, or 1.0 and 10 nM⁻¹ as measured by ELISA.

106. The polypeptide of claim 25, wherein the polypeptide comprises a single domain antibody Coa binding polypeptide.

107. The polypeptide of claim 25, wherein the polypeptide comprises a humanized or chimeric antibody.

108. The polypeptide of claim 25, wherein the polypeptide is recombinant.

109. The polypeptide of claim 108, wherein the recombinant polypeptide comprises at least 90% of one or more CDR domains from the VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibodies.

110. The polypeptide of claim 109, wherein the recombinant polypeptide comprises two or more CDR domains from the VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibodies.

111. The polypeptide of claim 109, wherein the recombinant polypeptide comprises three CDR domains from the VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibodies.

112. The polypeptide of claim 25, wherein the recombinant polypeptide comprises a sequence at least 90% identical to VH or VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibodies.

113. The polypeptide of claim 111, wherein the recombinant polypeptide comprises the six CDR domains from the VH and VL domains of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibodies.

114. The polypeptide of claim 113, wherein the recombinant polypeptide comprises the VH domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibody.

115. The polypeptide of claim 113, wherein the recombinant polypeptide comprises the VL domain of the 4H9.20, 4B10.44, 3B3.14, 4F1.7, 8C2.9, 2A3.1, 5C3.2, 2H10.12, 6D1.22, 5D5.4 or 7H4.25 monoclonal antibody.

116. The polypeptide of claim 109, wherein the recombinant polypeptide comprises one or more CDR domain from an antibody that specifically binds to Domains 1-2 of a Staphylococcal Coa polypeptide and a scaffold from a polypeptide selected from the group consisting of an immunoglobulin, a fibronectin or a *S. aureus* protein Z.

117. The polypeptide of claim 108, wherein the recombinant polypeptide is operatively coupled to a recombinant polypeptide that specifically binds to a second Staphylococcal protein.


118. The polypeptide of claim 108, wherein the polypeptide is an antibody comprising (a) a heavy chain comprising said VH region, and a human hinge, CH1, CH2, and CH3 regions from an IgG1, IgG2, IgG3 or IgG4 subtype; and (b) a light chain comprising said VL region, and either a human kappa CL or human lambda CL.


119. A purified monoclonal antibody that specifically binds to a Staphylococcal Coa polypeptide, wherein the purified monoclonal antibody is the 5A10, 8E2, 3A6, 7E2, 3F6, 1F10, 6D11, 3D11, 5A11, 1B10, 4C1, 2F2, 8D4, 7D11, 2C3, 4C5, 6B2, 4D5, 2B8, 1H7, 6C10.19 or 6C4.15 monoclonal antibody.

120. A pharmaceutical composition comprising the purified polypeptide of any of claims 25 to 118.


121. The pharmaceutical composition of claim 120, comprising a single unit dose of the purified polypeptide in a sealed container.

122. The pharmaceutical composition of claim 120 or 121, comprising at least a second anti-bacterial agent.
123. The pharmaceutical composition of claim 122, wherein the second anti-bacterial agent is an antibiotic, a Staphylococcal vaccine composition or a polypeptide that specifically binds to a second Staphylococcal protein.
124. A polynucleotide comprising a nucleic acid sequence encoding a polypeptide according to any of claims 25 to 118.
125. An expression vector comprising a nucleic acid sequence encoding a polypeptide according to any of claims 25 to 118 operably linked to an expression control sequence.
126. A host cell comprising the expression vector of claim 125.
127. A method of manufacturing a polypeptide of any of claims 25- to 118 comprising expressing a nucleic acid sequence encoding the polypeptide operably linked to an expression control sequence in a host cell.
128. A method of treating a patient having or at risk for *Staphylococcus* infection comprising administering to the patient an effective amount of a composition comprising the Coa binding polypeptide of any of claims 25 to 118.

**FIGs. 1A – 1B**



FIGs. 2A – 2B

**FIGs. 3A – 3B**

4/10






FIG 4




FIGs. 5A-5B-5C-5D

5/10



FIGs. 6A-6B-6C-6D



FIGs. 7A-7B-7C-7D

FIG. 8

Alignment of Coa from five *S. aureus* strains

USA300_Coa	ATGAAAAAGCAAATAATTGCCTAGGCGATTAGCAGTTGCATCTAGCTTATTACATGG	60
N315_Coa	ATGAAAAAGCAAATAATTGCCTAGGCGATTAGCAGTTGCATCTAGCTTATTACATGG	60
MRSA252_Coa	ATGAAAAAGCAAATAATTGCCTAGGCGATTAGCAGTTGCATCTAGCTTATTACATGG	60
MW2_Coa	ATGAAAAAGCAAATAATTGCCTAGGCGATTAGCAGTTGCATCTAGCTTATTACATGG	60
WIS_Coa	ATGAAAAAGCAAATAATTGCCTAGGCGATTAGCAGTTGCATCTAGCTTATTACATGG	60

USA300_Coa	GATAACAAAGCAGATGCGATAGTAACAAAGGATTATAGTGGGAAATCACAAGTTAATGCT	120
N315_Coa	GATAACAAAGCAGATGCGATAGTAACAAAGGATTATAGTAAAGAATCACAAGAGTGAATGAG	120
MRSA252_Coa	GATAACAAAGCAGATGCGATAGTAACAAAGGATTATAGTAAAGAATCACAAGAGTGAATGAG	120
MW2_Coa	GATAACAAAGCAGATGCGATAGTAACAAAGGATTATAGTGGGAAATCACAAGTTAATGCT	120
WIS_Coa	-----ATAGTAACAAAGGATTATAGTGGGAAATCACAAGTTAATGCT	42

USA300_Coa	GGGAGTAAAATGGGAC-ATTAAT--AGATAGCAGATATTTAAATTCTAGCTCTATTTA	176
N315_Coa	AAAAGTAAAAGGGAGCTACTGTTTC-AGATTATTACTATTGGAAAAATAATT---GATAG	176
MRSA252_Coa	AACAGTAAATACGATAC-ACCAATTCCAGATTG---CTATCTAGGTAGTATTAAACAG	176
MW2_Coa	GGGAGTAAAATGGGAA-ACAAATTGCAGATGGATATTATGGGAAATAATT---GAAAA	176
WIS_Coa	GGGAGTAAAATGGGAA-ACAAATTGCAGATGGATATTATGGGAAATAATT---GAAAA	98

USA300_Coa	TTTGGAAAGACTATATAATTAT---GCTATAGGATTAACTAATAAAATGAATATGGAG	232
N315_Coa	TTTAGAGG---CACAAATTACTGGACCAATAGACTTATTGGAAGATTATAAAATATGGAG	232
MRSA252_Coa	ATTAGGGGATCAAATATACAC---GCTAAGGAATTAACTAATAAAATACGAATATGGTG	232
MW2_Coa	TCTAGAAAACCA--GTTTAC-AATATTTTCATTACTGGATCAGCATAAATATGCAG	232
WIS_Coa	TCTAGAGAACCA--GTTTAC-AATATTTTCATTATTGGATCAGCATAAATATGCAG	154

USA300_Coa	ATAATATTTATAAAGAACCTAAAGATAGGTTGTTGAAAAGGTATTAAGGAAAGATCAAT	292
N315_Coa	ATCCTATCTATAAAGAACCGAAAGATAGATTGATGACAAGAGTATTAGGAGAAAGACCACT	292
MRSA252_Coa	AGAAAAGAGTATAAGCAACCGATAGATAAATTGATGACTAGAGTTGGGAGAAAGATCATT	292
MW2_Coa	AAAAAGAATATAAAGATGCAGTAGATAAATTAAAACTAGAGTTTAGAGGAAAGACCAAT	292
WIS_Coa	AAAAAGAATATAAAGATGCATTAGATAAATTAAAACTAGAGTTTAGAGGAAAGACCAAT	214

USA300_Coa	ATCTTTGGAGAGAAAGAAATCTCAATATGAAGATTATAAACATGGTATGCAAATTATA	352
N315_Coa	ATTTTATTAAAGAAAAAGATTGATGAATATGAGCTTATAAAAAGTGGTATAAAAGTT-CA	351
MRSA252_Coa	ATCTTATTAGAAAAAAAGAAGCACAATATGAAGCATAACAAAAATGGTTGAAAAACATA	352
MW2_Coa	ACCTGCTAGAAAGAAAAAAAGAAAAATACGAAATTATAAGAACTATATAAAAATACA	352
WIS_Coa	ACCTGCTAGAAAGAAAAAAAGAAAAATACGAAATTATAAGAACTATATAAAAATACA	274

USA300_Coa	AAAAAGAAAATCCTCGTACAGATTTAAAAATGGCTAATTTCTATAAATATAATTAGAAG	412
N315_Coa	AATAAGAACACT-----AATATGCTTACCTTCCTATAAATATAATCTTACAA	397
MRSA252_Coa	AAAGTAAAATCCACATTCTAGTTAAAAAGATTAAATTGACGATTTGATTATATA	412
MW2_Coa	AAAAAGAGAATCTTAATACTCAAGTTAAATGAAAGCATTGATAAATACGATCTGGCG	412
WIS_Coa	AAAAAGAGAATCTTAATACTCAGGTTAAATGAAAGCATTGATAAATACGATCTGGCG	334

USA300_Coa	AACTTTCGATGAAAGAATACAATGAACTACAGGATGCTTAAAGAGAGCACTGGATGATT	472
N315_Coa	ATTTAACATGAATGAATATAACGATTTTAACCTTGGAAAGATGCAGTTATCAAT	457
MRSA252_Coa	GATTAACGAAAGAAGAATACAATGAGTTACATCAATCATTAAAAGAAGCTGTTGATGAGT	472
MW2_Coa	ATTTAACATGGAAGAATACAATGAACTATCAAAATTATTAACAAAAGCATTGGATAACT	472
WIS_Coa	ATTTAACATGGAAGAATACAATGAACTATCAAAATTATTAACAAAAGCATTGGATAACT	394

USA300_Coa	TTCACAGAGAAGTTAAAGATATTAGGATAAGAATTAGACTTGAAGAACTTTAATGCAG	532
N315_Coa	TTAATAAAGAAGTTAAAGAAATAGAGCATAAAAATGTTGACTTGAAGCAGTTGATAAAG	517
MRSA252_Coa	TTAATAGTGAAGTGAAGAAATTCAATCTAACAAAAGGATTATTACCTTATGATGAAG	532
MW2_Coa	TTAAGTTAGAAGTAAAGAAAATTGAATCAGAGAATCCAGATTTAAACCATATTCTGAAA	532
WIS_Coa	TTAAGTTAGAAGTAAAGAAAATTGAATCAGAGAATCCAGATTTAAGACCATATTCTGAAA	454

USA300_Coa	CAGAAGAAGATAAAGCAACTAAGGAAGTATACGATCTGTATCTGAAATTGATACATTAG	592
N315_Coa	ATGGAGAAGACAAGGCAACTAAAGAAGTTATGACCTTGTGAAATTGATACATTAG	577
MRSA252_Coa	CAACTGAAAATCGACTAACAAATGGAATATATGATTGTTGCGAGATTGACACATTAT	592
MW2_Coa	GCGAAGAAAAGAACAGCATATGGTAAAATAGATTCACTTGTGATCAAGCATATAGTGTAT	592
WIS_Coa	GTGAAGAGAGAACAGCATATGGTAAAATAGATTCACTTGTGATCAAGCATATAGTGTAT	514

USA300_Coa	TTGTATCATATTATGGTATAAGGATTATGGGAGCAGCGAAAGAGTTACGAGCAAAAC	652
N315_Coa	TTGTAACTTATTATGCTGATAAGGATTATGGGAGCATGCGAAAGAGTTACGAGCAAAAC	637
MRSA252_Coa	ACGCAGCATTTTAATCATAGCCAATATGGTCATAATGCTAAAGAATTAAGAGCAAAAC	652
MW2_Coa	ATTTTCGCTACGTTACAGATGCACAACTAAACAGAAGCATTAAATCTTAGGGCGAAAA	652

MW2_Coa	-----ACGACACCGAACCTATTTAGAAGGTCTTGAAGGTAGCTCATCTAA 1269
WIS_Coa	ACAGGTGAAAGTACACCAACCGAACCTATTTAAAAGGTATTGAAGGAAACTCATCTAA 1224

USA300_Coa	CTTGAATAAAACCACAAGGTACTGAATCAACGTTAAAGGTACTCAAGGAGAATCAAGT 1338
N315_Coa	CTTGAATAAAACCACAAGGTACTGAATCAACGTTAAAGGTATTCAAGGAGAATCAAGT 1323
MRSA252_Coa	CTTGAATAAAACCACAAGGTACTGAATCAACGTTAAAGGTACTCAAGGAGAATCAAGT 1338
MW2_Coa	CTTGAATAAAACCACAAGGTACTGAATCAACGTTAAAGGTACTCAAGGAGAATCAAGT 1329
WIS_Coa	CTTGAATAAAACCACAAGGTACTGAATCAACGTTAAAGGTATTCAAGGAGAATCAAGT 1284

USA300_Coa	GATATTGAAGTAAACCTCAAGCAACTGAAACAAACAGAAGCTCTCAATATGGTCCGAGA 1398
N315_Coa	GATATTGAAGTAAACCTCAAGCAACTGAAACAAACAGAAGCTCTCAATATGGTCCGAGA 1383
MRSA252_Coa	GATATTGAAGTAAACCTCAAGCAACTGAAACAAACAGAAGCATCACATTATCCAGCGAGA 1398
MW2_Coa	GATATTGAAGTAAACCTCAAGCATCTGAAACAAACAGAAGCATCACATTATCCAGCAAGA 1389
WIS_Coa	GATATTGAAGTAAACCTCAAGCAACTGAAACAAACAGAAGCATCACATTATCCAGCGAGA 1344

USA300_Coa	CCGCAATTAAACAAAACACCTAAATATGTTAAATATAGAGATGCTGGTACAGGTATCCGT 1458
N315_Coa	CCGCAATTAAACAAAACACCTAACTGTTAAATATAGAGATGCTGGTACAGGTATCCGT 1443
MRSA252_Coa	CCTCAATTAAACAAAACACCTAACTGTTAAATATAGAGATGCTGGTACAGGTATCCGT 1458
MW2_Coa	CCTCAATTAAACAAAACACCTAAATATGTTAAATATAGAGATGCTGGTACAGGTATCCGT 1449
WIS_Coa	CCGCAATTAAACAAAACACCTAAATATGTTAAATATAGAGATGCTGGTACAGGTATCCGT 1404

USA300_Coa	GAATACAACGATGGAACATTGGATATGAAGCGAGACCAAGATTCAATAAGCCA----- 1512
N315_Coa	GAATACAACGATGGAACATTGGATATGAAGCGAGACCAAGATTCAACAAGCCAAGTGAA 1503
MRSA252_Coa	GAATACAACGATGGAACATTGGATATGAAGCGAGACCAAGATTCAACAAGCCAAG----- 1514
MW2_Coa	GAATACAACGATGGAACATTGGATATGAAGCGAGACCAAGATTCAATAAGCCATCAGAA 1509
WIS_Coa	GAATACAACGATGGAACATTGGATATGAAGCGAGACCAAGATTCAACAAGCCATCAGAA 1464

USA300_Coa	-----TCA----- 1515
N315_Coa	ACAAATGCATACACGTAACGACAAATCAAGATGGCACAGTATCATCGGAGCTGCCCA 1563
MRSA252_Coa	-----C----- 1515
MW2_Coa	ACAAACGCTACACGTAACGACAAATCAAGATGGCACAGTACATATGGCGCTGCCCA 1569
WIS_Coa	ACAAACGCTACACGTAACGACAAATCAAGATGGCACAGTATCATATGGGCGCTGCCCA 1524

USA300_Coa	-----GAAACAAATGCATATAACGTAACAACACATGCAAATGGTCAA 1557
N315_Coa	ACACAAAACAAGCCAAGTGAACAAACGCATATAACGTAACAACACATGCAAATGGTCAA 1623
MRSA252_Coa	-----GAAACAAATGCATACACGTAACGACAATCAAGATGGCACA 1557
MW2_Coa	ACACAAAACAACCAAGCAAAACAAATGCATACACGTAACAACACATGCAAATGGTCAA 1629
WIS_Coa	ACACAAAACAAGCCAAGCAAAACAAATGCATATAACGTAACAACACATGCAAACGCCAA 1584

USA300_Coa	GTATCATAACGGAGCTGTCGAC----- 1581
N315_Coa	GTATCATAACGGGCTCGCCCCACA----- 1647
MRSA252_Coa	GTATCATAATGGCGCTCGCCCCACA----- 1581
MW2_Coa	GTATCATAATGGCGCTCGCCCCACA----- 1653
WIS_Coa	GTATCATAATGGCGCTCGCCCCACATACAAGCCAAGTGAAACAAATGCATACACGTA 1644

USA300_Coa	-----CAAAACAAGCCAAGC 1596
N315_Coa	-----CAAAAAAAGCCAAGC 1662
MRSA252_Coa	-----CAAAACAAGCCAAGC 1596
MW2_Coa	-----CAAAACAAGCCAAGC 1668
WIS_Coa	ACGACAAATCGAGATGGCACAGTATCATATGGCGCTCGCCGACACAAAACAAGCCAAGC 1704

USA300_Coa	AAAACAAACGCTACACGTAACAACACATGGAAACCGGCAAGTATCATATGGCGCTCGC 1656
N315_Coa	AAAACAAATGCATACACGTAACAACACATGCAAATGGTCAAGTATCATATGGCGCTCGC 1722
MRSA252_Coa	GAAACAAACGCTACACGTAACAACACATGCAAACCGGCAAGTATCATACGGAGCTCG 1656
MW2_Coa	AAAACAAATGCATACACGTAACAACACATGCAAATGGTCAAGTATCATACGGAGCTCG 1728
WIS_Coa	GAAACGAATGCATACACGTAACAACACACGGAAATGGGCAAGTATCATATGGCGCTCGT 1764

USA300_Coa	CCACACAAAAAGCCAAGCAAGCAACAAATGCATACACGTAACAACACATGCAAACCGT 1716
N315_Coa	CCGACACAAAAAGCCAAGCAAGCAACAAATGCATATACGTAACAACACATGCAAATGGT 1782
MRSA252_Coa	CCGACACAAAAAGCCAAGCGAAACGCAACGCTACACGTAACAACACATGCAAACCGT 1716
MW2_Coa	CCGACACAAAAAGCCAAGCAAGCAACAAATGCATATACGTAACAACACAGCAAACCGT 1788
WIS_Coa	CCGACACAAAAAGCCAAGCAAGCAACAAATGCATATACGTAACAACACATGCAAACGGC 1824

USA300_Coa	CAAGTGTACACGGAGCTCGCCGACATACAAGAAGCCAAGTAAAACAAATGCATACAAT 1776
N315_Coa	CAAGTATACACGGAGCTCGCCGACATACAAGAAGCCAAGCGAAACAAATGCATACAAC 1842

10/10

A. CLASSIFICATION OF SUBJECT MATTER**A61K 39/395(2006.01)i, A61K 38/17(2006.01)i, A61P 31/04(2006.01)i, A61P 31/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 39/395; A61K 39/40; A61P 37/04; C07K 16/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models
Japanese utility models and applications for utility modelsElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & Keywords: Staphylococcus infection, Coa binding, polypeptide, antibody, Domain 1-2, compete, monoclonal**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHENG, A. G. et al., 'Contribution of coagulases towards Staphylococcus aureus disease and protective immunity', PLoS Pathogens, 2010, Vol. 6, Issue 8, Article Number e1001036. See abstract; fig. 2; and author summary.	25-27, 104-119
A	US 2011-0059085 A1 (KIM, S. A.) 10 March 2011 See abstract; and claims 1 and 4.	25-27, 104-119
A	MCADOW, M. et al., 'Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections', Journal of Innate Immunity, 03 January 2012 (E-pub.), Vol. 4, pp. 141-148. See abstract and page 143.	25-27, 104-119
A	US 2010-0183623 A1 (PATTI, J. M. et al.) 22 July 2010 See abstract; and claims 1 and 5.	25-27, 104-119
A	WATANABE, S. et al., 'Structural comparison of ten serotypes of staphylocoagulases in Staphylococcus aureus', Journal of Bacteriology, 2005, Vol. 187, No. 11, pp. 3698-3707. See abstract and results.	25-27, 104-119

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 24 June 2013 (24.06.2013)	Date of mailing of the international search report 25 June 2013 (25.06.2013)
Name and mailing address of the ISA/KR  Korean Intellectual Property Office 189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City, 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer CHOI, Sung Hee Telephone No. 82-42-481-8740

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2013/031927

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	MCADOW, M. et al., 'Coagulases as determinants of protective immune responses against <i>Staphylococcus aureus</i> ', <i>Infection and Immunity</i> , 23 July 2012 (E-pub.), Vol. 80, No. 10, pp. 3389-3398. See abstract; fig. 1; and results.	25, 105-108

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2013/031927**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-24, 128
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-24 and 128 pertain to methods for treatment of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. Claims Nos.: 3, 7, 12-14, 21, 77-100, 121, 123, 126
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 7, 12-14, 21, 77-100, 121, 123, and 126 are unclear, since they either directly or indirectly refer to one of claims which are not drafted in accordance with PCT Rule 6.4(a) (PCT Article 6).
Claim 3 is not clear because it is worded in reference to claim 3, itself (PCT Article 6).
3. Claims Nos.: 5, 6, 8-11, 15-20, 22-24, 28-76, 101-103, 120, 122, 124-125, 127-128
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2013/031927

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2011-0059085 A1	10.03.2011	AU 2009-246510 A1 CA 2760493 A1 CN 102089005 A EP 2291196 A2 EP 2291196 A4 IL 209257 D JP 2011-519974 A KR 10-2011-0017383 A WO 2009-140236 A2 WO 2009-140236 A3	19.11.2009 19.11.2009 08.06.2011 09.03.2011 30.05.2012 31.01.2011 14.07.2011 21.02.2011 19.11.2009 25.02.2010
US 2010-0183623 A1	22.07.2010	WO 2006-138627 A2 WO 2006-138627 A3	28.12.2006 12.07.2007

摘要

关于用于治疗或预防细菌感染,特别是葡萄球菌属细菌感染之方法和组合物的实施方案。包括用于提供针对所述细菌之被动免疫应答的方法和组合物的方面,在某些实施方案中,所述方法和组合物涉及结合凝固酶 (Coa) 的抗体。